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Summary 
National reports on the drug situation in Austria are drawn up annually for the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the federal ministry respon-
sible for health affairs. They deal with the subject of illicit drugs. This report gives an over-
view of current developments regarding the political and legal framework, the epidemiological 
situation and demand reduction interventions in the reporting period 2006/7. Every year spe-
cific issues are also highlighted; in this report, the themes of public expenditure, vulnerable 
groups of young people and drug-related research in Europe have been selected for detailed 
presentation.  
Summary and discussion of the most important trends 
This year, data from the nationwide documentation system of clients of Austrian drug help 
centres (DOKLI) have been available for the first time. In spite of a number of limitations be-
cause the reporting year has been the first year of data collection and analysis, the informa-
tion obtained still gives a comprehensive picture of the situation in life and patterns of drug 
use of clients of drug help centres. In addition, a few observations and trends of previous 
years could be verified or revised. 
Between one out of four and one out of five people undergoing treatment or receiving assis-
tance are younger than 20, and around half of the clients are between 20 and 29 years old. 
The DOKLI data also confirm the fact that the social situation of clients of drug help centres 
(as to housing, education, employment, etc.) is definitely worse compared to the general 
population. Around 10% of clients receiving long-term assistance and almost half of the cli-
ents of low-threshold centres do not have a stable accommodation. 
The share of women in the clients included in the DOKLI system is between 25% and 30%. 
This percentage corresponds to previous experience and primarily seems to reflect the gen-
der distribution among persons showing patterns of problem use of illicit drugs. Women are 
younger at the time of first use in the case of most substances and start to inject drugs 
slightly earlier than men. In sum, these data correspond to the studies and analyses of recent 
years. 
In the field of treatment, opiates definitely predominate as primary drugs, while cocaine, con-
trary to expectations, only plays a marginal role as a primary drug. This shows that in Austria, 
different to a number of other countries of the European Union, opiates (continue to) play a 
central role in the context of drug use relevant for treatment (see, e.g., EMCDDA 2006). Cli-
ents using cannabis as their (sole) primary drug very often contact the drug help system be-
cause of a treatment obligation after a report to the police relating to the Narcotic Substances 
Act. 
Furthermore, the DOKLI data confirm the observations of drug help centres in Vienna that 
snorting, also of heroin, plays a relevant role as a route of administration. Thus, the previous 
assumption that in the context of problem drug use especially opiates are primarily injected 
has to be revised with regard to the present situation. However, depending on the treatment 
setting, the share of i.v. users continues to be between 44% (clients receiving short-term as-
sistance) and 82% (inpatients). In addition, it shows that with rising age the percentage of i.v. 
IV
use is increasing considerably. This is an indication that the longer a drug career is, the more 
readily users tend to switch from snorting to injecting drugs. 
In view of the health consequences that intravenous drug use has (particularly infections dis-
eases, overdoses), specific prevention measures should be taken as a response to these 
findings. The DOKLI system also provides data on infectious diseases, which corroborate the 
prevalence rates that have so far been documented on the basis of a few small samples 
(HIV: max. 6%; hepatitis C-Ab: approx. 50%, hepatitis B: below 30 %). 
The number of directly drug-related deaths, i.e., 197 cases (2005: 191), has risen for the 
fourth time in a row since 2002. Parallel to this the average age of people who died because 
of a drug intoxication has continuously gone down and in view of other data in this context, 
obviously high-risk patterns of use seem to become more frequent in the group of young 
drug users. 
On 1 March 2007 the amended Narcotic Drugs Decree and the Oral Substitution Further 
Training Decree entered into force, thus the long-planned change of the legal basis of substi-
tution treatment has become effective, which also ensures certainty of the law for attending 
doctors, which was absent before. The objective of these amendments is to improve the 
quality of treatment, in particular by obligatory further training for physicians providing substi-
tution treatment and by strengthening the role of health authorities. In order to maintain a 
wide range of treatment options, slow-release morphines were not generally prohibited, but 
this group of substitution substances is no longer included in the substances that should 
preferably be prescribed, and in some aspects stricter regulations apply than for methadone 
and buprenorphine. The new legal framework continues to be an issue of highly controversial 
debate among experts. 
The Government Policy Statement of the new Federal Government also includes plans to 
draw up a national addiction and alcohol strategy for young people and to intensify activities 
that aim to prevent the misuse of alcohol, drugs and nicotine as well as gambling addictions. 
In November 2006 the Provincial Government of Carinthia adopted the Addiction Plan 2006–
10, which, in addition to illicit substances, also includes legal substances and addictive pat-
terns of behaviour at all levels of planning of the corresponding interventions. Its implementa-
tion is financed through provincial taxes earned from small-scale gaming operations. Gener-
ally speaking, the trend towards an integrated approach that encompasses both legal and il-
licit substances and various types of addiction has continued. This is also reflected by the 
observation that in the reporting period, the political discussion and the media more strongly 
focused on legal substances (binge drinking, protection of non-smokers) than illicit drugs. 
Almost all provinces introduced new, or adapted existing, services, which shows that the field 
of health-policy measures continues to be expanded. At present – in line with policy orienta-
tions – a strong focus of prevention activities has been placed on the legal drugs of alcohol 
and nicotine. In addition, an increasing number of measures taken include elements of both 
universal and selective prevention as well as early detection and early intervention. The drug 
help sector is also advanced continually, and treatment and assistance services that are pro-
vided aim to take into account specific needs of target groups and to address new groups. In 
this context a number of activities and services that are particularly oriented towards women 
have been offered by treatment and care units as well as low-threshold centres. 
VSelected issue: Public expenditures 
In Austria no routine documentation of expenditure for drug help centres, prevention of drug 
misuse, or of data on other costs directly or indirectly related to drug use exists. In the finan-
cial statements of the federal, regional and local authorities, only few expenditures are ear-
marked as drug-specific. Due to various methodology problems, it is also very difficult to give 
corresponding estimates. Therefore it is not possible to make even remotely reliable state-
ments on drug-related public expenditure in Austria for 2005. The most recent study in this 
field, limited to demand reduction, was conducted by ÖBIG within the framework of the Re-
port on the Drug Situation 2002.  
Selected issue: Vulnerable groups of young people 
There are no studies specifically focusing on vulnerable groups and their profiles with regard 
to drug abuse in Austria. Information on this issue can thus only be gained from projects with 
other focuses, especially surveys of individuals or groups who already show problem drug 
use. According to such surveys, massive problems in the family of origin accompanied by 
lack of social support, referral to institutions, low level of education and resulting unemploy-
ment as well as an unstable housing situation are risk factors for the social exclusion of 
(young) people which make them vulnerable with regard to drug problems. The responses 
and measures that are called for in the context of drug use among vulnerable groups are 
above all to create an adequate political and legal framework as well as to initiate activities in 
the field of prevention and treatment. In this respect integrative approaches with a priority on 
enabling the children and adolescents concerned to stay in their family of origin and in their 
course of training (school, apprenticeship) are of great significance. 
Selected issue: Drug-related research 
In Austria there is a broad range of approaches with regard to drug-related research, both at 
national and at provincial level. The established focuses of research cover clinical studies in 
the field of substitution substances and neurology as well as studies on consumption pat-
terns and social consequences of drug use, demand surveys, evaluation studies and projects 
relating to routine monitoring. Drug-specific research is financed at national level by individ-
ual ministries and institutes promoting research, indirectly from the budget of universities, 
and also from the budgets of the provinces and within the framework of EU programmes. 
The results of research are disseminated in specific publications and research reports or via 
the Internet.  
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1Introduction 
This is the 12th time the REITOX Focal Point at GÖG/ÖBIG (Austrian Health Institute) pre-
sents its annual Report to the EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) and the Austrian Federal Ministry responsible for health affairs. The REITOX Fo-
cal Point is a central link in Austria’s data and information network of drug-related matters 
and closely cooperates with the relevant federal and provincial agencies in this field as well 
as addiction and drug help centres. 
This report deals with illicit drugs and serves both as a national report on the situation in Aus-
tria and as Austria’s contribution to describing the drug situation in the European Union (EU). 
Similar reports are submitted by the REITOX Focal Points in all EU member states and by 
the EU candidates, according to guidelines issued by the EMCDDA. These reports are es-
sential as a basis of the EMCDDA’s Annual report on the state of the drugs problem in the 
European Union (latest publication: EMCDDA 2006).  
Part A of this report deals with new developments and trends with regard to the drug policy 
framework, the epidemiological situation and health-policy interventions aiming at demand 
reduction. It is based on previous reports (latest report: GÖG/ÖBIG 2006) and refers to the 
reporting period from summer 2006 to summer 2007, while routine statistics refer to the year 
2006. In Part B of the report selected issues are presented in more detail. In the present re-
port the corresponding chapters are: Public expenditure; Vulnerable groups of young people; 
and Drug-related research in Europe. The Annex includes a number of additional tables with 
detailed information and data. 
Every year the REITOX Focal Points also submit to the EMCDDA annual standard tables 
and structured questionnaires. These data and information have also been integrated in this 
report, with references to these sources given in the text. For an overview of all standard ta-
bles (= ST) and structured questionnaires (= SQ) please consult Annex C. 
This report is based on many different data and information communicated to GÖG/ÖBIG by 
various experts in the field of drugs. In this respect, the reports on the drug situation in the 
individual Austrian provinces drawn up by the Drug Coordinators and Addiction Coordinators 
have been especially significant. In addition, a number of experts provided background in-
formation and specific data for individual chapters of this report (see Selected Issues). We 
would like to express our gratitude for their cooperation. 
We are especially indebted to the members of the advisory working group of the REITOX 
Focal Point Austria, Mr Michael Dressel (Drug Coordinator of the City of Vienna and Provin-
cial Representative), Mr Thomas Neubacher (Addiction Coordinator of Vorarlberg and Pro-
vincial Representative), Mr Franz Pietsch (Federal Drug Coordinator and head of the Federal 
Drug Coordination), Mr Robert Scharinger (BMGFJ), Ms Johanna Schopper (head of the De-
partment of Drugs and Narcotic Substances at the BMGFJ) and Mr Wolfgang Werdenich 
(BMJ) for their helpful comments and invaluable input. 

PART A 
New Developments  
and Trends  
 

51 National Policies and Context 
The Narcotic Substances Act (SMG), which has been in force since 1998, constitutes the 
main framework of Austria’s drug policy. The SMG primarily focuses on quantity and not on 
kind of substance, with the exception of a special provision concerning cannabis, and pro-
vides a wide range of alternatives to punishment. At the federal level the central actors in the 
field of drug policy include the Federal Drug Coordination and the Federal Drug Forum, 
which has the task to coordinate policies with the provinces (see Figure 1.2). Due to the fed-
eral structure of Austria’s health and social care system, the provinces play important roles 
with regard to the adoption and implementation of drug policy measures. All nine provinces 
have drawn up drug strategies or addiction plans and nominated Drug or Addiction Coordina-
tors. Drug policy measures are financed primarily by the Provincial Governments, the social 
insurance funds and the Federal Government. The public discussion of drug issues primarily 
concentrates on questions related to public safety and to delinquency. Although Austria’s po-
litical parties take differing stands with regard to drug policy, they unanimously endorse the 
principle of therapy instead of punishment, which is also widely accepted by the general pub-
lic. 
1.1 Legal framework  
The reporting period did not see any amendments to the National Substances Act (SMG). 
Because the federal parliamentary period ended, this led to delays in the implementation of 
the European Framework Decision laying down minimum provisions on the constituents of 
criminal acts and penalties in the field of illicit drug trafficking (Council of the European Union 
2003), which requires an amendment to the SMG. In autumn 2007, the corresponding bill 
was submitted to experts for consideration. 
The plans to modify the legal basis of substitution treatment, which were described in detail 
in last year’s report (see ÖBIG 2005 and GÖG/ÖBIG 2006) were implemented in the report-
ing period. On 1 March 2007, the amended Narcotic Drugs Decree (Federal Collection of 
Statutes BGBl II 2006/451 and 2007/50, respectively) and the Oral Substitution Further 
Training Decree (Federal Collection of Statutes BGBl II 2007/449) entered into force (see 
also Chapter 5.3). Now that a general legal framework has been laid down under the Nar-
cotic Drugs Decree, certainty of the law exists for attending physicians, which was absent be-
fore. 
With regard to the implementation of the legal framework, information is available on the 
practices regarding statutory alternatives to punishment (for more detail see ÖBIG 2004 and 
SQ31). In 2006, the corresponding figures went down compared to the year before (from 
11 660 to 10 379 cases), as did reports to the police and convictions (see Chapter 8.2). This 
decline exclusively relates to waiving of reports to the police, which have seen a continuous 
rise for many years, while the number of suspended proceedings has gone up again for the 
first time since 2002 (see also Table A 16 in Annex A). 
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A comparison of the development of reports to the police, convictions (see Chapter 8.2) and 
alternatives to punishment reveals an interesting picture: on the basis of an index that was 
defined to be 100% in 1998, the year when the Narcotic Substances Act entered into force, it 
shows that in the period of analysis from 1998 to 2006, the share of convictions saw the 
greatest increase: their marked rise did not start before 2001 and was particularly high in 
2004 compared to the previous year (see Figure 1.1). 
Figure 1.1: Comparison of the index-related development of drug-related reports to the police, 
convictions and application of statutory alternatives to punishment in Austria, 
from 1998 to 2006 
 
Sources: BMI – Bundeskriminalamt (Federal Criminal Agency), Statistics Austria, BMGFJ; calculations 
by GÖG/ÖBIG; representation by GÖG/ÖBIG 
There are no obvious reasons for the disproportionate rise in convictions. It certainly cannot 
be explained by an increase in felonies (compared to misdemeanours; see Figure 8.1). 
However, to some extent it may result from changes in legal provisions due to the 
amendment to the SMG in 2001, which abolished the obligation of a temporary waiver of 
reports to the police in certain fields: now waivers lie within the discretion of the public 
prosecutors. Still, as no reliable database has been available so far, this development cannot 
be analysed in more detail. However, according to the Ministry of Health a modernisation and 
improvement of the Narcotic Substances Database, an important source in this regard, is 
under preparation, and as a result, more conclusive analyses will be possible in future. 
Salzburg again provided complementing analyses of the results of examinations according to 
Section 12 of the SMG (see also Chapters 2.1 and 4.3), which give insight into the imple-
mentation practice of the health authorities (Drogenkoordination des Landes Salzburg 2007). 
In 2006, one health-related measure was recommended for 32% of the persons examined, 
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and in 54% of the cases, several measures were regarded as necessary. For 15% no health-
related measure was indicated. By and large, this corresponds to the percentages of last 
year. As in 2005, medical supervision of the patients’ state of health was the measure that 
was recommended most frequently (75%). The share of people for whom psychosocial 
counselling and care was regarded as necessary has further declined (2004: 71%, 2005: 
62%, 2006: 51%). Analyses of the examinations according to Section 12 of the SMG are also 
available from Carinthia: in 2006, a health-related measure was indicated for only approxi-
mately half of the people examined, while in 47.5% of the cases no measures were regarded 
to be necessary (Prehslauer, personal communication). 
As a reaction to doubt regarding considerable differences in the examination practices of the 
individual district health authorities in Austria – which has already been mentioned in the re-
port of the previous year (see GÖG/ÖBIG 2006) – plans to define uniform standards now ex-
ist at the federal level. A working group was formed which includes provincial representatives 
and those in charge of the examinations, in order to draw up recommendations in this regard. 
 
1.2 Institutional framework, strategies and policies 
No major changes in the political and administrative framework took place in the reporting 
period (see also SQ 32). Autumn 2006 saw federal elections in Austria, and on 11 January 
2007 the new Federal Government was inaugurated. The Department of Health, which is in 
charge of federal drug coordination, became part of the current Federal Ministry of Health, 
Family and Youth (BMGFJ). Several chapters of the Government Policy Statement 
(Bundeskanzleramt 2007) also deal with objectives and plans related to the issue of drugs. 
The chapter on health includes a national addiction and alcohol strategy for young people 
among the measures planned and also refers to addictive behaviour in the context of meas-
ures aimed at promoting healthy lifestyles. The chapter on youth policy has a special section 
on the prevention of alcohol and drug misuse as well as glorification of violence and points to 
the need for intensified activities in order to prevent the misuse of alcohol, drugs and nicotine 
as well as gambling addictions. In addition, the chapter on internal security deals with an ex-
pansion of measures in the field of drug prevention, and the chapter on foreign policy refers 
to the cooperation with the United Nations in areas such as combating drug trafficking. Com-
pared to previous Government Policy Statements, the health and youth policies have no 
longer primarily been oriented towards illicit drugs: now legal substances and other forms of 
addiction play a more prominent role. This is in line with the change in the focuses of political 
and media discussions (see Chapter 1.4). 
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In the reporting period the Federal Drug Forum (see Figure 1.2) held two regular meetings, in 
November 2006 and in April 2007. The themes discussed again included the modification of 
the legal framework for substitution treatment (see Chapters 1.1 and 5.3), drug-related legal 
questions (including the implementation of the European Framework Decision; see Chapter 
1.1), the further advancement of drug monitoring and international cooperation. In June 2007 
an extraordinary meeting of the Federal Drug Forum also took place, focusing on harm re-
duction interventions in Austria’s drug help system (see Chapter 7.2). 
Also at provincial level only a small number of relevant changes have been registered. In 
November 2006 the Provincial Government of Carinthia adopted the Addiction Plan 2006–10 
(Prehslauer, personal communication). The new Plan is based on the Framework Plan of 
Addiction Prevention and Drug Help 2001–5. Its implementation is financed through provin-
cial taxes earned from small-scale gaming operations and coordinated by a steering group of 
representatives of the Health and Social Affairs Departments. The Addiction Plan is oriented 
towards the drug strategy of the European Union and Carinthia’s Patient’s Charter as well as 
international treatment standards. In addition to illicit substances, also legal substances and 
addictive patterns of behaviour have been included at all levels of planning of the corre-
sponding interventions. 
Lower Austria completed the restructuring (see GÖG/ ÖBIG 2006) of the drug sector that 
was started in 2005, which especially concerned the field of addiction coordination. In Salz-
burg, the Provincial Addiction Advisory Board was expanded (it now also includes represen-
tatives of fields such as probation assistance and prevention medicine). All provinces con-
tinue to focus their drug policy measures on implementing their regional drug policy or addic-
tion policy strategy papers on the one hand and on responding to new developments and 
demands on the other. 
1.3 Budget and public expenditure 
The financial regulations in the field of drugs did not see relevant changes in the reporting 
period. However, what is worth mentioning is that the implementation of Carinthia’s Addiction 
Plan 2006–10 is financed through the province’s tax revenues from small-scale gambling 
(see also Chapter 1.2). With regard to the individual budgets, the available information is lim-
ited and no general overview can thus be given (see Selected Issues Chapter 11). 
1.4 Social and cultural context 
In Upper Austria, the general population survey1 carried out in the context of drug monitoring 
was repeated for the third time in 2006 (Seyer et al. 2007), and again included questions 
about attitudes to drug policies among the general population. The results do not show sig-
nificant differences compared to the survey of 2003 (see Figure 1.3 below). A vast majority 
 
1 The general population survey of Upper Austria was conducted in May 2006 among a total of 1 507 people aged 15 or older, in 
the form of face-to-face interviews (see also Chapters 2.1 and 2.2). Such surveys were also conducted in 2000 and 2003, 
based on a similar method. 
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agree to the statement that drug addiction is a disease (90%), but very many respondents 
also say that illicit drug use should be punished more harshly (78%). Around one out of four 
people regard non-punishment of hashish as sensible up to a certain amount of drug in-
volved, and almost half approve of the view that the use of soft drugs should not be sanc-
tioned in order to avoid criminalisation (46%) and that drug users should only be punished if 
they put third parties at risk (44%). 
Figure 1.3: Attitudes towards drug policy measures among the population of Upper Austria, 
comparison of 2003 and 2006 (percentages show approval of the measure in question) 
Source: Seyer et al. 2007; representation by GÖG/ÖBIG 
Based on the statements obtained, in a further analysis categories with regard to drug policy 
attitudes were formed, distinguishing between liberal, mainstream and repressive. In sum, 
approximately 18% of the respondents were found in the liberal group, around 37% had re-
pressive views, and the rest, i.e., the largest group was in the mainstream category. Drug 
policy attitudes tend to become more strongly oriented towards repressive measures the 
older the respondents are. The more drug-related know-how people have, the more liberal 
their standpoints tend to become. 
The study also investigated which substances are considered to be risky. Heroin is regarded 
to be the most dangerous drug (89%: very dangerous), followed by LSD (83%), cocaine 
(81%) and ecstasy (69%), while cannabis (38%) and legal substances (nicotine: 23%; 
brandy: 27%; beer: 7%; wine: 6%) are thought to be very dangerous to markedly smaller de-
grees. In order to examine social problem awareness with regard to different substances, at 
the beginning of the survey the respondents were asked to name drugs spontaneously. The 
substance most frequently indicated was heroin (55%), followed by cocaine (52%) and hash-
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ish (47%). This was complemented by aided-recall questions asking which substances the 
respondents regarded as drugs: here heroin, cocaine and ecstasy (between 96% and 97%) 
were in the lead. Cannabis was indicated slightly more often than in 2003 (90% v. 84%). The 
percentages for alcohol and nicotine (76% and 74% in 2006 v. 67% and 66% in 2003) went 
up considerably, which reflects the fact that these substances have played a more important 
role as drugs in public awareness than in the past. 
This corresponds to the intensified public discussion on legal substances. In the reporting pe-
riod, especially in spring 2007, the issues of drinking (primarily binge drinking) and smoking 
(in particular protection of non-smokers in pubs and restaurants) were more intensively cov-
ered by the media than illicit drugs. In both 2006 and 2007 alcohol was at the centre of sev-
eral mass media campaigns2 that also addressed young people, while no campaigns had 
been launched in the field of illicit drugs. This is well in line with the principle of addiction pre-
vention, which rather focuses on comprehensive, sustainable measures (see Chapter 3). 
 
2 See www.fgoe.org
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2 Drug Use in the Population 
In Austria, experience of illicit drug use primarily concerns cannabis, with prevalence rates of 
approximately 30% to 40% among young adults. According to the majority of representative 
studies, experience of ecstasy, cocaine and amphetamines is found among approximately 
2% to 4% of the population, and of opiates, among between around 1% and a maximum of 
2%. In recent years, the range of substances taken in the context of experimental use has 
widened. In certain scenes and groups of young people, high prevalence rates for a variety 
of substances are found, including biogenic drugs as well as solvents and inhalants. New re-
sults of representative studies indicate that this has led to a general increase in prevalence 
rates, in particular among adolescents and young adults.  
2.1 Drug use in the general population 
In Upper Austria, the representative population survey3 was repeated for the third time in 
2006 (see Seyer et al. 2007). A comparison to the previous surveys (2000 and 2003) shows 
a general rise in lifetime experience of illicit drugs (see Table A1 in Annex A). Around 28% 
(2000: 24%) of the respondents indicated that they had already used cannabis, approxi-
mately 7% said they had experience of ecstasy and amphetamines, and around 6%, of co-
caine. For the rest of substances (heroin, morphine, LSD), the corresponding percentages 
were between 4% and 5%. Experience of solvents and inhalants (8%) and biogenic drugs 
(7%), which are not among the “illegalised” substances, was similar to ecstasy and am-
phetamines (see ST1). These prevalence rates appear to be very high compared to other 
representative surveys. For instance, the 2004 nationwide general population survey in Aus-
tria revealed a lifetime prevalence of cannabis of approximately 20%, and around 2% to 3% 
regarding ecstasy, amphetamines and cocaine (see Table A1 in Appendix A). For control 
purposes, a non-existent fantasy drug was also included, and use of this drug was also indi-
cated by around 3% of the respondents, therefore the results obtained should be interpreted 
with caution. In addition, the authors of this report point to the fact that at present, lifetime 
prevalence is also rising for the very reason that the share of older respondents with little 
drug experience has gone down from one survey to the next, while the share of younger 
people with more drug experience is rising at the same time. 
Therefore, it is more significant to consider current drug use (i.e. drug use in the past 12 
months). Naturally, the corresponding figures are significantly lower (cannabis: approx. 10%, 
ecstasy: around 3%, all other substances: 2% or lower) than those of lifetime use, but still, a 
rise compared to 2003 has shown for all substances (see Figure 2.1). 
 
3 The general population survey included a total of 1 507 people aged 15 or older (see also Chapters 1.4 and 2.2). For the inter-
pretation of the results regarding experience of use, only the data relating to the age group between 15 and 59 (n = 1 284) 
were included. 
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Figure 2.1: Illicit drug experience in the past 12 months among the population of Upper Austria: 
comparison of the years 2003 and 2006 (percentages) 
Source: Seyer et al. 2007, representation by GÖG/ÖBIG 
Such a strong rise within only three years is in fact unlikely. However, the data do suggest a 
certain increase in current illicit substance use. The corresponding percentages are higher 
for men than for women with regard to almost all substances (e.g., cannabis use: 12% v. 7% 
in the past 12 months). The 12-month prevalence rates also show that illicit drugs are con-
sumed primarily up to the age of 30, afterwards current drug use goes down considerably 
(Seyer at al. 2007). 
The results of the Austrian Health Interview Survey4 (Klimont et al. 2007) are significantly 
lower than those of the Upper Austria survey: around 10% of the respondents aged between 
15 and 64 indicated lifetime experience of cannabis. The highest lifetime prevalence was 
found in the group between 25 and 34 years: 15% (see Table A1 in Annex A). In sum, only 
1.3% of the respondents reported use in the past 12 months, with the highest percentage 
found in the youngest age group (15 to 24 years: 2.7%). The drug prevalence rates are gen-
erally lower among women than among men. The prevalence rates shown here are below 
those of all drug-specific studies of the last few years (see Table A1 in Annex A). A reason-
able explanation for this is that the setting of the survey (few questions about cannabis in the 
 
4 In the context of the Austrian Health Interview Survey (ATHIS) of 2006/7, throughout Austria a total of 15 492 people aged 15 
years or older (from 15 to 64; n = 11 822) were interviewed about their state of health and health-related behaviour. HIS have 
been conducted since 1973, at irregular intervals. The current survey for the first time followed the modules for unified Health 
Interview Surveys developed at European level (Eurostat) and included a number of questions regarding cannabis as well as 
the legal substances of alcohol and nicotine. 
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context of a health survey) resulted in unwillingness to admit drug use and thus an underes-
timation of prevalence rates. 
In Salzburg, on the basis of a comparison over several years of medical examination results 
from the district health authorities (see Chapter 1.1) the conclusion is drawn that there is a 
trend towards a continuous rise in the share of cocaine, while the shares of cannabis and 
hallucinogenic drugs remain unchanged and a downward trend seems to show with regard to 
ecstasy use. After initial declines, opiate use seems to be rising again (Drogenkoordination 
des Landes Salzburg 2007). Here, aspects of problem drug use also occur (see also Chapter 
4.3). 
2.2 Drug use in the school and youth population 
As adolescents and young adults are the group where drug experience is found most fre-
quently (see above), in the context of the general population survey of Upper Austria5 an ad-
ditional separate analysis was made for the age group between 15 and 24 (see Seyer et al. 
2007). As expected, the prevalence rates are higher in this group compared to the general 
population, and a rise since 2003 has also shown (see Table A2 in Annex A). Again, canna-
bis is the most frequent drug, with lifetime experience shares of approximately 37%. For ec-
stasy and amphetamines, lifetime prevalence rates are around 8% to 9%, while the rates for 
solvents and inhalants (13%) and biogenic drugs (10%) are slightly higher (see ST1). Again, 
the high prevalence rates in this age group should not be taken at face value, however, be-
cause here, use of  the non-existent fantasy drug that was included in the questionnaire in 
order to check the reliability of responses was also indicated by as many as around 7% of 
the respondents. This leads to the conclusion that actual illicit drug experience is likely to be 
smaller than indicated. The methodology of the survey may also account for these rather 
high percentages: in order to create a situation of confidence, special attention was paid to 
the fact that the interviewers should be of the same age as the interviewees.  
Lower prevalence rates of current drug use (i.e., in the past 12 months) are also found 
among the group between 15 and 24 years (see Figure 2.2), however, the differences to life-
time experience are less pronounced than among the general population (see Chapter 2.1). 
In addition, the differences according to gender are smaller among people aged from 15 to 
24 than in the overall population. Again, a significant rise compared to 2003 has been regis-
tered. 
Drug consumption in the past month was also surveyed, but as the prevalence rates were 
low, no detailed analysis is possible. What has become apparent is that the highest 30-day 
prevalence rates are found at the age between 18 and 19: 22% of the young people in this 
group said they had taken an illicit substance in the past month. Again, one must bear in 
mind that these figures have to be interpreted with utmost care because they are likely to 
lead to an overestimation of actual drug use. 
 
5 The general population survey included a total of 1 507 people aged 15 or older (see also Chapters 1.4 and 2.1). The sample 
for the age group between 15 and 24 was overrepresented (n = 669) and analysed separately.  
Chapter 2: Drug Use in the Population  
15
Figure 2.2: Illicit drug experience in the past 12 months among the population of Upper Austria 
aged between 15 and 24: comparison of the years 2003 and 2006 (percentages) 
 
Source: Seyer et al. 2007; representation by GÖG/ÖBIG 
Furthermore, recent results of the international WHO HBSC survey of 20066 are available 
(Dür and Griebler 2007): approximately 7% of the young people aged 15 said they had al-
ready taken cannabis once or twice. Another 7% indicated use of cannabis at least three 
times (see ST2). Compared to 2001 (once or twice: 8%; at least three times: 6%) the situa-
tion has hardly changed (see Table A2 in Annex A). However, the share of 15-year-olds who 
said they had already been drunk has doubled (2001: 28%; 2006: 57%). 
2.3 Drug use among specific groups 
In past years, almost all data on drug use among specific groups in Austria (e.g., conscripts, 
ethnic minorities, immigrants etc.) referred to specific youth scenes (e.g., see ÖBIG 2004). 
Drug use in groups of at-risk youths is described in Selected Issues Chapter 12. 
In addition, a recent diploma thesis deals with ketamine as a party drug: for this purpose, 
people with experience of ketamine use were interviewed (Baumgartner 2007). The thesis 
does not aim to give representative data but focuses on a better understanding of patterns of 
use and the motives for and experience with the use of ketamine, primarily with regard to 
 
6 The WHO project Health Behaviour in Schoolaged Children (HBSC) focuses on the state of health and health behaviour of 
school students and has been conducted at regular intervals in Austria since the school year 1983/4. The survey of the school 
year 2005/6 was the second survey after 2001/2 in which also cannabis use among students aged 15 (n =1 239) was investi-
gated (data source: WHO-HBSC-Survey 2006, Dür and Griebler 2007). 
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secondary prevention and social work interventions (see Chapters 3.2 and 7.2). This survey 
was carried out on the spot at freetekno and goa events as use of ketamine is of particular 
relevance in these two scenes. In total, 62 persons were interviewed, who indicated high 
consumption rates of a variety of substances: in the past 30 days the majority had used al-
cohol (94%), cigarettes (86%) and cannabis (77%), and about half had taken amphetamines 
(58%) and cocaine (53%). Ecstasy (27%), ketamine (23%), mushrooms and LSD (21% each) 
were not indicated as often. Ketamine is typically snorted (85%) and use is often connected 
to the use of other substances – primarily alcohol, cannabis and speed – within six hours be-
fore or after ketamine consumption. Here the risks of mixed use, particularly combinations 
with alcohol, tend to be underestimated. 
The reason why ketamine is regarded as interesting by the users is primarily the mix of psy-
chedelic effects on the one hand and sedation on the other. Curiosity was indicated as the 
most important motive for first use, which took place at the age of 20 on average. The major-
ity of respondents said they had not felt any negative effects of ketamine use, but around one 
third reported negative aspects. Most of the users did not think that ketamine use had led to 
changes in their lives, however, almost 80% reported a negative development of the general 
mood (dejected, irritated, aggressive atmosphere etc.) at parties where much ketamine was 
used. 
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3 Prevention 
According to the EMCDDA classification of prevention, this chapter has been divided into 
three subchapters: universal prevention, selective prevention and indicated prevention7. This 
approach is different to the distinction between primary and secondary prevention8 that has 
primarily been used to so far. In line with Austria’s comprehensive view of addiction, many 
prevention measures are not aimed at specific substances but also encompass forms of ad-
diction that are not linked to substances. In Austria, the corresponding measures are primar-
ily implemented at local and regional levels, in accordance with expert consensus. In this 
context, the provincial Addiction Prevention Units (see Chapter 1.2), the Addiction Prevention 
Forums of Salzburg and Vienna, as well as regional coordination bodies (Salzburg) play cen-
tral roles. As a rule, the prevention measures are aimed at long-term effectiveness and sus-
tainability. In addition to a number of standard programmes that are carried out routinely and 
at nationwide level, numerous regional projects or measures exist that have also been effec-
tively implemented for longer periods already and have been advanced regularly. Further-
more, new strategies and approaches are developed continually in order to optimise the 
quality of prevention activities. Other important fields that deserve mention are networking 
and public relations work, (financial) support of prevention initiatives and organising further 
training programmes for experts, e.g., the expert meeting on methods of addiction prevention 
that the Working Group for Addiction Prevention held in Bolzano in autumn 2006. 
This chapter focuses on the presentation of new developments. The wide range of preven-
tion measures taken in Austria, including the activities mentioned in this report, are described 
in more detail on the individual websites and in the annual reports and newsletters of the Ad-
diction Prevention Units, the Ministry of Education (BMUKK), the Healthy Austria Fund 
(GÖG/FGÖ) and other relevant actors, as well as in previous reports on the drug situation 
and in the EDDRA database (see Bibliography). What characterised the reporting period was 
a strong focus of prevention activities that was placed on the legal drugs of alcohol and nico-
tine (see Chapter 1.4), which will not be presented in more detail, however. Another aspect 
worth mentioning is the rising number of activities that include elements of both universal and 
selective prevention as well as early detection and early intervention and also counselling 
and treatment services. 
 
7 Universal prevention is aimed at large groups of the population (e.g. school communities, towns) that, independent of the in-
dividual situation, are equally likely to develop patterns of substance use. Selective prevention focuses on smaller groups that, 
due to biological, psychological, social or environmental risk factors – independent of the individual situation – are more likely 
to develop patterns of substance use than the general population (e.g., children of addicted parents). Indicated prevention 
addresses individual persons who already show early signs of substance use or problem patterns of behaviour that are asso-
ciated with drug use but do not yet meet the criteria for a diagnosis of dependence and for whom the risk of developing addic-
tive behaviour is thus particularly high. A requirement for indicated prevention is that medical experts have already diagnosed 
psychiatric, social or behavioural problems, which are known to constitute risk factors regarding the development of addictive 
behaviour, e.g. ADHS. 
8 Primary prevention aims at avoiding the development of a disease, in this case, an addiction disease, already before drug use 
or drug problems have arisen. Secondary prevention addresses drug users who already have problems, which have not yet 
become manifest to their full extent, however.  
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3.1 Universal prevention 
For an overview of Austria’s universal prevention activities and the general framework of pre-
vention please consult SQ22/25. Schools play an important role as settings of implementa-
tion. Here, prevention takes place on a statutory basis, in the context of the educational prin-
ciple of health promotion9. It is recommended that prevention measures at schools involve all 
stakeholders of the school community as well as regional addiction experts. On this basis, 
training courses on addiction prevention and further training events are organised, teaching 
materials and projects are prepared and teachers, heads of school and school medical offi-
cers10 are offered practical assistance in planning and implementing prevention activities. A 
number of new booklets published by the BMUKK are available in this field and provide an 
overview of the range of possible prevention options (Haller, personal communication). The 
BMUKK and GÖG/FGÖ organised a workshop with experts on the theme of mental health at 
school, where recommendations for the further development of this subject were compiled 
(Dür and Griebler 2007a). This includes a framework plan with guidelines and standards for 
the implementation of health promotion and the involvement of school medical officers. Salz-
burg is currently preparing the structural basis for forward overall planning of addiction pre-
vention at school (Drogenkoordination des Landes Salzburg 2007). In this context, as of 
2007 the KIS Contact Point of Addiction and Health Matters has organised the establishment 
of a new system of health officials at schools, who will address the themes of diet, exercise 
and life skills, which also includes prevention activities in school settings. In Styria, a new 
curriculum was developed so that, as of autumn 2007, it will be possible in basic primary and 
secondary education as well as education of children with special needs to place an individ-
ual focus on the prevention of drugs and addiction in school contexts (Ederer, personal 
communication). Since autumn 2006, the Dialog association of Vienna, through the service 
centre of prevention and early detection, has provided assistance in the development and 
implementation of projects tailored to meet specific demands or measures according to Sec-
tion 13 of the SMG, as well as training programmes, and in addition, counselling for young 
people is organised11. The Internet-based computer programme feel ok, which addresses 
school students between 12 and 18, is available in most of the provinces by now, and the 
project Eigenständig Werden (Becoming Independent) – see MUSTAP programmes12 - was 
implemented in the whole of Lower Austria (Mellish, personal communication). ARGE Sucht-
vorbeugung (Working Group on Addiction Prevention) prepared plus, a four-year prevention 
programme for schools, which aims to promote psychosocial health and specifically includes 
of the themes of addiction, violence and suicide. At present, it is being tested in the Tyrol13.
Based on the life skills approach, it is oriented towards existing resources, experience and 
adventure aspects, takes into account gender-specific needs and follows a participatory 
 
9 Health promotion, in accordance with the Ottawa Charter of the WHO, is understood as the process of enabling people to in-
crease control over, and to improve, their health, i.e. to reach a state of complete physical, mental and social well-being. 
10 For further details on the corresponding materials and services see, e.g., www.schulpsychologie.at.
11 www.dialog-on.at (1 Aug. 2007) 
12 Multi-session Standardised Printed Programmes, which the EMCDDA defines as programmes that cover a defined subject for 
each lession and provide printed material for teachers and pupils, which may be adapted to meet local demands. 
13 www.kontaktco.at (25 May 2007) 
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structure. Its target group is school students between 10 and 14, and it is implemented by 
form teachers and teachers of individual subjects. 
In kindergartens, the focus continues to be placed on further training schemes, provision of 
information materials and work with parents. Regarding new developments, what deserves 
mention is the further training programme for kindergarten teachers that has been offered in 
Upper Austria since 200614. Consisting of five modules, it includes basic knowledge and self-
reflection on the themes of addiction and prevention, dealing with problem situations, ways of 
implementing the subject of prevention and presentation of concrete projects. 
The measures addressing parents primarily concentrate on information events on addiction 
and prevention. For instance, early in 2007, a cooperation agreement between the Addiction 
Prevention Unit and the police was concluded in Styria, in the context of which specially 
trained police officers have organised information evenings for parents (see SQ22/25). Police 
officers also hold workshops for students, which are complemented by courses for teachers 
organised by the Addiction Prevention Units in order to permit further treatment of this issue 
at school. New services for parents of young people are available in Styria (Was geht ab?! 
[What’s wanting?!], VIVID 2007a) and Lower Austria (Mellish, personal communication). 
Work with parents has become a new focus of activities of Salzburg’s Addiction Prevention 
Forum (Drogenkoordination des Landes Salzburg 2007). Central objectives here are to build 
information structures, in particular with regard to groups that have little contact to education, 
and to define standards for the subjects treated in the context of parent training. In the Pin-
zgau region of Salzburg, a major regional information campaign on solvents and inhalants 
was initiated for the target group of parents (Drogenkoordination des Landes Salzburg 2007). 
Prevention measures are also found in workplace settings, particularly for trainees. The cor-
responding activities focus on further training measures for instructors of trainees (e.g., new 
activities in Styria as of 2006), but there are also training programmes for managerial staff, 
and internal step-by-step plans for approaching workers who whose behaviour gives rise to 
concern may be developed. Salzburg, in the context of a EuRegio project and a transbound-
ary cooperation with Bavaria, started a mobile information and counselling point for work-
place prevention in small and medium-sized enterprises (GÖG/FGÖ 2007). In Vorarlberg, a 
guideline on drug use during traineeship was published for the target group of trainee instruc-
tors, which also aims to provide a variety of assistance services15. As of 2006 Salzburg’s pro-
ject Lehrlinge ins Zentrum! (Trainees in the Centre) has also included workshops and focal 
groups at workplace level for trainers and trainees (Drogenkoordination des Landes Salzburg 
2007). 
The prevention activities at community level that address young people also focus on fur-
ther training programmes for multipliers. In the reporting period, particularly coaches of youth 
teams in the Lower Austria Football Association and youth officials in the Provincial Fire Bri-
gade Association were addressed (Fachstelle für Suchtvorbeugung, Koordination und Bera-
tung 2007, VIVID 2007b). The Amstetten Model of addiction prevention in schools, which has 
been run since 2004, was expanded to cover also youth social work at community level, i.e., 
 
14 www.praevention.at (4 June 2007) 
15 www.supro.at (4 June 2007) 
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outside school (Mellish, personal communication). Apart from further training, special action 
days and events for parents, networking with the social departments of Amstetten (Lower 
Austria) forms a central part of this project. 
The last few years have seen a marked increase in prevention activities at community level 
in Austria, which in addition to awareness-raising among the general population, are aimed 
at the development and implementation of concrete measures that respond to specific re-
gional situations. With regard to the sustainability of the projects, different results have been 
reported. The project groups of Salzburg’s Guat beinand (Feeling Good) towns (see 
GÖG/ÖBIG 2006) have continued to play important roles in supporting prevention measures 
also after the conclusion of the project, while experience with the regional coordination bod-
ies has shown that long-term effectiveness of the projects has been more difficult to achieve 
due to restricted resources regarding staff and work hours (Drogenkoordination des Landes 
Salzburg 2007). In autumn 2006, ISP of Upper Austria started a new community-oriented 
project, in cooperation with the town of Freistadt: Suchtprävention in Freistadt (Addiction Pre-
vention at Freistadt), which, for instance, includes individual projects in youth contexts, lec-
tures and public information events as well as further training programmes16.
Other activities in the reporting period that deserve mention are lectures on addiction and 
preventing addiction that were organised in Lower Austria for all young men shortly before or 
at the early stages of military service, in cooperation with the military authorities. The objec-
tives of these lectures were to communicate relevant general knowledge and raise the 
awareness of addiction-related issues among the young men on the one hand and to reduce 
prejudice and reservation regarding assistance providers on the other (Fachstelle für Sucht-
vorbeugung, Koordination und Beratung 2007). ISP of Upper Austria, cooperating with the 
Provincial Theatre of Linz, staged the play Motte & Co. (Moth & Company), which aims to 
communicate to children and their parents protective factors such as self-confidence, the 
ability to deal with conflicts and adequate ways of coping with difficult feelings. In cooperation 
with BildungsMedienZentrum (EducationMediaCentre) a new media leaflet on the prevention 
of addiction was prepared17. The Working Group on Addiction Prevention drew up new in-
formation sheets on addiction and “hangover cards”, which provide easy-to-grasp information 
on the effects and risks of substances, patterns of use, prevalence and prevention regarding 
drinking, smoking and various illicit drugs. 
3.2 Selective prevention 
As a result of the activities undertaken by the ENCARE network, in the reporting period the 
field of selective prevention (see also SQ26) also focused on drinking, i.e., children in fami-
lies with alcohol problems. In order to expand the focus of this network and transfer it to the 
regional level, the Addiction Prevention Units established provincial networks for children in 
families with addiction problems (ENCARE Österreich 2006). In autumn 2006 and spring 
2007, the first two ENCARE regional meetings took place (ENCARE Österreich 2007), where 
the basis of future cooperation was defined and a variety of activities were planned. For in-
 
16 www.praevention.at (10 Oct. 2006) 
17 www.praevention.at (5 April 2007) 
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stance, demand was identified for sustainable low-cost services for parents and children, in 
particular children who do not seem to be distressed outwardly, as well as further training 
programmes in order to enhance the level of competence among the occupational groups 
concerned (e.g., motivational interviewing). A strategy and guideline for the cooperation with 
assistance providers (Styria, Tyrol) were drawn up, and specific services for children from fa-
milies with addiction problems (Styria, Vorarlberg) were developed. Further plans include the 
organisation of expert meetings, investigations of the current situation and an expansion of 
Vorarlberg’s project Kasulino (see GÖG/ÖBIG 2006) to cover the whole province. As of the 
beginning of 2007 a new homepage18 has been online to facilitate an interregional exchange 
in the context of ENCARE Austria, and in June 2007 an interregional meeting was held. 
In addition to the aforementioned focus, specific prevention activities undertaken in Austria 
are primarily found in spare time contexts, with the aim to communicate a critical approach to 
psychoactive substances (risk competence) as well as alternatives to drug use. Here, youth 
social work in recreational settings plays an important role: although addiction and the 
use of addictive substances are not treated as issues of primary relevance, they are still ad-
dressed repeatedly. In Lower Austria, the services provided in the context of street social 
work are expanding: GOOSTAV at Deutsch Wagram (GOOSTAV 2007) is a new service pro-
vider in this field, and MOJA’s activities now encompass additional towns (MOJA 2007). In 
Vienna, new approaches to secondary prevention were discussed at the expert meeting on 
current developments in work with young people at risk of becoming addicted (Sucht- und 
Drogenkoordination Wien 2007). 
The members of the club and party scene have been identified as a specific at-risk group. 
In the Tyrol, MDA basecamp focused its activities on girls and young women in 2006 (MDA 
basecamp 2007). It had shown that the share of female drug users was markedly higher in 
the drug counselling centre for young people and in the online counselling services provided 
by MDA basecamp than at the information stands at parties and events, therefore specific 
counselling and information services will be planned in cooperation with existing centres, on 
the basis of a questionnaire survey among girls and young women. Baumgartner (2007) rec-
ommended specific assistance services at freetekno events to target the ketamine users in 
the scene (see Chapters 2.3 and 7.2). Central requirements for this type of assistance in-
clude the involvement of physicians because medical emergencies have occurred rather of-
ten, combined with providing information and counselling, and frequent presence at events 
(three to four times a month). The latter is important in order to keep in touch, as these 
events often are not announced and take place at remote locations. In summer 2007 the 
secondary prevention project ChEck iT! offered its services at a freetekno party for the first 
time and was able to analyse a considerable number of samples, and information talks and 
counselling took place as well (VWS 2007b). Since 2007, ChEck iT! has also run its home-
base centre in Vienna where, in addition to various counselling services, theme-centred eve-
ning events are organised at regular intervals. 2006 also saw the production of a number of 
fact sheets on various recreational drugs. The plans for the next few years include the ad-
vancement of the toxicological analysing procedures and intervention research (VWS 
 
18 www.encare.at
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2007a). In this context, a questionnaire on the use of the ChEck-iT! homepage was drawn 
up, which is now available online. 
In Vorarlberg, Supro has run a youth orientation project which especially addresses young 
people who have shown problems for the first time. By means of early intervention and 
early detection, crisis intervention and networking of system partners at local level, specific 
assistance is provided19. In addition to a group training programme on early intervention, 
which is run in cooperation with the courts, the police and outpatient addiction counselling 
centres, specific measures and new services are drawn up on the basis of an analysis of cur-
rent demand, and the young people are offered assistance in social education centres. 
Immigrants form the target group of Vorarlberg’s Migration and Addiction Platform, which 
aims to raise awareness of the issue of addiction in particular among parents and young 
people of Turkish origin and to make it easier for the young people concerned as well as their 
parents to get access to information and existing assistance services20. The corresponding 
measures and projects are planned and implemented by three working groups. 
3.3 Indicated prevention 
Indicated prevention in the sense of the EMCDDA definition (see above) has not been an is-
sue of discussion in Austria nor has it been implemented so far. This has been confirmed by 
talks with experts in the field of addiction research and prevention. In addition to general pre-
vention, also measures for specific target groups are taken in Austria, but this is always 
linked to social factors (e.g., children in families with addiction problems). The treatment of 
children and young people with behavioural problems such as ADHS is not regarded as ad-
diction prevention in Austria. 
An approach that might cover aspects of this definition is the cooperation existing since au-
tumn 2005 between the Drug Counselling Centre of the Province of Styria and the Depart-
ment of Child and Youth Neuropsychiatry of the Sigmund Freud Provincial Neurological Hos-
pital. The objective here is to get into contact as early as possible with drug abusing young 
people undergoing inpatient treatment or who receive counselling at an outpatient depart-
ment. The fact that drug counsellors are present regularly has met with a positive response 
and made it easier for the young people to turn to the counselling centre during or after their 
stay in hospital (Drogenberatung des Landes Steiermark 2007). However, the reasons why 
the young people are admitted as inpatients are very heterogeneous: they range from prob-
lems resulting from substance use to autoaggression or running away from home as other 
frequent reasons, while the problem of drug use as such is only raised during the stay in 
hospital. Thus, these activities do not exactly meet the EMCDDA’s definition of indicated pre-
vention. 
 
19 www.mariaebene.at (24 May 2007) 
20 www.mariaebene.at (4 June 2007) 
23
4 Problem Drug Use 
Problem drug use here means the frequent use of “hard drugs” (in particular opiates and co-
caine), which is often accompanied by dependence and consequences for the health, social 
and legal situation of the consumers (see also Chapters 6, 8 and 12). One has to bear in 
mind, however, that it is primarily patterns of use and not substances as such that are risky 
or safe. In addition, it is difficult to distinguish between experimental use and problem drug 
use. This problem is further aggravated by the fact that hardly any scientific analyses are 
available in this field. 
In Austria, poly-drug use with opiates, often administered intravenously, has traditionally 
played a central role. In the past decade the range of substances consumed in the context of 
poly-drug use has widened. Intravenous use of cocaine has also become more relevant in 
the street scene. However, now that nationwide data on patterns of use among clients of the 
drug counselling system in 2006 have been available for the first time, it has shown that opi-
ates continue to play a predominant role as primary drugs. 
According to recent estimates, a prevalence rate of 25 000 up to a maximum of 35 000 prob-
lem opiate users, probably in the context of multiple drug use in the majority of cases, seems 
realistic for Austria. However, prevalence estimates of problem drug use are difficult to give 
as methodological problems arise due to the complexity of the subject, and the figures ob-
tained are conclusive to a limited extent only. Thus any results given are rough approxima-
tions and have to be interpreted with caution. 
4.1 Prevalence and incidence estimates of PDU 
In Austria scientific estimates regarding the prevalence of problem drug use are only avail-
able for opiates or poly-drug use with opiates. The most recent data that are available (see 
above) refer to the year 2004 and have already been presented in more detail in the report of 
2006 (GÖG/ÖBIG 2006; see also ST7). The data gathered in the context of Austria’s uniform 
documentation and reporting system of clients of Austrian drug help centres (DOKLI)21 pro-
vide important insights regarding the interpretation of the results of prevalence estimates. On 
the one hand, it shows that opiates play a predominant role in the context of drug use that is 
relevant for treatment. This means that the prevalence estimate mentioned above covers a 
large part of drug use relevant for treatment. On the other hand, it also reveals that nasal use 
of opiates plays an important role especially among younger opiate addicts (see Chapter 
12.1). Therefore, different to previous assumptions, the prevalence data obtained cannot be 
regarded as equivalent to the prevalence rates of i.v. drug use (see Chapter 4.2). 
 
21 In the DOKLI documentation system, which was established on behalf of and financed by the BMGFJ, nationwide data on cli-
ents of drug help centres are centrally collected and analysed at GÖG/ÖBIG in accordance with the documentation standards 
of the EMCDDA. (for details see http://tdi.oebig.at and GÖG/ÖBIG, under preparation). With the exception of the province of 
Vorarlberg, which reports only data from the inpatient drug treatment sector, a major part of Austria’s drug help system is 
covered by the DOKLI system. The corresponding data may thus be regarded as highly representative regarding the drug 
help network of Austria. Results from the DOKLI system are presented in Chapters 4.2, 6, 8, 12 as well as in ST3 und ST34). 
A separate report is under preparation (GÖG/ÖBIG 2007a).
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4.2 Treatment demand indicator 
The year 2006 is the first for which data from the DOKLI nationwide documentation system of 
clients of Austrian drug help centres are available. When interpreting the results, one has to 
bear in mind that, while double counts of clients of one centre can be excluded, due to the 
aggregate character of the data double counts of clients who turned to several centres in 
2006 cannot be avoided. The share of such cases of multiple treatment can only be guessed 
at. The report of Vienna’s BADO Basic Documentation (see GÖG/ÖBIG 2006, IFES 2005b) 
gives a general idea of the magnitude of this aspect as in the case of BADO, double counts 
of clients who contacted several drug help centres during the reporting period can be de-
tected by means of an identifier. In 2004, 14% of the clients registered in BADO were pro-
vided services by more than one centre (10%: 2 centres; 4%: more than 2 centres – see 
IFES 2005b). However, as drug help centres are more easily accessible in Vienna due to the 
higher geographical density compared to rural areas, the share of double counts might be 
slightly smaller in the rest of Austria. 
As not all cases of treatment that was started before 2006 were documented retrospectively, 
the DOKLI data generally refer to those persons who started to undergo drug treatment in 
2006 (= all treatments). The Austrian drug help centres covered by the DOKLI system re-
ported data on a total of 4 200 people who started long-term outpatient treatment in 2006. 
For 1 949 of them it was their first drug-specific treatment in life (= first treatments). 1 403 cli-
ents began long-term inpatient treatment, 211 of them received long-term treatment for the 
first time in life. In addition to people undergoing drug-related treatment in a strict sense, 
DOKLI also registered 563 new clients of low-threshold assistance centres, and 5 089 
people receiving drug counselling in the form of short-term contacts.
Between one out of four and one out of five people undergoing treatment or receiving assis-
tance are younger than 20 – with the exception of people treated in the context of inpatient 
settings, where this share is 12%. Around half of the clients are between 20 and 29 years old 
(see Figure 4.1 and Table A23 in Annex A). 
Figure 4.1: Number of people starting drug-specific treatment in 2006, by age and type of treatment  
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Source: GÖG/ÖBIG, DOKLI analysis of client year 2006; representation by GÖG/ÖBIG 
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In all settings analysed, the share of women was between 25% and 30%. This roughly corre-
sponds to past experience (e.g. gender distribution regarding patients undergoing substitu-
tion treatment – see below – and drug-related deaths; see Chapter 6.1) and primarily seems 
to reflect the gender distribution with regard to problem users of illicit drugs. Generally speak-
ing (with the exception of short-term contacts) the share of women in people receiving treat-
ment tends to go down with rising age (see Figure 4.2). 
Figure 4.2: Share of women in persons starting drug-specific treatment in 2006, by age and type of 
treatment 
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Source: GÖG/ÖBIG, DOKLI analysis of client year 2006; representation by GÖG/ÖBIG 
This situation also shows in the data on substitution treatment and drug-related deaths and 
corresponds to experience reported from the majority of countries of the European Union 
(EMCDDA 2006). In addition, the DOKLI system reveals that women are younger at the time 
of first use of most substances and also start intravenous drug use slightly earlier than men 
(see below). These data are confirmed by studies and analyses of recent years, which also 
reveal that women begin to show problem patterns of drug use at a younger age but also 
seem to stop drug use earlier, which, for instance, may be due to greater problem awareness 
or pregnancy (EMCDDA 2006, GÖG/ÖBIG 2007a, Haas 2005). 
In sum, approximately half of the clients are undergoing substitution treatment when they 
turn to the drug help centres (except short-term contacts, for which this aspect is not docu-
mented). Substitution treatments that are started only after the clients’ turning to the drug 
help centre have not been registered. 
In most cases, the clients contacted the corresponding drug help centres on their own initia-
tive. In the case of low-threshold assistance and inpatient treatment this was a predominant 
motivation for almost half of the patients, and for about one out of four people undergoing 
outpatient treatment. This is different with regard to short-term contacts, where court inter-
ventions (directives, obligatory therapy; 58%) constitute the primary impulse and other rea-
sons do not play an important role. Court orders are relevant triggers also in the case of long-
term outpatient (23%) and inpatient (19%) treatment, but not with regard to low-threshold as-
sistance. 
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The share of i.v. drug users (related to lifetime use) strongly depends on the treatment set-
ting (short-term contacts: 44%; low-threshold assistance: 66%; outpatient long-term treat-
ment: 46%; inpatient treatment: 82%; see Table A28 in Annex A). Women obviously start to 
use drugs intravenously at a younger age. In long-term outpatient and inpatient therapy set-
tings and in low-threshold contexts, the share of women who started to inject drugs before 
the age of 20 is higher than the corresponding share of men (e.g., 64% v. 51% in the case of 
long-term outpatient treatment). This is in line with other data and analyses from the field of 
drug monitoring and might be explained by the fact that girls are ahead of boys in their de-
velopment during adolescence (see ÖBIG 2005, Haas 2005).  
In the conventional treatment sector, opiates definitely predominate as primary drugs22. What 
is surprising is that cocaine only plays a marginal role as a primary drug (see Figure 4.3 and 
Table A27 in Annex A). 
This shows that in Austria, different to a number of other countries of the European Union, 
opiates (continue to) play a central role in the context of drug use relevant for treatment (see, 
e.g., EMCDDA 2006). What is surprising is the large shares accounted for by cannabis as a 
primary drug in all settings. However, this can be qualified due to the fact that a fairly high 
percentage of persons who are referred to compulsory treatment through the judicial system 
used cannabis as their sole primary drug. For instance, this applies to 61% among clients 
undergoing long-term outpatient treatment. 
 
22 For compiling the DOKLI case history, clients are first asked which drugs they have ever taken. Then the drugs mentioned 
are classified according to current patterns of use, as primary drugs, additional drugs, drugs only taken in the context of ex-
perimental use and drugs not relevant for treatment. The primary drug is the drug which causes the greatest problems from 
the personal point of view of the client. Here, problems – on the basis of ICD 10 – are understood as psychosocial and health-
related problems and not solely legal problem situations. As a rule, the primary drug also is the drug because of which the cli-
ent has started the current treatment. If a client cannot decide on a certain drug as their primary drug, several drugs may be 
named. Additional drugs are drugs which the client has used in addition to the primary drug in the past six months and which 
also constitute a problem for the client. Experimental drug use refers to intermittent use of the corresponding drug in the past 
six months without harmful use or manifest addiction problems. Drug use not relevant for treatment means that the drug in 
question has occasionally been taken for more than half a year but without harmful use or manifest addiction problems, or if 
the drug was used in the past but not during the six-month period preceding treatment (GÖG/ÖBIG 2007a). 
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Figure 4.3: People starting drug-related treatment in 2006, by primary drug and type of treatment 
 
Note: multiple answers were permitted. 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006; representation by GÖG/ÖBIG 
Only few gender-specific differences regarding primary drug have been found. In inpatient 
and outpatient settings as well as in the context of short-term contacts, women name opiates 
as primary drugs more frequently and cannabis less often than men. With rising age, opiates, 
cocaine and tranquillisers/hypnotics are indicated as primary drugs increasingly often – with 
the exception of inpatient treatment settings, where this trend only shows with regard to opi-
ates. Cannabis, on the other hand, is named less often by older clients in all settings. 
Further information on age of first use and predominant form of administration is available 
only for clients undergoing long-term outpatient and inpatient treatment. Regarding median 
age of first use it has shown that it is between 17 and 20 years for the majority of drugs. It is 
lower only in the case of cannabis (15 years), solvents and inhalants (15 years) and alcohol 
(14 years). What is consistent compared to the results regarding intravenous drug use (see 
above) is that as a rule women are one year younger than men when they use drugs for the 
first time (see Figure 4.4). 
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Figure 4.4: Age of first drug use (median) of persons starting long-term outpatient treatment in 2006, 
by substance and gender 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006; representation by GÖG/ÖBIG 
Regarding the predominant form of heroin use, the data relating to long-term outpatient 
treatment confirm the surprising observation reported to BADO (Vienna) in the last few years, 
namely that snorting is indicated more often (50%) than i.v. use (42%). 
Figure 4.5: Predominant form of administration of heroin (n = 1 892) and cocaine (n = 1 999) among 
people starting long-term outpatient treatment, by age 
Source: GÖG/ÖBIG, DOKLI analysis of client 2006; representation by GÖG/ÖBIG 
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While the majority of clients undergoing inpatient treatment indicated intravenous drug use 
(54%), the share of snorters (41%) is still high also in this group. However, it shows that with 
rising age, the percentage of injecting users is increasing considerably (see Figure 4.5). 
These findings could mean that the longer a drug career is, the  more readily users tend to 
switch from snorting to injecting drugs. 20% of clients in outpatient settings and 40% of peo-
ple undergoing inpatient treatment administered cocaine intravenously. Also in the case of 
this drug, an increase of injecting use as clients grow older is registered. Around two thirds of 
amphetamines are taken nasally, and one third, orally. 
National monitoring of substitution treatment is performed by the BMGFJ and based on the 
reports of attending doctors. Although these reports are not always complete and frequently 
not provided in due time (see ÖBIG 2003), they still give a general impression of both quanti-
tative developments and characteristics of clients. A significant deficit regarding data quality 
is the problem of ghost cases23. In order to get this problem under control, the BMGFJ 
started to take comprehensive correction measures in 2007, based on enquiries to attending 
doctors. In addition, the amendment to the Narcotic Drugs Decree (see Chapter 5.3), which 
entered into force on 1 March 2007, has been likely to improve the completeness of reports. 
As a result of these corrections and new developments, a number of discrepancies in com-
parison to the figures reported in previous years have shown, but they hardly have any ef-
fects on the trends described. Only the rise in the number of treatments registered and in 
particular of first treatments from 2005 to 2006 may (in part) also have been caused by the 
increased coverage of cases. 
The growing acceptance of, and resort to, substitution treatment is reflected in the annually 
rising number of persons reported as currently undergoing substitution treatment (see Fig. 
4.6). 
Figure 4.7 shows that the rise in first treatments in recent years has primarily been ac-
counted for by the age group up to 19 and the group between 20 and 24. From 1995 to 2000 
the share of these two groups was between 35% and 40%, continuously rising since then to 
52% in 2004. In 2006 it was 50%. On the one hand this increase may indicate easier access 
to substitution treatment for young opiate users. On the other, it may also point to an in-
crease in prevalence rates of (poly-)drug use with opiates (see GÖG/ÖBIG 2006). What is 
also interesting in this connection is that the rise in first treatments considerably differs ac-
cording to region. While the corresponding numbers have remained roughly the same in 
Carinthia, Upper Austria and Salzburg, a rise has been registered in Lower Austria, Styria 
and Vienna (BMGFJ, calculations by GÖG/ÖBIG; see Table A21 in Annex A). However, also 
this context, one should bear in mind that the amendment to the Narcotic Drugs Decree (ob-
ligation to report substitution treatments) might have influenced the situation, and possibly to 
different degrees in the individual provinces. 
 
23 If the end of treatment is not reported, the corresponding clients appear in the statistics as people currently undergoing treat-
ment also in the years after the actual end of treatment (= ghost cases; for details see GÖG/ÖBIG 2006). 
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Figure 4.6: Development of annual registrations of persons currently undergoing substitution treatment 
in Austria by first treatment and continued treatment, from 1997 to 2006 
 
Note: continued treatment means treatment started before the respective year or repeated treatment of persons already hav-
ing undergone substitution treatment in the past. First treatment means treatment of persons who have never been in 
substitution treatment before. Any differences to the figures given in previous years (GÖG/ÖBIG 2006) result from correc-
tion on the part of the BMGFJ. 
Sources: BMGFJ, calculations by GÖG/ÖBIG; representation by GÖG/ÖBIG 
Gender-related analyses show that the share of women in persons undergoing substitution 
treatment for the first time has been between 25% and 35% over several years. In 2006 it 
was slightly lower, i.e., 22%. In this year, as in previous years, the share of women in the 
group under 20 undergoing treatment for the first time (37%) was higher than in the other 
age groups, where men clearly predominated (see also ST3). This observation corresponds 
to the findings from the DOKLI system that have been described and interpreted above. 
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Figure 4.7: First substitution treatment in life, by age, from 1997 to 2006 
 
Sources: BMGFJ, calculations by GÖG/ÖBIG; representation by GÖG/ÖBIG 
4.3 PDUs from non-treatment sources 
Salzburg (Drogenkoordination des Landes Salzburg 2007) and Carinthia (Prehslauer, per-
sonal communication; see Chapters 1.1 and 2.1) provided analyses of patterns of use among 
persons examined according to Section 12 of the SMG (i.e., because of a reasonable suspi-
cion of drug abuse and who, after a report to the police, information by a heads of school, a 
military agency or driving licence authority, were medically examined with regard to the need 
for undergoing a health-related measure). It shows that use of cannabis predominates in this 
group of persons (Salzburg: 89% out of a total of 379 examinations; Carinthia: 76% out of 
805 examinations). In Salzburg, 11% of the examinations were related to opiate use, com-
pared to 6% in Carinthia. The shares for cocaine are 13% and 7%, respectively. 
Graz reported the results of a non-representative scene study among injecting drug users, 
which was carried out in the context of planning a drug treatment contact point (see Chapter 
7.2). A total of 102 intravenous drug users (71% men, 29% women) among the clients of the 
Kontaktladen and Streetwork low-threshold centres were interviewed. The average age of 
the respondents was 27 years. 75% of them were undergoing substitution treatment at the 
time of the survey. 98% of the respondents indicated experience of heroin consumption (av-
erage age of first use: 18 years), 95% reported cocaine use (average age of first use: 18), 
99% had experience of substitution substances (average age of first use: 22 years), and 86% 
reported experience of benzodiazepine use (average age of first use: 20 years). 72% of the 
respondents indicated injecting use as their preferred route of administration of both substitu-
tion substances and cocaine (no indications regarding preferred form of administration of 
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heroin). Nine percent said that heroin was their primary drug, 99% indicated substitution sub-
stances and 23%, benzodiazepines (no indications regarding cocaine as a primary drug; 
Zeder 2007). 
In recent years qualitative reports from a few provinces have pointed to a possible misuse of 
substitution medicines in the context of opiate consumption (e.g., Neubacher, personal 
communication; Mentlvilla, personal communication). This has been corroborated by the 
scene study among intravenous drug users of Graz (Zeder 2007) and the rise in seizures of 
substitution medicines described in Chapter 10.1 (see also Chapter 5.3). 
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5 Drug-Related Treatment  
Austria attributes great importance to a diversification of the available treatment options. As a 
result, in the past decade the inpatient sector saw a development from long-term to short-
term treatment and generally, to more flexibility with regard to possible kinds of therapy, for 
instance in the form of modular systems. The aim of this development is to take into account 
to a greater extent individual needs and the patients’ situation in life. This also means that a 
variety of substitution substances may be prescribed. In quantitative terms, substitution 
treatment has become the most important form of therapy in Austria, and efforts to improve it 
have continuously been made (see Chapter 4.2). 
Drug-specific counselling, care and treatment services are provided both by specialised cen-
tres and in the context of the general health care system (e.g., psychiatric hospitals, psycho-
social services, established physicians). These services, primarily in the outpatient sector but 
increasingly often also for inpatients, include both measures oriented towards drug-free 
treatment and substitution treatment, therefore they can be classified to a limited extent only. 
As the general aim is to build a comprehensive treatment and care network, most centres 
also organise a variety of preparatory and aftercare measures as well as recreational and re-
integration services (see Chapter 9.1) and also measures for specific target groups (e.g. 
young people or persons with psychiatric comorbidity). The Addiction Help Compass24 pro-
vides an overview of the whole range of available drug help services. In addition the web 
sites as well as the annual reports and newsletters of the individual centres and ÖBIG’s pre-
vious reports to the EMCDDA and the database of the EDDRA (see Bibliography) also give 
detailed descriptions of these services. 
5.1 Treatment system 
By now Austria has an almost nationwide network of drug-related counselling, care and 
treatment centres (see Maps 5.1 and 5.2). In 2006, inpatient and outpatient treatment or 
counselling related to addition or illicit substances were provided by a total of 194 specialised 
centres (investigations by GÖG/ÖBIG). As in previous years, there are still waiting lists, and 
waiting times have to be accepted (see GÖG/ÖBIG 2006). In a few regions the waiting time 
for the first counselling talk is up to six weeks, up to eight weeks until therapy may be started, 
and in the case of inpatient withdrawal treatment even up to four months. Several centres re-
port a rise in the number of clients needing intensive counselling and treatment, which takes 
more time. For instance, a larger number of cocaine users have turned to the Landeck coun-
selling centre in the Tyrol (B.I.T. 2007). 
In the reporting period, the treatment and counselling networks of Carinthia and Upper Aus-
tria were expanded. Villach (Carinthia) now has a new outpatient clinic for drug users 
(ROOTS), where counselling, diagnosing, care and treatment are available (Prehslauer,  
 
24 http://suchthilfekompass.oebig.at
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personal communication). Lower Austria started to build a new inpatient department for with-
drawal treatment in the hospital at Amstetten/Mauer (Hörhan, personal communication). 
In addition, activities have been undertaken to orient assistance and treatment services more 
specifically towards individual target groups and to address new groups. For instance, in 
Carinthia a strategy of outreach psychosocial assistance (system of reference assistance 
workers) was developed as a cooperation of the drug outpatient clinic of Klagenfurt and the 
Neustart association for persons with severe addiction problems. It has proven its worth and 
is now practised in both drug outpatient clinics of Carinthia (Prehslauer, personal communi-
cation). According to Carinthia’s new Addiction Plan (see Chapter 1.2), in future the provision 
of addiction-related services for young people will be transferred to the youth welfare system 
in order to promote social integration. In the Tyrol, a project group on uppers developed a 
new strategy for counselling settings regarding ecstasy use as a primary problem, which 
specifically addresses young users of designer drugs (B.I.T. 2007). Improvements in clinical 
psychology diagnosing aim to permit drawing up more specific counselling and treatment 
schedules at the B.I.T. association. In Graz, Styria, an action plan for early prenatal counsel-
ling as well as postnatal assistance for mothers undergoing substitution treatment is being 
prepared in the context of a cooperation between the competent Municipal Department and 
the Provincial Hospital. In addition, the activities targeting immigrants will be improved by re-
ducing language barriers and promoting sociocultural and migration-related background 
knowledge (Drogenberatung des Landes Steiermark 2007). In order to expand the services 
for women in Styria, a network focusing on the issue of women and addiction has been 
planned (see Chapter 7.4). In the context of a cooperation between the Walkabout therapy 
department and the Kontaktladen centre in Graz, monthly information talks on withdrawal 
and detoxification have been organised at Kontaktladen in order to make it easier to get into 
contact with drug users (see ÖBIG 2005, Kontaktladen 2007). Lower Austria aims to promote 
services adapted to specific regional needs by establishing drug advisory boards at local 
level. In Vienna, guidelines for gender mainstreaming in addiction and drug social work were 
published (Sucht- und Drogenkoordination Wien 2006) so that a gender-sensitive orientation 
of addiction assistance centres, services and research may be ensured in future. Work with 
the relatives of drug users is another focus of the counselling centres, which has played an 
increasingly important role. In autumn 2006, the Anton Proksch Institute organised the first 
networking meeting (ANGNET) in order to establish a network of all organisations that are 
active in the field of work with relatives, to make known the available services and to define 
perspectives for the future (ENCARE Österreich 2006). In this context, also a list of require-
ments regarding aspects such as financing of assistance services for relatives of addiction 
patients was drawn up. 
b.a.s, Styria’s Society for Addiction Issues, published a paper of principle25, which aims to 
make transparent the ethical attitude that b.a.s. pursues in its work in the field of illegalised 
drugs: while an orientation towards abstinence is maintained as an objective, what takes 
precedence at the start of treatment is the dialogue between the counsellor and the client, 
which is relevant for deciding on the concrete treatment process. 
 
25 www.bas.at (25 May 2007) 
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The reporting period again saw a number of events that aimed to improve networking and 
cooperation as well as to analyse the current situation and services, the potential for im-
provement and to discuss addiction-related topics. A new edition of the publication on opiate 
addiction by Beubler et al. (2007) has been printed; it focuses on promoting a rational ap-
proach to opiate addiction. Therefore a number of new articles on various medical problem 
fields, the practice of examinations, fitness to drive, psychosocial assistance and treatment 
by means of heroin were included. 
5.2 Drug-free treatment 
No relevant changes took place in the field of drug-free treatment. In Austria withdrawal 
treatment is primarily carried out in inpatient departments, but more and more often also in 
outpatient settings. Generally, the trend towards more flexible programmes of differing dura-
tion has continued in Austria. The Anton Proksch Institute (API), because of little demand, 
did not prolong its offer of a three-month short-term therapy for persons having undergone 
withdrawal treatment at another institution. Several treatment institutions have registered a 
rising demand for withdrawal treatment as well as for inpatient alternatives to this type of 
treatment, which the API will cover by means of a programme aiming at stabilisation and 
psychological recovery in a drug-free protective environment where assistance is available 
and where partial withdrawal treatment (e.g., alcohol, cocaine) is possible (API 2007). Addi-
tional plans include inpatient crisis intervention and relapse treatment as well as special pro-
grammes for cocaine users. In all types of service, a certain number of places is reserved for 
young people. As a first step the number of beds at the withdrawal department was in-
creased from 20 to 24. In the medium run, also rebuilding measures will become necessary 
so that different treatment services may be provided simultaneously. From the point of view 
of the API an increase in the six-months programme parallel to a downwards trend regarding 
twelve-month treatment is to be expected in the field of inpatient long-term therapy, and 
strategies for chronified courses of disease should be considered. 
The Lukasfeld therapy department (Vorarlberg) reports good results regarding the approach 
of encouraging the patients’ active participation in decision-taking processes26. In 2006 a 
working group was established to deal with the issue of self-inflicted injuries: a systematic in-
vestigation of persons treated has now been started. 
A state-of-the-art paper by the Austrian Association for Psychiatry and Psychotherapy 
(ÖGPP) points to the fact that regarding opiate withdrawal treatment, the state of the art is to 
administer decreasing doses of opioids (Fischer and Kayer 2006) and that buprenorphine 
seems to be the best substance for this purpose. 
 
26 www.mariaebene.at (24 May 2007) 
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Map 5.1: Specialised providing treatment, counselling and care services for drug users and drug patientscentres
2 Number of centres (to the right of the symbol) if more than
one centre of the category in question is available in one district
Inpatient centres for short-term treatment
Inpatient centres for physical withdrawal
Outpatient drug centres and departments
Low threshold centres
Counselling centres
Outpatient counselling centres (open less than 15 hours/week)
Inpatient centres for long-term treatment
Therapeutic centres in prison
(Sopron/
Hungary)
Note:
The map provides an overview of selected drug-related centres, broken down by district. The map does not specify quantitative and qualitative aspects (i.e., opening hours or number and qualification
of personnel, respectively). However, a distinction was made in the field of counselling, which is frequently provided by general centres covering a broader range of services (psychosocial counselling
centres,addiction counselling centres, etc.) though limited to a few hours a week. Specialised drug counselling centres with limited opening hours have been listed seperately (see legend). Please no-
te that in addition general services (e.g., general practitioners, hospitals) are available for drug users and addicts - they are not included in this map.
Source: GÖG/ÖBIG - based on information by the Drug Coordinators and Addiction Coordinators, as of August 2007  
u3l3
l
n
vu
u
u
u
q2
q
l
r
p
u
r2
r
r3
r3
<
r3
<
q5
n
<7u3
p2
u
u
<
r2
<
v
<
<
v v2
u
u
vu2
<
<
<
<
<
u
l2
r
q
v
p
n
u
l
< l3
<
l
r
r
r
r
r r
r
r
r
r
r
r
l
r
r
v
n
l
l3
l
r
r
r
r
r
r
r
r
r
r
r
r
<
<
<
<
<<
<
<
<
<
r
r
Prevention of infectious diseases - testing and vaccination
Outreach work (Streetwork, bus, connection services, mobile youth work, etc.)
Housing for former drug addicts - aftercare (HalfWayHouse, housing communities, etc.)
Housing for drug addicts (temporary sleeping facilities, etc.)
Occupation projects for drug addicts (low threshold)
Occupation projects for former drug addicts (aftercare, reintegration, etc.)
Prevention of infectious diseases - syringe exchange and distribution
Outpatient psychotherapy for drug addicts
2 Number of services (to the right of the symbol) if more than
one service of the category in question is available in one district
Map 5.2: Specialised treatment, counselling and care for drug users and drug patientsservices
Note:
The map provides an overview of selected drug-related services, broken down by district. The map does not specify quantitative and qualitative aspects (i.e., opening hours or number and qualificati-
on of personnel, respectively). It distinguishes between kinds of service and not centres (see Map. 5.1), therefore a single centre can appear in several categories. Please note that general services
(e.g., the public employment service or emergency shelters) are also available for drug users and addicts - they are not included in this map.
Source:GÖG/ÖBIG - based on information by the Drug Coordinators and Addiction Coordinators, as of August 2007  
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5.3 Pharmacologically assisted treatment 
The framework of substitution treatment changed when the corresponding decrees27 entered 
into force on 1 March 2007 (see Chapter 1.1). The relevant changes were explained and an-
nounced by means of the Introductory Ordinance by the BMGFJ of 26 April 2007. The objec-
tive of the new decrees is to unify and optimise substitution treatment and to reduce the 
abuse of slow-release morphine (see Chapter 4.3). Still, the amendments continue to be con-
troversial issues of debate among experts (GÖG/ÖBIG 2006). The most important details of 
the ensuing changes in substitution treatment are briefly described below. The Further Train-
ing Decree has already been described in the report of last year. 
In the case of people addicted to opioids for a relatively short time only (< 2 years) and in the 
case of very young people (younger than 20) it should very carefully be considered if alterna-
tives to drug-free therapy were sensible indeed. Persons under 18 are eligible for substitution 
treatment only if this is the only possibility to avoid further addiction-related harm. In these 
cases, an expert opinion by a psychiatrist or youth psychiatrist (or alternatively, also the ex-
pert opinion by a physician working in an institution in a relevant field according to Section 15 
of the SMG) should be obtained. 
Methadone and buprenorphine are to be prescribed primarily while other substances such as 
slow-release morphines should only be administered if the former two substances are contra-
indicated. The person defining the stabilising dosage has to issue a substitution certificate 
that specifies the type of substitution medicine and the daily dose, which has to be submitted 
to any person in charge of further treatment, for inspection and completion if necessary. The 
person deciding on the dosage or the person in charge of treatment has to report every sub-
stitution patient to the BMGFJ for entry in the substitution registry. 
The attending physician has to prescribe the controlled administration of the substitution 
substance, i.e., it has to be taken under supervision every day. On principle, apart from bu-
prenorphine prescriptions and administration on weekends or holidays, exceptions are ad-
missible only in individual cases: if the substitution patient is in a stable condition and if there 
is evidence that the patient is unable to take the daily dose of substitution substance under 
supervision due to their work, education and training programmes, certain temporary reasons 
(e.g., holidays, disease) or also long-term reasons that deserve special consideration. Slow-
release morphine may be dispensed to patients to take along only if there is no other way of 
ensuring the availability of the substitution substance under conditions of controlled admini-
stration and if the substitution patient has been treated by the same person for at least six 
months (12 weeks in the case of other substitution substances). Exceptions regarding daily 
doses and minimum period of treatment may be granted after consultation with a public 
health officer if the attending physician regards this as necessary and if the reason for this is 
documented. The aim here is to restrict the dispensation to take along substitution sub-
stances to such cases where the patient’s stabilisation and psychosocial integration has pro-
 
27 Novelle zur Suchtgiftverordnung (Amendment to the Narcotic Drugs Decree), Federal Collection of Statutes BGBl II 2006/451, 
and Weiterbildungsverordnung orale Substitution (Oral Substitution Further Training Decree), BGBl II 2006/449 
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gressed and if there is no suspicion that the substance in question could be used in another 
way as for the intended purpose, i.e. diverted into the black market. 
From the point of view of a number of physicians, the provisions described above constitute 
a massive encroachment on their treatment competence, and in addition objections regard-
ing data protection have been voiced. Eventually it is criticised that the provision on psycho-
social assistance was changed from discretionary to obligatory. However, there are also ex-
perts concerned who welcome the amendment and e.g., regarding data protection, agree 
with the Ministry of Health that a more intensive exchange between the agencies involved is 
necessary. At provincial level, an error management system is to be established in the form 
of expert commissions including the Addiction or Drug Coordinators, the Medical Association 
and Public Health Departments, in order to deal with cases in which this exchange does not 
work as intended. At federal level, a committee on the quality and security of substitution 
treatment was established, which will focus on questions and problems of substitution treat-
ment on the basis of the scientific state of the art. 
By 30 June 2008 the BMGFJ has to present an evaluation of the effects of the new Decree. 
A few provinces report a decline in established physicians providing substitution treatment 
(e.g., Lower Austria and Upper Austria), which has led to bottlenecks in the provision of this 
service and counteracted efforts to widen the basis of treatment (e.g., Salzburg). In part, this 
development is attributed to additional paperwork that is now required and the obligation to 
obtain further training. On the other hand, there are also regions where interest in further 
training does exist. For instance, in Styria 50 physicians and 20 public health officers regis-
tered for further training (Ederer, personal communication). Vienna reports that as a conse-
quence of the stricter regulations for dispensing substitution substances that may be taken 
along, the cases of controlled administration of substitution substances have markedly risen. 
Nevertheless, further increases in the number of substitution patients have been registered in 
Vienna (Pietsch, personal communication). 
Parallel to the commencement of the amended Decree, a special remuneration item for phy-
sicians was introduced in the Tyrol, similar to Vienna’s performance-oriented remuneration 
system, so that the costs of providing substitution therapy can be taken over by the social in-
surance funds. 
In autumn 2006 Carinthia established the first quality circle of addiction medicine in order to 
ensure the quality of treatment, and a check list of safety criteria was drawn up that may 
serve as a reference document regarding the dispensation of substitution substances to pa-
tients to take along. In addition, a treatment standard for outpatient clinics was defined and a 
paper on substitution treatment was prepared for public health officers that lays down rules 
for the communication between attending and supervising physicians in the context of the 
amended Decree. The newly established Austrian Society of Pharmacologically Assisted 
Treatment of Addiction (ÖGABS; see Chapter 7.2), drew up an expert statement on the new 
regulations for substitution therapy and its practical implementation28.
28 www.medical-tribune.at (4 June 2007) 
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The ÖGPP’s state-of-the-art paper mentioned above (Fischer and Kayer 2006) underlines 
that while a drug-free life continues to be a long-term goal of pharmacologically assisted 
treatment, a therapy of long-term stabilisation accompanied by psychological education has 
become the state-of-the-art treatment. The doses of opioids prescribed should be reduced 
step by step, and slowly, and this should only be started after a long period of treatment 
(from several years to decades), provided the patient has not taken other additional sub-
stances that had not been prescribed. Short-term intervention is not thought to be helpful 
(with regard to sustained abstinence) and the involved risk of elevated acute mortality is also 
underlined. The authors refuse to recommend a certain substance that should be preferred. 
Regarding the provision of substitution medicines that patients may take home, it is stated 
that this is sensible in a number of cases and contributes to enhanced self-responsibility on 
the part of substitution patients. However, it is not regarded as advisable only during the first 
three weeks of treatment or in cases of irregularity or increasing psychopathological prob-
lems. Regarding slow-release morphines, an attitude of great diligence is recommended. 
The experience that the H.I.O.B. counselling centre in the province of Vorarlberg has made 
with regard to intensive care substitution (see GÖG/ÖBIG 2006) shows that high quality sub-
stitution treatment exclusively with methadone and buprenorphine is possible if it is accom-
panied by committed medical and psychological care measures (Mayrhofer, personal com-
munication). As problems arose with regard to slow-release morphines (see GÖG/ÖBIG 
2006, in the first half of 2006, all persons formerly substituted with these substances were 
prescribed methadone instead. This did not lead to negative consequences, and in the case 
of a few persons, even a positive development showed. Recently, the focus of implementa-
tion of intensive care substitution has been placed on establishing a smooth interdisciplinary 
cooperation of the entire team, which also meant that a unified formal framework had to be 
defined and a harmonisation of methods adopted had to be ensured (H.I.O.B. 2007). 
The nationwide decrease in reports of first treatments with slow-release morphines that was 
mentioned in last year’s report (see GÖG/ÖBIG 2006) has not continued. In 2006 the share 
of substitution patients taking methadone in the total of first treatments registered in Austria 
was 38%, while 31% of patients were treated with slow-release morphines, 30% took bupre-
norphine and 1%, codeine (see Figure 5.1). 
Still, an analysis of DOKLI data (see Chapters 4.1 and 4.2) shows that in the group of substi-
tution patients registered there, slow-release morphines are the substance that is taken most 
frequently: it was prescribed to 55% of clients receiving low-threshold assistance and 66% of 
patients undergoing long-term outpatient treatment. Only one out of four substitution patients 
of each group was prescribed methadone, and buprenorphine played a major role primarily 
in the youngest age group. These figures differ from the substitution monitoring data of the 
BMGFJ, which might be due to a number or reasons: on the one hand, the substitution data 
analysed by DOKLI – different to the BMGFJ’s substitution monitoring – do not relate only to 
first treatments, and on the other, until 1 March 2007, it was not obligatory for all attending 
physicians to report treatments to the BMGFJ for entry in the substitution registry, therefore 
the data are incomplete (see Chapter 4.2). It should also be taken into account that data from 
the field of established physicians are not included in the DOKLI system and as 2006 is the 
first year that was analysed, the data cannot be compared to those of other years. The dif-
ferences found may be due to differences in the prescription practices of low-threshold cen-
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tres, counselling and care centres and established physicians, and effects on new treatments 
of changes in the legal situation may also be felt. This can only be verified in future years, 
however, and if checks against other data sources are made. A more detailed interpretation 
of the data does not seem to make sense at present.  
Figure 5.1: Development of kinds of substitution substance used for first treatment, from 1999 to 2006 
 
Source: BMGFJ, calculations by GÖG/ÖBIG; representation by GÖG/ÖBIG 
Finally, two studies deserve mention that investigate the current situation in life of substitu-
tion patients. The study by Angerer and Popig (2007)29 shows that substitution treatment re-
sults in a number of positive developments of the patients’ situation. Almost all respondents 
indicated that the long-term goal they pursued with this treatment was to improve their physi-
cal and mental state of health. The majority said that access to substitution treatment was 
easy and adequate. The level of satisfaction with the substance, doses and oral way of ad-
ministration was very high, namely 83%, independent of the duration of substitution treat-
ment. When asked what could be improved the respondents primarily mentioned the regula-
tions for dispensation of substitution substances to take along, but a wider range of available 
substitution medicines was also demanded. Many respondents voiced the opinion that a con-
trolled dispensation of heroin would help to reach a larger number of opiate addicts. 
 
29 Carried out in 2005/6, the study is based on interviews with experts at the preparatory stage and interviews with persons who, 
at the time of the survey, were undergoing substitution treatment in Upper Austria. 429 out of a total of 829 questionnaires 
were returned and analysed by means of SPSS.  
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The study by Huber (2006)30, which focuses on the personal perspectives of substitution pa-
tients in their sociocultural environment, confirms the positive effects that were felt regarding 
substitution treatment combined with psychosocial assistance. In addition to support services 
provided in the context of substitution programmes, what is also important for the integration 
of substitution patients is the availability of additional resources. People suffering from addic-
tion who cannot rely on support by their families strongly depend on psychosocial services in 
the context of substitution therapy. 
 
30 The study was carried out in 2005/6 and is based on qualitative interviews with six selected persons who at the time of the 
study were undergoing substitution therapy at the SMZ Liebenau hospital in the province of Styria. The selection criteria in-
cluded gender, social background, age, period of former drug use as well as reliability, i.e., that the respondents actually 
managed to come to scheduled meetings. 
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6 Health Correlates and Consequences 
The Ministry of Health has collected data on drug-related deaths in Austria since 1989. After 
the mid-1990s the overall number of directly drug-related deaths went down temporarily. In 
recent years, however, a rise has again been registered 
Infectious diseases are relevant in particular because of the risk of transmission due to intra-
venous drug use. The available data in this context are based on a few small samples from 
treatment institutions or low-threshold centres. While the HIV prevalence rate still was around 
20% in the early 1990s, it has remained at a low level since then (1% to 6%). However, the 
prevalence rate of hepatitis C-Ab has remained around 50%, and in the case of hepatitis B it 
is below 30%. 
Psychiatric comorbidity in the context of drug dependence has increasingly often been dis-
cussed in Austria. Although no routine data have been collected in this field, many data and 
reports from the treatment sector are available. These data indicate a high prevalence of 
psychiatric comorbidity (dual diagnoses) among problem drug users. 
6.1 Drug-related deaths and mortality of drug users 
Regarding drug-related deaths, a distinction is made between deaths directly caused by drug 
use and indirectly related deaths. The situation regarding indirectly related deaths is de-
scribed in Chapter 6.4. 
In 2006 the number of directly drug-related deaths (intoxications) rose to 197 (2005: 191 
cases, see Tables A3 and A4 in Annex A, ST5, GÖG/ÖBIG 2007b). In 23% of these cases, 
the toxicological analyses revealed only illicit substances (one drug or a combination of sev-
eral drugs). In addition, psychoactive substances were also found in 47% of the cases, in 
14% alcohol was detected as well, and 17%, both substances, i.e., alcohol and psychoactive 
drugs (see Tables A6 and A7 in Annex A). As in previous years, poly-drug intoxications with 
opiates clearly predominate (81% of all intoxications with known substances; see Figure 6.1). 
The share of persons who had exclusively taken opiates (16%) has slightly gone down com-
pared to previous years (2003: 25%; 2004: 22%; 2005: 18%). Patterns of multiple drug use, 
where the effects of different substances may be potentiating and thus are difficult to control, 
continue to be wide-spread and constitute serious health hazards (see Chapter 4).  
Chapter 6: Health Correlates and Consequences 
44
Figure 6.1: Number of directly drug-related deaths in Austria by cause of death, from 1997 to 2006 
 
Source: GÖG/ÖBIG 2007b; representation by GÖG/ÖBIG 
Figure 6.2: Age distribution of directly drug-related deaths in Austria, from 1997 to 2006  
 
Source: GÖG/ÖBIG 2007b; representation by GÖG/ÖBIG 
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Until 2002 the average age of persons who died as a direct consequence of drug use was 
rising. Since 2003, the grouped median31 has continuously gone down and was 24.6 years in 
2006 (2003: 28.4 years; 2004: 26.1; 2005: 25.9). The share of persons under 20 was at a 
similar level as in previous years (2003: 12%; 2004: 22%; 2005: 15%; see Figure 6.2). The 
share of persons between 20 and 24 years was 25%, which corresponds to the average of 
the last few years (2003: 23%; 2004: 22%; 2005: 25%). The share of women in directly drug-
related deaths, i.e., 21%, is in line with the long-term average. 
In 2006, the greatest number of drug-related deaths was registered in the province of Vi-
enna, which is not surprising as drug problems tend to be more pronounced in and around 
urban areas. In Vienna, 8.4 cases of directly drug-related deaths per 100 000 inhabitants 
aged between 15 and 64 were registered in 2006 (see Tables A4 and A7 in Annex A). Lower 
Austria ranked second, with 3.6 deaths per 100 000 inhabitants (GÖG/ÖBIG 2007b). Aus-
tria’s national average was 3.5 drug-related deaths per 100 000 inhabitants in 2006. 
The places where the persons concerned died have systematically been recorded for the 
second time now. This provides important information on locations where fatal overdoses 
typically occur. The first analysis of 2005 has already shown that the majority of directly drug-
related death occur in flats in private houses, which also applies to the year 2006 (79%; 
ÖBIG 2006, GÖG/ÖBIG 2007b). This may be interpreted to mean that a large part of high-
risk drug use takes place in private contexts, which, however, involves the risk that in the 
case of intoxication help may not be available quickly enough, which in turn increases the 
probability of fatal overdoses. In addition, analyses were made of diseases other than addic-
tion that were diagnosed in persons who had died as a direct consequence of drug use (see 
Chapter 6.4). 
Any variations in the number of directly drug-related deaths have to be interpreted with cau-
tion because their numbers are small in a statistical sense, and they must not at all be re-
garded as indicators of the development of the drug situation as such. However, as the num-
ber of directly related deaths has risen four years in a row until 2006, it is plausible to as-
sume that the situation regarding directly drug-related deaths has worsened. This should 
give rise to a consideration of specific health policy measures for risk minimisation. If other 
results from the field of drug monitoring (prevalence estimates, data from the treatment sec-
tor; see Chapter 4) are also taken into account, the rise in the number of drug-related deaths 
(also in view of the fact that the average age has gone down and has reached its lowest level 
so far) may be interpreted as an indicator of an increase in problem opiate use in Austria. 
6.2 Drug-related infectious diseases 
The available data for the reporting year provided by low-threshold centres and inpatient 
treatment institutions (see Table 6.1) point to hepatitis B (HBV) rates between 5% and 27% 
(2005: 0% to 28%). The hepatitis C antibody (HCV-Ab) prevalence rate of 2006 was between 
38% and 55%, which is lower than the level of the year before, i.e. 50% to 60%. The figures 
 
31 Grouped median means that 50% of cases are above this figure and 50% are below this figure. 
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regarding drug-related deaths also reflect this slight decline in HCV-Ab prevalence rates 
(2005: 32% and 48%, respectively; 2006: 19% and 32%, respectively, as the highest and 
lowest prevalence rates). The drug help centres again report low HIV prevalence rates be-
tween 0% and 3%, and the expert opinions on drug-related deaths indicate HIV prevalence 
rates between 4% and 7% (2005: 7% to 12%). The increase in HIV rates particularly among 
young i.v. drug users that was mentioned in our report of last year cannot be confirmed on 
the basis of this year’s data (GÖG/ÖBIG 2006). The nationwide data on infectious diseases 
provided by drug help centres for the DOKLI system for the first time generally confirm the 
HIV, HCV-Ab and HBV prevalence rates formerly taken from ST9 (see Table 6.1 and Chap-
ter 4.2). 
Table 6.1: Data on hepatitis B, hepatitis C-Ab and HIV infection rates in 2006 
Data source HBV rate HCV-Ab rate1 HIV-rate 
Lukasfeld therapy department 7% (2/29)2 38% (11/29)  0% (0/29) 
API long-term therapy department       17% (12/72)3 43% (31/72)  1% (1/72) 
Low-threshold centre Ganslwirt       27% (20/73)4 55% (44/80)  2% (2/113)  
Caritas Marienambulanz outpatient department 5% (5/97)5 52% (50/97)  0% (0/97) 
Drug outpatient department of General Hospital Vienna n.a.  44% (33/75)  3% (2/71) 
DOKLI6 21% (61/288)  54% (195/359)  1% (2/359) 
Drug-related deaths (intoxications) in 2006 n.a.  19% (37/197) 7 
32% (37/116) 7 
4% (8/197) 7 
7% (8/112) 7 
1 These prevalence rates relate to persons in whom HCV antibodies were found (HVC-Ab), and not to HCV-PCR tests, which 
permit a direct detection of the virus. 
2 This percentage relates to persons in whom antibodies to hepatitis B were found and whose medical history did not indicate a 
hepatitis B vaccination. 
3 This percentage relates to persons in whom antibodies to hepatitis B were found and for whom it was established that they 
had not received vaccinations or been cured. 
4 This percentage relates to persons in whom hepatitis B antibodies or antigens were found and who had not yet received 
hepatitis B vaccinations (data obtained from Ganslwirt’s vaccination project). 
5 Positive test results only refer to HBV-cAb positive and HBV-sAb positive results. In the reporting year, no HBV-sAg positive 
cases were found. 
6 These data refer to intravenous drug users who started drug-specific treatment in 2006; information on their infection status 
was obtained either by status testing or based on the case history. 
7 Only 116 and 112, respectively, out of a total number of 197 expert opinions on directly drug-related deaths explicitly men-
tioned the presence or absence of HCV Ab and HIV infections. In the remaining cases it is not clear whether no tests for the 
relevant infections were carried out or whether the results were negative and thus not mentioned. The two percentages given 
therefore indicate maximum and minimum levels of HCV and HIV infection prevalence rates. 
Sources: Duspara, Stolz-Gombocz, Haltmayer, Anderwald, Bauer, Fischer, personal communications; GÖG/ÖBIG 
2007a, GÖG/ÖBIG 2007b; see also ST9; representation by GÖG/ÖBIG 
The information provided by clients for Vienna’s BADO documentation indicates a HCV 
prevalence rate of 35% and a HBV prevalence rate of 4%. Regarding HIV infections, signifi-
cant differences again show in the individual age groups: only 1% of people under 18, but 
7% of clients over 40 indicated to suffer from HIV infections. The group of homeless people 
is affected to a particularly large degree: HIV infections were reported by 18% (IFES 2006). 
With regard to hepatitis C, the prevalence rates relating to HVC antibody (HCV-Ab) and 
HCV-RNA tests have been documented separately also in the reporting year. This is relevant 
in particular because it is primarily HCV-RNA positive results based on PCR tests that reflect 
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a chronic development of HCV. The individual HCV-RNA prevalence rates, related to all 
HCV-Ab positive tests, range between 88% and 35%. Regarding HCV genotypes, Vorarlberg 
(Lukasfeld) reports that in 2 out of a total number of 9 HCV-RNA positive patients, genotype 
1 was found, in 2 persons genotype 1a was detected, and in 5 persons, it was genotype 332.
One should bear in mind, however, that again reliable statements on developments and 
trends with regard to the above infectious diseases cannot be given as the data from the re-
spective sources are not representative. 
In the case of 89 out of a total of 267 persons with positive hepatitis C results documented in 
the DOKLI system a manifest liver disease was found: 71 out of these 89 patients had a 
manifest hepatitis. For 6 out of the 12 HIV positive patients, data on AIDS exist: 5 patients 
were suffering from manifest AIDS (see Chapter 4.2; GÖG/ÖBIG 2007a), and the forensic 
expert opinions on directly drug-related deaths included AIDS diagnoses in the case of 8 
people with HIV infections. 
For the reporting year 2006, the DOKLI data provide TBC information on 36 people, with a 
prevalence rate of 0%. Thus, again no relevant TBC problems have shown in Austria. A ba-
sic immunisation status against TBC resulting from a previous vaccination was found in less 
than 10% of people for whom valid data exist (see Chapter 4.2; GÖG/ÖBIG 2007a). In two 
cases out of the total of 197 drug-related deaths, concomitant lung tuberculosis was diag-
nosed in the context of the forensic autopsy of the internal organs (GÖG/ÖBIG 2007b). 
6.3 Psychiatric comorbidity 
This year, nationwide data on secondary diagnoses (ICD-10 codes) have been provided by 
the treatment sector for the first time33, which confirm the high prevalence of psychiatric co-
morbidity. Secondary diagnoses concerning the group of mental and behavioural disorders 
(F00–F99) are found in 127 (62%) of the 206 patients with entries of non-addiction-related 
ICD-10 secondary diagnoses. The most frequent diagnoses are affective disorders such as 
depression, and personality or behavioural disorders (see Chapter 4.2; GÖG/ÖBIG 2007a).  
Recent data on psychiatric comorbidity have been reported by several drug treatment cen-
tres in 2006: 52 out of 72 persons newly admitted to the Anton Proksch Institute (API) took 
part in clinical psychology examinations. In around 11% of the patients one personality disor-
der according to DSM IV34 was diagnosed, and in 85%, two or three DSM-IV disorders were 
found. Only approximately 4% did not suffer from a personality disorder. The most frequent 
diagnosis was antisocial personality disorder starting after the age of 15 (36%), followed by 
antisocial personality disorder starting before the age of 15 (23%) and borderline personality 
disorder (19%; API 2007). In 2006, Grüner Kreis treated 104 patients in whom, apart from 
addiction, also another psychiatric disease was diagnosed. Regarding ICD-10 diagnoses35,
the majority patients suffered from affective disorders (32%), followed by personality disor-
 
32 For details on the individual drug-related infectious diseases, HCV-RNA prevalence rates and HCV genotypes see also ST 9. 
33 In the DOKLI system, in addition to addiction-related ICD-10 codes, up to 10 other ICD-10 diagnoses may be included. For 
206 out of the total of 1 048 patients for whom medical data were available in 2006, at least one additional diagnosis was en-
tered. 
34 Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
35 International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD 10) 
Chapter 6: Health Correlates and Consequences 
48
ders (30%) and schizophrenia (28%). Neurotic disorders (8%) and eating disorders (3%) 
were diagnosed less often. In particular eating disorders were found significantly more often 
in women than in men (Grüner Kreis 2007a). 
As in the year before, around one out of five clients of drug help centres in Vienna (see 
Chapter 4.2) reported to have undergone psychiatric treatment in the last 12 months before 
the start of addiction treatment (see GÖG/ÖBIG 2006). While no differences regarding age 
were found, differences according to gender and treatment settings did show: among men, 
inpatient treatment predominates (inpatient treatment: 64%; outpatient settings: 50%), while 
in the case of women, the corresponding percentages are at similar levels (inpatients: 61%; 
outpatients: 59%). 10% of new clients said that they were suffering from a psychiatric dis-
ease (see Table 6.2 on the following page). In general, the data on other types of assistance 
provided outside the current treatment setting that were gathered in the context of the BADO 
documentation also indicate that psychiatric comorbidity plays a relevant role. The corre-
sponding services were rendered to 53% out of the total of 2 252 people concerned: 15% 
said they were getting medical psychiatric treatment, 4% named psychological assistance 
and 8%, psychotherapy (IFES 2006). 
6.4 Other health correlates and consequences 
In addition to psychiatric comorbidity and the health-related consequences of the aforemen-
tioned infectious diseases, also other somatic diseases and problems due to chronic effects 
of toxins or the precarious living conditions that are frequent among i.v. drug users have 
been registered. 
The following representation of physical comorbidity (concomitant organic diseases) is based 
on the findings (macroscopic and microscopic histological tests on internal organs) of 197 fo-
rensic expert opinions on directly drug-related deaths, 186 of which include statements on 
concomitant diseases (see Chapter 6.1, GÖG/ÖBIG 2007b). 41 of the corresponding expert 
opinions do not diagnose pathological changes of the organs; 40 opinions describe damage 
of one organ, and in 77 cases damage of two or three organs is listed. Diseases of more 
than four organs were found in 24 persons, and in four cases, the expert opinions referred to 
six affected organs. 
As in the previous year, the forensic expert opinions on directly drug-related deaths mention 
pronounced physical lesions (see GÖG/ÖBIG 2006, GÖG/ÖBIG 2007b). In 2006, a total of 
31 deaths were found to be indirectly related to drug use36. The majority of these cases (18 
persons) had died of diseases such as myocarditis, cirrhosis or cancer. 7 persons had com-
mitted suicide, five had died in accidents and four of these, in road accidents. One person 
had been stabbed to death. 
 
36 In the case of indirectly related deaths, death has not been caused by an acute intoxication with a drug of abuse. However, 
because of the patient’s history of drug use, her/his death may be related to drug consumption. As a classification is only 
possible if a suspicion of an indirect drug relation is reported, the data cannot be assumed to be complete (see GÖG/ÖBIG 
2007b) 
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According to the statistics of BADO (Vienna), 65% of the patients registered said that they 
were suffering from health problems. This is an increase by 6% compared to the year before 
and contrary to the trend described in the reports of past years, which indicated a declining 
tendency of health problems (see GÖG/ÖBIG 2006, Table 6.2 and Table A22 in Annex A). 
Table 6.2: Current health problems, comparison from 2002 to 2005; percentages 
(n = 2 244 in 2005), client year 2005 
Health problems 2002 2003 2004 2005 
Current health problems 70 66 59 65 
Chronic hepatitis C 42 39 30 35 
Dental problems 22 22 19 23 
Gastrointestinal problems 12 13 11 16 
Psychiatric diseases 11 9 9 10 
Dermatological and venous problems 8 9 7 10 
Spasms, epileptic seizures 6 7 5 6
AIDS/HIV infections 7 5 4 4
Chronic hepatitis B 5 5 4 4
Gynaecological problems 1 3 2 4
Chronic ill health 2 1 1 1
STD (sexually transmitted diseases) 1 1 0 1
Other health problems 7 10 9 8
No current health problems 30 34 41 35 
Source: IFES 2006; representation by GÖG/ÖBIG 
Secondary diagnoses that are not related to addiction, which have been gathered for the first 
time in the context of DOKLI, in addition to ICD diagnoses of psychiatric comorbidity (see 
Chapter 6.3), primarily list viral hepatitis (24%). 17% of the diagnoses (total: 206 patients) 
concern rehabilitation measures in the context of addiction to pharmaceutical substances or 
illicit drugs, 5% refer to diseases of the respiratory system, and another 5% to episodic and 
paroxysmal disorders of the nervous system such as epilepsy. The rest of secondary diag-
noses are accounted for by shares of less than 5% (see Chapter 4.2; GÖG/ÖBIG 2007a). 
In the reporting year, the low-threshold centres of Vienna reported 72 instances of life-saving 
measures taken, for which either ambulance services had been called or artificial respiration 
was necessary. According to statistics of Vienna’s ambulance service, in Vienna the number 
of patients with suspected overdoses of illicit substances was 546 in 2006 (VWS 2007a, 
Sucht- und Drogenkoordination Wien 2007). 
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7 Responses to Health Correlates and  
Consequences 
In Austria the responses to health correlates and consequences include a wide range of in-
terventions. The relevant measures focus on drug-related infectious diseases, as well as low-
threshold assistance aimed at harm reduction. For instance, syringe exchange, hepatitis 
vaccinations and information on safer use/safer sex are typical services performed by low-
threshold centres and outreach services (street social work)37. Treatment of health conse-
quences is primarily provided by the general health-care system (e.g. emergency physicians, 
psychiatrists). In recent years the prevention of overdoses and the issue of comorbidity have 
played increasingly important roles. Regarding the general state of health of drug users, the 
themes of gynaecological health care and pregnancy have become central aspects of the 
services addressing women. Staff training in the exchange and sale of syringes is regularly 
organised primarily in low-threshold centres. 
7.1 Prevention of drug-related deaths 
A number of provinces started new initiatives to prevent overdoses. Burgenland is preparing 
a programme of first-aid training courses for different stakeholders, e.g., drug users, relatives 
and staff of drug help centres. In Upper Austria the centres give drug users small booklets 
and key rings with information and emergency phone numbers. Practitioners in the drug help 
field have again reported problems in certain provinces regarding the consequences when 
ambulance services are called because of overdoses: for instance, the ambulance services 
sometimes also call the police, and there are provinces, e.g., Lower Austria, where the drug 
users concerned have to pay for the emergency services provided. Generally speaking, the 
range of measures taken to prevent drug-related deaths obviously is insufficient. 
7.2 Prevention and treatment of drug-related infectious 
diseases 
Preventing infections continues to play a central role in low-threshold centres and outreach 
work, here the exchange and sale of syringes is of particular relevance. In this field, no na-
tionwide programmes exist in Austria, but the corresponding measures are taken at provin-
cial level. The reporting period did not see any relevant changes with regard to these inter-
ventions (see GÖG/ÖBIG 2006). In Styria the Addiction Coordinators, in cooperation with the 
Federal Streetwork Association (BAST) plan to integrate the issue of drugs in the context of 
street social work addressing young people at transregional level, on the basis of uniform 
quality standards. One goal here is that the standard scope of street social work should also 
include counselling, information and harm reduction measures as well as syringe exchange 
.
37 http://suchthilfekompass.oebig.at
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This reorientation has become necessary as also at present, 30% of the work time of youth 
street social workers is accounted for by drug issues (Ederer, personal communication).  
Figure 7.1: Distribution of injection equipment at the Komfüdro centre, from 2000 to 2006  
 
Source: Komfüdro 2007; representation by GÖG/ÖBIG 
The Komfüdro low-threshold centre in the Tyrol (see Figure 7.1) is a place that is contacted 
by drug users from the entire province. In order to expand its syringe services, opening hours 
in the evening once a week were introduced for a trial period especially for syringe ex-
change, but this was discontinued after four months due to lack of demand.  
All centres that communicated figures on syringe exchange in the reporting year stated that 
there were further increases of both the sale and exchange of injection equipment, and con-
stant good return rates between 94% and 98%. The trend of recent years has thus continued 
(see GÖG/ÖBIG 2006). The Vienna Social Projects Association (VWS) presents the follow-
ing tentative explanation of these rises (2005: 1 667 845; 2006: 1 902 001): apart from the 
assumption that the number of injecting users has been going up and that the increase in co-
caine consumption in the street scene has also led to rises in i.v. use, the safer use informa-
tion campaigns are likely to have taken effect and therefore needle sharing is practiced less 
often. In addition, practical experience has shown that the groups of clients and customers of 
the syringe exchange programme are expanding and that larger numbers of users of better 
social integration also use this service (VWS 2007a). 
In addition to the syringe exchange and sale programmes at provincial level, it is also possi-
ble in Austria to buy injection equipment in pharmacies. In Graz, Styria, around 13 000 sy-
ringes are sold by pharmacies every month. In Salzburg, a survey on syringe distribution was 
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carried out in pharmacies, organised by the Drug Counselling Centre of the Province of Salz-
burg in cooperation with the Chamber of Pharmacists. This showed that in the city of Salz-
burg, a monthly average of 10 to 80 syringes are sold per pharmacy, but in certain focal ar-
eas, the sales may be as high as 900 syringes. Outside the capital of Salzburg, the average 
is 10 syringes (Drogenkoordination des Landes Salzburg 2007). Upper Austria reports the 
problem that several pharmacies have refused to sell syringes to drug users (Schwarzen-
brunner, personal communication). 
Hepatitis vaccination projects at regional level or run by individual centres are other important 
interventions in the context of the prevention and treatment of drug-related infectious dis-
eases (see also GÖG/ÖBIG 2006). 30% of the patients at the API were immunised against 
HBV, which is an increase in the vaccination rate compared to the previous year (19%). All 
persons who had not yet been vaccinated obtained basic immunisation at the API (API 
2007). The outpatient drug department of Innsbruck administered a total of 30 HBV vaccina-
tions in 2006 (Giacomuzzi, personal communication), and the hepatitis A and B immunisation 
programme of Ganslwirt (Vienna) has been continued. The available DOKLI data on clients’ 
immunisation status38 show that the share of persons immunised against HAV and HBV is 
smaller among the i.v. users registered than in the total group of clients (HAV: 18% v. 23%; 
HBV: 25% v. 29%; see Chapter. 4.2; GÖG/ÖBIG 2007a). 
In Vienna an initiative aiming at the optimisation of diagnosing and treatment of HCV-positive 
drug users was started at the end of 2006, organised by the interdisciplinary Austrian Society 
of Pharmacologically Assisted Treatment of Addiction (ÖGABS) as the responsible agency, 
in cooperation with the Medical Association of Vienna (see Chapter 5.3). In the context of this 
social medicine treatment network, quarterly quality circles are held which, in addition to im-
proving the communication among sectors relevant for treatment, also aim to optimise the 
care and treatment services for HCV-positive drug users, to develop a structure for crisis 
management, to facilitate the exchange among experts as well as to identify and remove 
treatment barriers. The participants in the regular meetings include physicians from special-
ised hepatitis or drug outpatient departments, psychologists, social workers, representatives 
of support groups, general practitioners providing substitution treatment and established psy-
chiatrists. In the medium and long runs, the interdisciplinary approach of this network will fa-
cilitate the cooperation across different fields of expertise, which has proved to have good 
results in particular for the treatment of drug users. Because of the positive effects that 
showed, in July 2007 a second quality circle was set up in Innsbruck, Tyrol (Haltmayer, per-
sonal communication). 
The establishment of safe rooms as a complementing harm reduction measure regarding 
new infections was again discussed in Austria. The debate was triggered by an analysis of 
current demand that was carried out in June 2006 as a cooperation of the Drug Coordinators 
of the City of Graz, Styria, the Kontaktladen centre and the Addiction Coordinators of Styria 
(see Chapter 4.3). The analysis, which was based on 102 interviews with injecting users in 
Graz, showed the following picture: The majority of respondents said that they planned in 
 
38 Data on HAV vaccination status are available for 330 clients, and regarding HBV, for 326 clients. 
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advance when and where to take drugs. Almost half of them occasionally or almost exclu-
sively consume their drugs in public toilet facilities, and some people also outdoors or in 
parks. More than 50% indicated that they had already been affected by a drug emergency. 
When asked about the need for a users’ room in Graz, 90% of respondents agreed and ap-
proximately 72% said they would maybe use such a facility. On the basis of these results, an 
implementation plan was drawn up for a drug treatment contact point (DTA) that is integrated 
in the existing system of low-threshold and outpatient centres (Kontaktladen 2007; Zeder 
2007). As a consequence, the Federal Drug Forum discussed this issue in April at the federal 
level. Eventually, because of the topicality of this question, a Special Federal Drug Forum on 
harm reduction measures was held in June 2007, for a first exchange of positions regarding 
users’ rooms. Generally, the implementation of safe rooms continues to be a controversial 
issue: for instance, at present neither the Federal Government nor the City of Vienna see any 
need for providing such a service.  
Talks about safer use and safer sex still are central themes of outreach drug social work; 
they usually take place in the context of syringe exchange. In the reporting period Vienna’s 
low threshold service providers registered around 4 650 talks (2005:3 800), which focused on 
harm reduction in connection with drug use (VWS 2007a). In the course of restructuring the 
counselling centre in Karlsplatz square (Vienna), a weekly series of events named Zur Sache 
(Getting to the Point) was initiated, where harm reduction themes are addressed: the first few 
events focused on safer use, HIV and HCV infections and first aid. The paper published by 
Ganslwirt in Vienna regularly provides information on safer use as well. For instance, in one 
edition, under the subject of Fairy Tales and Myths, typical misinformation that circulates in 
the scene was corrected (VWS 2006a). In spite of the long-standing focus on safer use in the 
centres, experience from the low-threshold sector shows that safer use measures are not 
applied to a sufficient extent. For instance, clients report that syringes and also filters are 
used several times by one person, that only the needle is exchanged but not the pump, and 
that the same site is injected repeatedly (Schwarzenbrunner, personal communication). In 
order to optimise the corresponding prevention measures it would be sensible further to in-
vestigate this discrepancy between what clients know and what is actually practised. The 
theme of safer use and risk reduction in the party scene, in particular regarding use of keta-
mine, is also treated in a diploma thesis on ketamine as a party drug, published in coopera-
tion with ChEckiT! in Vienna (Baumgartner 2007, see Chapters 2.3 and 3.2). 
7.3 Interventions related to psychiatric comorbidity 
All centres and institutions in the drug help sector provide specific care services for their cli-
ents in the field of psychiatric comorbidity (see GÖG/ÖBIG 2006). 
Around 15% of all persons receiving care and treatment at Grüner Kreis have case histories 
that include diagnoses of psychiatric comorbidity. In the treatment and care settings, this re-
quires intensive medical management because additional regular treatment by a general 
practitioner and psychiatric care or crisis intervention are needed. The majority of patients 
take neuroleptics, antidepressants and/or mood stabilisers, which require frequent lab tests, 
as well as ECG and EEG examinations (Grüner Kreis 2007a).  
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The Addiction Plan 2006–10 of the province of Carinthia stipulates a diversification of pre-
vention and treatment options and also includes the group of chronic addiction patients with 
psychiatric comorbidity (Prehslauer, personal communication; see Chapter 1.2). In Inns-
bruck, the outpatient addiction prevention department of the city’s social and health care dis-
trict also provides psychiatric and psychotherapeutic outpatient treatment of drug users. In 
2006, a total of 125 persons were treated, and 2 250 individual therapy sessions as well as 
45 hours of counselling and information talks with relatives were held (Kern, personal com-
munication). 
7.4 Interventions related to other health correlates and 
consequences 
Interventions and measures that aim at the general state of health of drug users are inte-
grated in all treatment and care fields covered by the drug help network, with different fo-
cuses depending on the setting in question. For instance, in Carinthia treatment by general 
practitioners was integrated in the services provided by drug outpatient departments because 
many drug users were found to be in a bad state of general health. In 2006 the aftercare ser-
vices of API placed the focus on the theme of health because it showed that psychological 
and physical stabilisation, crises, interferon treatment, diet, exercise, stress and medication 
were identified as recurring aspects of aftercare (API 2007). In the outpatient clinic of the 
Ganslwirt low-threshold centre in Vienna the service most frequently provided in 2006 again 
was treatment with pharmaceuticals (4 187 times), followed by treatment of acute withdrawal 
symptoms (1 423 times), transitional treatment (1 127 times) and medical consultation talks 
(863 times) (see VWS 2007a). 
In addition to general health-care services, the drug help centres increasingly often have 
dealt with the theme of safer sex in the context of revenue-raising prostitution for buying 
drugs. In Vienna, as of 2006 Ganslwirt’s newspaper has regularly published tips for male 
prostitutes, and since its reopening, the mobile contact point in Karlsplatz square (Vienna) is 
open until late at night several times a week in order to establish better contacts to the drug-
related prostitution scene. The weekly Zur Sache (Getting to the Point) information events 
focus not only on specific harm reduction themes such as safer use, HIV and HCV infections 
but also the issue of safer sex, which is separately treated for women and men (VWS 
2006b). The outpatient drug help sector of Vorarlberg expanded the project strategies on 
prostitution in order to provide adequate support to those concerned, who are often con-
fronted with combined problem situations such as trauma, experience of violence and abuse, 
drug addiction, infectious diseases and psychological disorders (Stiftung Maria Ebene 2007).  
The themes of women’s health, gynaecological questions and pregnancy/children have in-
creasingly often been raised in contacts with female clients. In the Tyrol, Vorarlberg and Sty-
ria women’s networks have existed for some time in order to promote a professional ap-
proach to the theme of women and substance use, identify and study necessary fields of ac-
tion at structural level, and eventually prepare practical ways of implementation and provide 
concrete services for clients (see Chapter 5.1). The outpatient drug help centre of Vorarlberg 
has continued its activities in the field of pregnancy and motherhood (see GÖG/ÖBIG 2006). 
A central focus of 2006 was to ensure gynaecological care for drug-using women in all dis-
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tricts and to build a system of liaisons in the maternity wards of the hospitals and start a co-
operation with youth welfare departments. In October 2006, the drug help centres, physicians 
and youth welfare agencies cooperated to organise a conference on addiction, parenthood 
and the welfare of children, in which more than 80 persons took part. As a result of this con-
ference, a project group was established to prepare practical guidelines for the cooperation 
of the corresponding social welfare agencies and to draw up a cooperation agreement in the 
interest of drug-using parents and their children (Stiftung Maria Ebene 2007). The low-
threshold sector also offers specific services in the field of women’s health and pregnancy. 
Komfüdro (Innsbruck, the Tyrol) cooperated with the AIDS Assistance Service of the Tyrol to 
organise a further training programme for drug-using women, which places a special focus 
on the issue of sexual health (Komfüdro 2007). Ganslwirt’s paper published a comprehensive 
article on birth control and pregnancy, and in addition, the theme of pregnancy and drugs has 
been an integral part of the regular Zur Sache series of events (VWS 2006b). In 2006, 68 
pregnancy tests were carried out at Ganslwirt (2005: 56 tests). Seven clients were treated 
under the diagnosis of pregnancy, but not all diagnoses were obtained through Ganslwirt’s 
internal testing services. In Graz, the specific services for women provided by Kontaktladen 
were expanded to include a monthly gynaecological clinic, and a cooperation with the Drug 
Counselling Centre of the Province of Styria was started, which focuses on treatment and 
care services for both drug-using women and their children (Drogenberatung des Landes 
Steiermark 2007, Kontaktladen 2007).  
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8 Social Correlates and Consequences 
Homelessness, unemployment and debts continue to be the most pressing social problems 
of drug users, in particular severely addicted users in the street scene (see also Chapter 12). 
Reports to the police relating to violations of the Narcotic Substances Act (SMG) have gone 
down for the first time since 2003, and what deserves special mention here is the decrease 
in reports concerning cannabis. Convictions because of misdemeanours according to the 
SMG have also declined, while the number of convictions resulting from felonies has re-
mained at the same level as in 2005. 
8.1 Social exclusion 
Among the clients of 2006 registered in the Austrian DOKLI system (see Chapter 4.2), the 
share of people with jobs is smallest in the group undergoing inpatient treatment (13%). 
Here, the percentage of persons who indicated that they were unemployed was also the 
highest (45%). In all groups, the share of women who have jobs is smaller to varying degrees 
compared to men (e.g., clients of low-threshold centres: 12% of women and 18% of men). 
While smaller shares of women stated that they were jobless, recipients of welfare assis-
tance are found more often among women than among men. The trends regarding source of 
income, which at present can be studied only on the basis of the BADO39 documentation of 
Vienna, show that the share of gainfully employed people has remained constant from 2003 
to 2005. On the other hand, the percentage of people receiving unemployment benefit (2003: 
20%; 2005: 13%) or unemployment assistance (2003: 30%; 2005: 23%) has significantly de-
clined. At the same time, the share of clients covered by BADO who do not have any source 
of income has massively risen (2003: 9%; 2005: 31%). An average of 53% of clients of low-
threshold centres whose data are covered by DOKLI said they had a stable accommodation, 
compared to 90% out of the group of people receiving long-term treatment. Regarding edu-
cational level, more than half of the clients of Austrian drug help centres aged 19 or older 
said that their highest degree was a lower secondary school leaving certificate. Around one 
out of five women and one out of four men said they had completed an apprenticeship. How-
ever, the share of women is overrepresented in the categories referring to completion of a 
vocational intermediate secondary school as well as general education and vocational edu-
cation upper secondary schools (IFES 2006, GÖG/ÖBIG 2007a). 
The social situation of the clients of drug help services in Austria continues to be worse com-
pared to the general population (as to housing, education, employment, income and health). 
However, it should by no means be concluded from this that drug problems arise mainly in 
the group of socially disadvantaged persons. What it does signify is that this group will more 
readily turn to the drug help service system than people who (still) have their own social and 
financial resources (see Chapter 4.2). 
 
39 Basic Documentation of clients of drug help centres of Vienna, compiled by the Viennese Working Group on Documentation. 
The Basic Documentation of 2005 covers 28 centres with data sets on 3 452 persons. The data collected in the context of 
BADO (client year 2006) are also included in the DOKLI data and thus form part of the analyses of DOKLI. 
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A new diploma thesis40 provides information on the theme of social exclusion and the result-
ing interactions of the groups concerned, i.e., police officers, social workers and drug users. 
This also revealed how difficult it is for social workers and even more so for police officers to 
recognise and respect fields of activity that are the specific domain of the other group. As a 
protection area was defined for Karlsplatz in 2005, the places where members of the drug 
scene may stay have been reduced massively, which in turn has increased the pressure on 
this group (see ÖBIG 2005). The interviews have shown that Karlsplatz is a typical place to 
spend time not only for drug users but for socially excluded people in general, e.g., homeless 
people, people placed under guardianship or people who are not socially adjusted in one 
way or other (Etl 2006). 
Also in 2005 TEAM FOCUS, on behalf of the Social Vienna Fund (FSW), carried out a gen-
eral analysis of how public places are used and of social patterns around Karlsplatz square. 
The focus was placed on typical points of interaction and conflict between groups of users as 
well as possible problems that might result. The project report confirms the statements by Etl 
2006 that the area around Karlsplatz square is in fact a meeting point and place to spend the 
night for socially excluded groups such as homeless people, immigrants, persons with alco-
hol problems and people suffering from psychiatric diseases. Recently, also increasing num-
bers of adolescents and young adults have been found to frequent the Karlsplatz area but 
their patterns of behaviour differ from the established scene (FSW/Team Focus 2005, GÖG/ 
ÖBIG 2007a; see also Chapter 12).  
8.2 Drug-related crime 
In 2006, the number of reports to the police on the basis of the Narcotic Substances Act 
(SMG) was 24 008 (2005: 25 892; see also Table A9 in Annex A and ST11), which is a de-
cline compared to the previous year. A total of 22 690 reports relate to narcotic drugs, the 
rest to psychotropic substances. Regarding type of report (see Figure 8.1), in 2006 the num-
ber of reports for misdemeanours (possession and small-scale trafficking – Section 27 of the 
SMG) was considerably smaller than in 2005, and regarding felonies (large-scale trafficking, 
professional trafficking – Section 28 of the SMG) it was slightly higher. The trend regarding 
reports because of felonies has thus continued, although it has become weaker, while the 
number of reports relating to misdemeanours has gone down by 11% (see Chapter 1.1). 
 
40 In the context of a qualitiative research setting, Ms Sabine Etl talked to police officers, social workers and drug users in 
Karlsplatz square in Vienna, a traditional meeting place of Vienna’s open drug scene, and also in the Streetworker bus at Vi-
enna’s Westbahnhof railway station. 
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Figure 8.1: Development of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act by misdemeanours and felonies in Austria, from 1997 to 2006 
 
Note: the Narcotic Drugs Act was replaced by the Narcotic Substances Act on 1 January 1998. In order to facilitate comparison, 
for the period from 1998 to 2001 only reports concerning narcotic drugs have been considered here. The difference to the 
total number of reports results from reports that are not assignable.  
Source: BMI/Bundeskriminalamt (Federal Criminal Agency); representation by GÖG/ÖBIG 
In terms of substances involved (see Table A11 in Annex A and Standard Table 11), com-
pared to the previous year there have been slight decreases in the number of reports to the 
police with regard to all substances except LSD as well as psychotropic and other sub-
stances (see Figure 8.2 on the following page). The declining trend in reports to the police 
because of heroin and opiates that showed already in 2005 has continued and become con-
siderably more pronounced. However, a simultaneous rise in reports relating to pharmaceuti-
cals containing opioids has also been registered (see Chapter 10.1). As in the year before, 
the reports because of ecstasy have decreased further, a development which since 2005 has 
also shown with regard to reports concerning amphetamines. 
In 2006, 24 008 reports led to a total of 3 292 arrests (2004: 3 929) in connection with nar-
cotic drug investigations; however, regarding arrests no detailed indication of the type of of-
fence, substances involved, etc. can be given. 
As explained in previous years and also stressed by the responsible Ministry of the Interior 
(BMI 2007), the data concerning reports to the police permit only limited conclusions as to 
the development of illicit drug use and misuse, because they primarily reflect the intensity 
and focus of police measures in this field. 
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Figure 8.2: Development of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act by type of substance, from 1997 to 2006 
 
Note: the Narcotic Drugs Act was replaced by the Narcotic Substances Act on 1 January 1998. 
Source: BMI/Bundeskriminalamt (Federal Criminal Agency); representation by GÖG/ÖBIG 
The number of convictions for violation of the SMG (5 795) declined in 2006, as did the num-
ber of unsuspended prison sentences (1 499). The decrease in the total number of convic-
tions relating to the SMG in 2006 has also stopped the rising trend as to the shares of SMG 
convictions in total convictions showing in recent years (1999: 5.4%; 2005; 13.4%; 2006: 
13.3%; see Table A13 in Annex A).
Again, there were significantly more misdemeanours (Section 27 of the SMG – possession 
and small-scale trafficking), namely 4 246 cases (2005: 4 702) than felonies (Section 28 of 
the SMG – trafficking; 1 464 cases compared to 1 357 in 2005; see Table A14 in Annex A). 
The number of convictions because of felonies remained near the level of the previous year 
regarding both young people and adults, while a decline shows for both age groups as far as 
misdemeanours are concerned. 66% of all persons convicted (2005: 70%) were punished 
with imprisonment (see Table A15 in Annex A). The share of sentences that were suspended 
on probation in all convictions was 44% (2006: 42%), thus again a slight rise has shown 
compared to previous years. 
In addition to convictions, the data on the provisional waiving of reports (Section 35 SMG) 
and suspension of proceedings (Section 37 SMG) are also relevant (see Chapter 1.1 and 
Table A16 in Annex A). As yet there are no reliable data on the suspension of sentences on 
the basis of the principle of therapy instead of punishment (Section 39 of the SMG). How-
ever, such data would be an important source of information on the practical implementation 
of this principle. 
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As before, no data on offences committed to finance drugs and drug-related crimes are 
available. 
However, there is a recent study that shows that drug users frequently also are the victims of 
various types of crime. Women, homeless people and persons with mental illnesses are es-
pecially affected groups41 in this regard. The average age in the Austrian sample was 27.2 
years; men accounted for a share of 80%, 86% were out of work. In Austria, the probability to 
become the victim of a crime has shown to be smaller than in any of the other countries stud-
ied – but still as high as 60% (Stevens et al. 2007; see Chapter 13.2). 
8.3 Drug use in prison 
The existing information on drug use in prison was presented in detail in the Key Issue chap-
ter on drug use in prison in 2001 (ÖBIG 2001a). According to recent information, in Austria 
around one out of three prisoners suffering from opiate addiction is offered substitution ther-
apy. In sum, the group of persons who are serving prison sentences in Austria and in whom 
drug addiction has been diagnosed has strongly risen in recent years. The share of this 
group of inmates is around 30% in the Jakomini prison of Graz, Styria (Kontaktladen 2007).  
8.4 Social costs 
Studies on public expenditure for drug purposes are hardly available in Austria, and no rou-
tine data on this aspect exist (see Chapter 11). 
However, a study of 2004 dealing with costs incurred in the context of cerebral diseases in 
Austria also included the category of addiction (Wancata et al. 2007). An interesting aspect 
here is that the cost of addiction in overall costs was EUR 1 444 million (in terms of PPP42), 
but a major part of this sum (EUR 1 043 million) was accounted for by indirect costs (e.g., 
sick leave, premature retirement). 
 
41 For this study, which was carried out from 2003 to 2004, a total of 545 people were interviewed in Austria (150 people), Eng-
land, Germany and Switzerland. The respondents came from the groups of clients undergoing compulsory or voluntary treat-
ment in drug help centres. 
42 PPP, or purchasing power parity, means that the purchasing power of consumers in a country is taken into account in order to 
permit comparisons across countries. 
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9 Responses to social correlates and  
consequences 
Measures for the social (re)integration of (former) drug addicts address both clients who 
have undergone drug-free treatment and people who are currently using drugs. In Austria, 
such measures have traditionally played an important role, especially with regard to housing, 
work, education and training (see SQ28, latest update). Some of the pertinent measures are 
part of the chain of treatment and integrated in the corresponding care modules, while others 
are services provided by low-threshold centres in the context of accepting drug assistance 
(see Chapter 5). Recently, activities in recreational settings have increasingly often been or-
ganised. In Austria’s prisons and police detention centres a wide range of drug-related 
measures for prisoners exist, from prevention of addiction, substitution treatment and preven-
tion of infectious diseases to drug-free treatment. 
9.1 Social reintegration 
In the field of training and employment, a number of projects described in previous years 
(e.g., drugaddicts@work) were phased out. Others, such as fix und fertig, have been carried 
on with good results, and the personnel development strategy started in 2005 has been con-
tinued (GÖG/ÖBIG 2006). For instance, four vocational orientation programmes and three 
job application training events took place in 2006. In the context of personal counselling, 120 
talks with 23 clients were held from May to December 2006. On average, the clients re-
mained with fix und fertig for 12 months, and nine out of 27 people could be referred to the 
regular labour market. Another three clients who were regarded to be job-ready did not find 
work, and one person started a therapy. The evaluation of objectives drawn up in 2005 
shows the following results in the fields of training and employment as well as financial situa-
tion: the goals that were set with regard to work values were met (in part) in the case of 21 
out of 24 transitional workers. Similar results were achieved with regard to job application 
skills and outplacement readiness. 11 people completed qualification training or on-the-job 
training, and success also showed in fields such as managing to make ends meet and han-
dling financial crises, and 10 clients made progress regarding debt regulation (VWS 2007a). 
The Vienna Job Exchange (WBB) also focused its activities on intensifying contacts to the 
regular labour market, which is extremely difficult as a rule because often massive reserva-
tions regarding contacts to addicted people exist that cannot be overcome. A good coopera-
tion was started with a building contractor to whom a few clients were referred with support 
by the Public Employment Service (AMS). In addition, the contacts to the socioeconomic en-
terprises (SÖB) and to outplacers were intensified (Wiener BerufsBörse 2007). 
As a result of the close cooperation between the Vienna Job Exchange and the Grüner Kreis 
association, a wide range of education and training opportunities have been made available 
to patients. Wherever possible, further qualification is encouraged, for instance, through vo-
cational orientation, job application training and external on-the-job training. For a further  
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improvement of the quality of occupational therapy services, a joint project was started by 
Grüner Kreis and diepartner more than one year ago, where information on qualification and 
occupation is gathered, analysed and interpreted. Both clients and staff take part in the pro-
ject so that measures of personnel and organisation development may be realised more ef-
fectively and the commitment of stakeholders is enhanced (Grüner Kreis 2007b). 
The second Austrian addiction aid fair scheduled for November 2007 is oriented towards job 
reintegration of addiction patients, and also presents qualification measures as well as offers 
of daily paid work for (former) drug users who are undergoing (medical) treatment because of 
their addiction disease. At the fair, Austrian socioeconomic employers and enterprises will 
take part, and services provided by the Public Employment Service will be made known. In 
addition, lectures on these themes will be delivered. 
In the field of housing, a part-time-home system was established for patients of the Grüner 
Kreis association who suffer from an addiction disease and also a psychiatric disorder (co-
morbidity). After inpatient long-term treatment, they may spend the evening or the whole 
night and their spare time outside the inpatient facility, while the entire daily structure includ-
ing treatment and meals are organised by this facility. Grüner Kreis rented flats in the 
neighbourhood of its inpatient departments, which patients may use as their part-time 
homes. In 2006 eight people (two women and six men) took part in this programme; the av-
erage time of stay is around 40 months (Grüner Kreis 2007). 
Regarding medium-term housing, a new development is that the three large transitional 
homes run by the City of Vienna (Haus Hernals, Haus Siemensstraße, Haus Wurlitzergasse) 
have partly been opened also to drug users. A quota regulation provides that a maximum of 
20% of the available places may be used by clients with drug problems. The women’s ac-
commodation centre is another important place where homeless drug-using women may find 
accommodation (VWS 2007a).  
2006 was an especially good year for the Assisted Housing project, as in the reporting year 
nine (out of 15) clients could be referred to regular council flats. Since the establishment of 
Assisted Housing 10 years ago, around half of the clients have been referred to regular ac-
commodations (two thirds of the women and almost half of the men), they had previously 
lived in an Assisted Housing accommodation for 22 months on average. In 2006 it was de-
cided that six of the 15 places of accommodation (i.e., 40%) should preferably be made 
available to women in order to achieve a better gender balance among the residents (VWS 
2007a). 
As social integration is more than having a place to live and a position of financial and social 
security, since May 2006 Assisted Housing has also organised monthly recreational activi-
ties for all residents. By the end of 2006, nine activities had taken place with a total of 19 
people participating: e.g., a barbecue on Donauinsel recreational area, bicycling, visiting an 
exhibition and Schönbrunn zoo, bowling, billiards, etc. (VWS 2007a).  
In the context of social integration measures, the Anton Proksch Institute runs LOG IN, a 
network of supporting integration measures and health-oriented sports and cultural events as 
central elements of aftercare. In January 2006, in a cooperation of the ASKÖ sports associa-
tion of Vienna and LOG IN, a football team was set up, which has seven core members who 
also attend the regular training hours. For the clients, this environment with its orientation to-
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wards abstinence is regarded as protective and a model with which they may identify (API 
2007; see EDDRA).  
Although it is no measure in the field of social reintegration as such, the Help U pilot project, 
which was started already in September 2005 as a cooperation of the public transport sys-
tem of Vienna and the Addiction and Drug Coordinators, nevertheless contributes to enhanc-
ing the feeling of personal safety and avoiding social problems in public areas. From October 
to December 2006, the Help U team, for which additional staff was hired in May 2007, pro-
vided assistance in more than 7 500 situations, and in 70% of the cases they became active 
of their own accord. The shop owners in the neighbourhood have increasingly often con-
tacted the team either by phone or in person, and Help U is now present on the street until 
10 p.m. Because of its good results and after a positive evaluation, the project has been con-
tinued as a regular service (Sucht- und Drogenkoordination Wien 2007; see ÖBIG 2005). 
9.2 Prevention of drug-related crime 
 
The legal and organisational framework of drug-related interventions in prisons, which was 
described in great detail in the Report on the Drug Situation 2001 (ÖBIG 2001a), has not 
changed in the reporting period. As recent data and information have shown, imprisonment 
on account of felonies due to violations of the SMG still plays a relevant role (see Chapter 
8.2) 
In September 2007 the New Society of Criminology (NKG) held its 11th scientific expert 
meeting in Innsbruck, which dealt with the themes of drugs, addiction and delinquency (Hal-
ler, personal communication). 
Because of the tight staffing situation, the Austrian prisons cannot perform the task of prepar-
ing social reintegration to a sufficient degree. On the one hand, the scope of work of prison 
psychologists has increased because of projects such as suicide screening or drug-free 
zones, and on the other, an increasing number of inmates show massive psychological dis-
tress, also due to addiction problems. For instance, in the prison of Suben one social worker 
is in charge of 280 prisoners, and in Klagenfurt, there is one psychologist for 300 prisoners43.
In this context, it should also be mentioned that the Minister of Justice considers to close two 
prisons in Vienna, i.e. Favoriten and Mittersteig, as the buildings are in urgent need of repair. 
Favoriten is a special prison that focuses on addiction treatment44.
The workload of the prison staff has eased to a certain extent as a result of the cooperation 
with drug help centres. For instance, the number of visits to the Jakomini prison of Styria by 
staff of the Drug Counselling Centre of the Province of Styria has greatly increased: 66 visits 
to 16 men and eight women. During these visits, the treatment of clients who were already 
treated at the drug help centre before is continued, and services to other inmates are also 
provided. The possible treatment options and ways to practice therapy instead of punishment 
 
43 Salzburger Nachrichten of 24 May 2007 
44 Salzburger Nachrichten of 21 July 2007 
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under the SMG are explained. In addition, the motivation for and goals of treatment are dis-
cussed (ÖBIG 2002a; Drogenberatung des Landes Steiermark 2007). 
The principle of therapy instead of punishment continues to be an important component of all 
drug strategies and drug policy plans in Austria (ÖBIG 2002a). The related measures are im-
plemented by all actors in the drug help system of Austria rather than by specialised services 
(see Chapter 5). 
A cooperation agreement was concluded between Grüner Kreis and B.A.S.I.S. in order to be 
able to provide a flexible treatment and counselling programme that takes into account indi-
vidual needs and does not require a change of counsellors – and in particular, it aims to pro-
vide a treatment model that specifically addresses clients in prison. By means of this coop-
eration the available resources and synergy may be used in the best possible way and the 
requirements regarding economy on the part of the judicial authorities may also be met with-
out reducing the quality of treatment. Eventually, the imprisoned clients benefit from advan-
tages such as shorter waiting times and uninterrupted counselling/treatment45.
A point of criticism is that in Austria, the types of treatment facilities and thus the number of 
available beds is fairly limited and that the treatment options especially for young drug users 
are not as diversified as is desirable. The number of therapy forms that are actually available 
is also reduced due to the  lack of harmonised cost coverage agreements between the Minis-
try of Justice and the individual treatment centres (Kontaktladen 2007). 
 
45 www.vereinbasis.com (3 Aug. 2007) 
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10 Drug Markets 
The substance most frequently seized in Austria is cannabis, followed by cocaine and heroin. 
However, quantities seized are not a good indicator of the availability of a substance in Aus-
tria, as Austria often is not the final destination of these drugs but a transit country, and be-
cause these figures also reflect the intensity of police activities. Regarding potency and con-
centration of the substances available in Austria, experience of recent years has shown that 
there are considerable variations. This applies to both substances used by the traditional 
street scene (opiates and cocaine) and also new synthetic drugs (ecstasy and ampheta-
mines). The fact that the actual ingredients and potency are often unknown constitutes a 
considerable risk factor for drug use.  
 
10.1 Seizures 
According to the Austrian Federal Ministry of the Interior (BMI), in 2006 a decline in the num-
ber of seizures was registered for all drugs with the exception of amphetamines and LSD, 
(see Figure 10.1 and Table A17 in Annex A). 
 
Figure 10.1: Number of seizures of narcotic drugs in Austria from 1997 to 2006 
 
Source: BMI/Bundeskriminalamt (Federal Criminal Agency); representation by GÖG/ÖBIG 
The amount of substances seized reflects these trends only to a limited extent, as individual 
seizures of exceptionally large quantities strongly influence the general picture (BMI 2007, 
see Table A18 in Annex A and ST13).  
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While cocaine reaches Austria primarily by air from Latin America, the route over the Balkans 
is the dominant trafficking route for heroin. Cannabis products are imported from various 
countries and regions such as the Netherlands, the Balkan countries and Morocco; to a small 
extent, they are home grown in Austria. Amphetamines and derivatives are mainly imported 
from the Netherlands (BMI 2007). 
The special analysis of seizures of pharmaceuticals containing addictive substances, which 
the BMI conducted for the first time in 2007 shows that 1 530 seizures refer to substitution 
substances. The number of seizures of substitution substances has strongly risen over the 
years (2002: 328; 2004: 783; 2005: 1 081). 
10.2 Price/purity 
In the context of the ChEck-iT! project (see Chapter 3.2), which tests the purity and ingredi-
ents of substances bought as ecstasy or speed during events of the party and clubbing 
scene, in 2006, 134 samples bought as ecstasy and 75 samples purchased under the name 
of speed were analysed during a total of eight music events (freetekno, goa, techno, elec-
tronic) in the provinces of Burgenland, Lower Austria and Vienna (VWS 2007a). The per-
centage of pills bought as ecstasy that did not contain psychotropic substances other than 
MDMA, MDE or MDA was roughly the same as in the previous year (77%). Also as in the 
previous year, an extreme variation in the degree of potency per pill was registered (between 
14 mg and 97 mg).  
Only 24% of the substances bought as speed and analysed by ChEckiT! had amphetamines 
as their only ingredients, while 29% combined amphetamines and caffeine, and 24% con-
tained amphetamines with additions of other psychotropic substances (see Tables A19 and 
A20 in Annex A ST15). Unknown amphetamine derivatives continue to be a problem in this 
regard. These substances may either originate from inappropriate production procedures of 
amphetamines using cheap base substances, or they may be newly developed designer 
drugs. The effects and risks of these substances are unknown and cannot be assessed 
(VWS 2007a). 
As in the previous year, in 2006 both seizures and use of ecstasy pills containing the ingredi-
ent mCPP were reported. Compared to MDMA, the psychoactive effect of mCPP is weaker, 
but very frequently, the latter ingredient causes unpleasant side-effects such as headaches, 
kidney pain, nervousness, heavy breathing, tiredness and hangover lasting for several days. 
Furthermore, simultaneous use of MDMA may lead to convulsions (see for example VWS 
2007a). In addition, the drug 1-(3-trifluoromethylphenyl-)piperazine (BZP group), which has 
as yet hardly been examined, was sold as amphetamine, and dihydrofuran-2-on (GBL – a 
precursor substance of GHB) was offered as GHB. 
Information by the Ministry of the Interior on the potency and prices of various drugs sold at 
street level is given in Table 10.1 (see also ST14 and ST16). As in the previous year, a con-
siderable variation of the potency of drugs sold at street level has been noted.  
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Table 10.1: Purity and price (EUR per gram*/pill**) of various drugs sold in the street in 2006 
Herbal 
cannabis * 
Cannabis
resin* 
Brown 
heroin* 
White 
heroin* Cocaine* 
Ampheta-
mine* Ecstasy** LSD** 
Minimum 0.1% 0.04% 0.2% – 0.5% 0.7% 12% – 
Maximum 22% 19% 39% – 93% 97% 100% – 
Pu
rit
y
Typical 6% 5% 6% – 32% 19% 33% – 
Minimum 3 6 40 80 50 15 7 30 
Maximum 4 8 70 90 70 25 10 35 
Pr
ic
e
Typical 4 7 60 85 65 20 10 30 
Note: data are based on information and fictitious purchases by undercover police agents. For the individual drugs, between 76 
and 423 analyses were carried out.  
Source: BMI/Bundeskriminalamt (Federal Criminal Agency); representation by GÖG/ÖBIG 
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11 Public Expenditures 
It was proposed by the EMCDDA to derive drug-related expenditures from the budget (la-
belled expenditure) according to the COFOG classification.46 Drug-related expenditures not 
classified as such (e.g., in the field of justice) are to be calculated according to expert esti-
mates on the basis of the corresponding budget. This methodology for estimating the ex-
penses on the basis of budgets as proposed by the EMCDDA was tested for the fiscal year 
2005 and turned out to be inappropriate for Austria (see Chapter 11.1).  
11.1 National estimates of labelled drug related 
expenditures 
The preliminary budget of the Provinces and the federal financial statement for 2005 were 
examined for drug-related or addiction-specific expenditures. On closer inspection of the in-
dividual budgets, different classification practices and names of budget items become appar-
ent. For example, Vienna47 as the largest province as well as Burgenland48 have no separate 
budget items for addiction or drug-related measures, but include these items in, e.g., expen-
ditures for health, social matters and education. Expenditures specifically attributed to drug 
therapy services and the fight against drug abuse were only indicated by Styria49 (for drug 
therapy), the Tyrol50 (for the emergency sleeping facility Mentlvilla), Carinthia51 (drug coordi-
nation and drug outpatient services), Lower Austria52 (drug counselling centre) and the Fed-
eral Government53 (BMGFJ: fight against the abuse of addictive substances). In Salzburg54, 
Vorarlberg55, 56, Upper Austria57, Carinthia and the Tyrol there are budget items covering ad-
diction in general, or addiction and drugs are included under one and the same item. Based 
exclusively on the expenditures classified as drug-specific in 2005, the corresponding propor-
tion is relatively small in Austria, namely EUR 4 mill (the largest share of which is spent by
                                                
46 COFOG, the Classification of Functions of Government, comprises ten functions, which are subdivided into groups and clas-
ses. In Austria, at present the expenditures are only available according to the ten COFOG functions, but not according to 
groups and classes. 
47 http://www.wien.gv.at/finanzen/budget/va05/ (27 July 2007) 
48 http://www.burgenland.at/media/file/124_budg5.pdf (27 July 2007) 
49 https://sterz.stmk.gv.at/lve/public/SiteCostEstimation.do (27 July 2007) 
50 http://www.tirol.gv.at/fileadmin/www.tirol.gv.at/themen/zahlen-und-fakten/budget/downloads/2005/budgeta05oaoh.pdf 
(27 July 2007) 
51 http://www.kaerntner-landtag.ktn.gv.at/cgi-bin/evoweb.dll/web/akl/11660_DE-Budget-Landesvoranschlag-2005.htm 
(27 July 2007) 
52 http://www.noe.gv.at//SERVICE/F/F1/Budget/voranschlag/2005/VA_Hauptteil.pdf (27 July 2007) 
53 http://www.rechnungshof.gv.at/fileadmin/downloads/BRA/BRA_2005/BRA2005_Band_1.pdf (27 July 2007) 
54 http://www.salzburg.gv.at/erlaeuterungen_landesvoranschlag2005.pdf (27 July 2007) 
55 http://www.vorarlberg.at/pdf/kurzinformationzumentwur1.pdf of 27 July 2007 
56 http://vlb-lotus.vorarlberg.at/vlr/vlr_gov.nsf/vlr/vlr_gov.nsf/40C1FFFAB4B3D2EEC125717A00714273?OpenDocument (27 July 
2007) 
57 http://www1.land-oberoesterreich.gv.at/budget/ (27 July 2007) 
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the federal government), as the major part of the expenditures in question are included in 
other budget items (see Chapter 11.2). If we compare this figure to the latest available esti-
mate of EUR 67 million in the year 2001 (ÖBIG 2002a), it becomes clear that the figures de-
rived from the budget are by no means significant. 
11.2 Estimation of non-labelled drug-related expenditures  
In 2002 ÖBIG carried out a survey of public expenditures for drug-related demand reduction. 
As shown in the Report on the Drug Situation 2002, drug-related demand reduction meas-
ures are mainly financed by the federal government, the provinces, local governments, the 
social insurance funds and the Public Employment Service (AMS). According to the survey, 
the provinces play the most significant role here (approx. 43%), followed by the social insur-
ance funds (approx. 22%). As indicated in the survey, the federal government bears a mere 
13% of the estimated total expenditure in the field of drug-related demand reduction. In 2001, 
total expenditures on drug-related demand reduction were estimated at approximately EUR 
67 million (ÖBIG 2002a).  
As in 2002, research in 2007 which has been designed more broadly to include the field of 
supply reduction as well shows great structural differences with regard to the various public 
funding sources. At the federal level, means or expenditures have been assigned specifically 
under the heading of addictive substances or drugs by the Federal Ministry for Health, Family 
and Youth. In the preliminary budget as well as in the financial statement, this Ministry re-
ports several items of expenditure for the purpose of combating the abuse of addictive sub-
stances which are ear-marked for, e.g., the promotion of prevention and drug help services, 
the funding of operative tasks as provided by law (supplying prescriptions for addictive sub-
stances) and specific projects (such as publishing information material, allocating certain re-
search and development contracts, etc.). However, a strict method of limitation of these 
means to the field of (illegal) drugs is not possible, as they partly cover more comprehensive 
areas. For example, the booklet Zum Thema Sucht (On Addiction) financed under this head-
ing offers information not only on illegal drugs, but also on the whole range of psychoactive 
substances and to some extent on addictive behaviour irrespective of substances. Not all 
drug-specific expenditures are specified as such: e.g., the funding of research institutions, 
especially of the REITOX Focal Point, is included under a different heading, as there is no 
corresponding specification of tasks. Inaccuracies also occur in the field of personnel expen-
ditures on account of the lack of task specification, which means that regarding personnel 
costs in the field of illegal drugs, only a rough estimate is possible.  
The expenditures on combating drug-related crime spent by the Federal Ministry of the Inte-
rior cannot be indicated, either. Here, the problem is that it is hard to distinguish or separate 
the fight against drug-related crime from the fight against other forms of crime, therefore it 
cannot be measured (Mader, personal communication). Also with regard to law enforcement 
and the costs connected to criminal procedures (drug-related offences), it is not possible to 
render meaningful and significant data, calculations or estimates. However, currently report 
systems are being designed which may facilitate a cost estimate regarding persons impris-
oned for offences against the Narcotic Substances Act  (Kahl, personal communication).  
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To sum up, while the Federal Government spends part of the public expenditures allocated 
to the field of drugs, the classification of means is regulated by budget law standards and 
therefore it is not consistently feasible to relate these expenditures directly to the field of 
drugs. 
Rather than an estimate of the costs incurred by health insurance funds, expenditures for 
treatment in hospitals can be specified. Table 11.1 indicates the costs of inpatient admission 
and beds occupied by patients with drug dependence/toxicomania as primary diagnosis. In 
2005, there were 98 571 care days accounted for by patients with drug-specific primary di-
agnoses, which results in expenditures of an estimated EUR 24.1 million. 
Table 11.1: Inpatient hospital stays and beds occupied* by patients with drug 
dependence/toxicomania** as primary diagnosis, 1999–2005 
Indicator / year 1999 2000 2001 2002 2003 2004 2005 
Inpatient stays 4 466 4 704 4 795 4 981 4 984 5 258 5 252 
Care days 86 335 87 196 84 299 88 481 89 638 93 745 98 571 
Estimated expenditures*** 17.8 18.5 18.4 19.9 20.7 22.2 24.1 
* excluding patients with a stay of more than 365 days 
** selected according to the diagnosis group Drug dependence, toxicomania of the European Shortlist (ICD-10 F11, F12, F13, 
F14, F15, F16, F18, F19) 
*** million EUR 
Sources: BMGFJ – DLD 1992–2005; calculations by GÖG/ÖBIG; representation by GÖG/ÖBIG 
11.3 National studies on drug-related public expenditures 
In Austria hardly any studies on drug-related public expenditures are conducted, so no rou-
tine data exist in this respect.  
The few studies that are available have been presented in the corresponding Key issue 
chapter of the Report on the Drug Situation 2002. A survey on the social costs related to ad-
diction diseases is included in Chapter 8.4. 
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12 Vulnerable Groups of Young People 
In Austria, there are no surveys available on the basis of which the requirements of the 
EMCDDA could completely be met in the context of this chapter. Neither is there a system 
corresponding to the ACORN classification58 used in the UK. As the EMCDDA guidelines do 
not fit the reality in Austria, which is characterised by an integrative approach, they cannot be 
complied with; this chapter is an attempt to approach the subject on the basis of the current 
data situation.  
12.1 Epidemiology related to vulnerable groups 
Although, as mentioned before, there is no literature specifically dealing with the profile of 
vulnerable groups in Austria, statements on the issue may be extracted from surveys with 
different focuses. For example, the description of the clients of the Mentlvilla house in Inns-
bruck, which offers emergency accommodation, is perfectly suited for drawing a profile that 
generally applies to extremely vulnerable groups. Half of the Mentlvilla occupants are be-
tween 18 and 27 years old and have been dependent on drugs for several years, which 
means that they started using drugs when they were minors. In addition, the persons con-
cerned have been homeless for some time. They are young people who grew up in changing 
foster families or institutions, or who come from socially disadvantaged families with a low 
level of education and training, in which already the parents had addiction diseases. How-
ever, it should also be mentioned at this point that any youth may become addicted 
(Mentlvilla, personal communication). 
It has turned out that many young drug users have come into conflict with the law very early 
(see also below) and that delinquency is continued later on (although only in the context of 
minor offences, in many cases). However, one must bear in mind that young drug users – 
apart from their drug consumption which is mostly illegal – are not per se criminals. In many 
cases, the connection between juvenile delinquency and drug use is either non-existent or 
very complex, as both behaviours often originate from the same causes: lack of opportuni-
ties, perspectives, and self-esteem, the desire to be accepted and loved, to have a family, a 
regular life etc. 
Refugees, asylum seekers and immigrants illegally staying in Austria are an at-risk group 
which is becoming more and more noticeable. Admittedly, from the point of view of assis-
tance services it is impossible to tell whether these persons have developed their addiction 
only upon coming to Austria or whether they were dependent on drugs before. But also in 
these cases, their mostly bleak situation and the lack of perspective which many of these in-
dividuals experience is clearly conducive to the development of an addiction and of problem 
drug use. (Mentlvilla, personal communication). 
                                                
58 The ACORN classification used in the United Kingdom is the leading geodemographic tool for describing the population and 
their demand for products and services on the basis of the 287 lifestyle variables and other factors. In addition, HealthACORN 
offers the option to describe a mix of persons at the level of neighbourhoods and identify four groups according to disease 
status and lifestyle. 
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Looking at the interrelation between drug use and truancy according to the ESPAD school 
survey59 of 2003 (Uhl et al. 2005b, Table 12.1), it becomes apparent that individuals who do 
not often play truant have a lower lifetime prevalence for the use of illegal drugs than those 
who stay away from school more often. However, a possible bias in the answers of the 
school students should be taken into account. And one should take into account that the 
number of cases in some instances is very small. 
Table 12.1: Prevalence rates in the context of the number of truancy days within the past 30 days 
(%; n = 5.270) 
Lifetime prevalence Number of truancy days 
within the past 30 days Cannabis use 
average: 22% 
Illegal drugs apart from cannabis 
average: 10% 
Cannabis and alcohol 
average: 17% 
None 17.1 7.4 12.4 
One day 30.2 13.6 24.7 
Two days 38.4 16.7 33.8 
Three or four days 46.9 22.3 33.7 
Five or six days 54.0 21.6 46.9 
Seven or more days 55.8 34.2 46.7 
Source: Uhl et al. 2005b ; representation by GÖG/ÖBIG 
The question whether the connection between staying away from school and indicated sub-
stance use points to consequent development of problem drug use later in life cannot be an-
swered on the basis of the available studies. The ESPAD survey does not appear to be a 
very appropriate source of information on (the possibility of) social marginalisation, as the 
group of young people engaging in massive drug misuse is mainly not composed of school 
students. As a common background for the various psychological and social risk factors, a 
lack of affection, structure, orientation and positive relationships as well as perspectives was 
registered among the young people concerned. It should be added that not a single risk fac-
tor, but rather an accumulation of problem situations and the simultaneous lack of resources 
(protective factors) are responsible for the development of an addiction (ÖBIG 2002b). This 
observation is also confirmed by a survey carried out in Lower Austria60 in late 2005 on the 
issue of drug use. According to the authors, opiates, cocaine and other hard drugs played a 
minor role among the young respondents, and experimental use of these drugs was also 
rare. Only a small number of vulnerable young people who experience an accumulation of 
several strain factors that may lead to an addiction seem to turn to such drugs and become 
dependent on them (Gartner-Schiller & Neumayr 2006). 
Individuals regarded as belonging to especially vulnerable groups among the clients re-
ceiving assistance or undergoing treatment are those who have no job qualifications or 
are unemployed and live in a precarious housing situation. If young people are already af-
fected by these factors, they may be defined as a vulnerable group by any standard (e. g., 
social exclusion on account of homelessness, diseases, etc.; see also GÖG/ÖBIG 2006). 
                                                
59 In the context of the ESPAD survey, in 2003, 5 270 Austrian ninth- and tenth-graders were interviewed about alcohol and o-
ther drugs. 
60 In the context of a survey carried out by the counselling service Auftrieb in the Wiener Neustadt region (Lower Austria), 1 404 
young people aged between 12 and 19 were interviewed. 
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Therefore, below a special focus of attention is placed on this group of persons undergoing 
treatment. In order to present the development of treatment/assistance data over time, the 
BADO61 Basic Documentation which has been maintained in Vienna since 2002 serves as a 
basis (IFES 2006). For the present purposes only those data are supplied which contain a 
representation by age.  
One fourth of those aged between 16 and 20 who are assisted in the Vienna drug help ser-
vices have only completed primary school, which reflects the high share of persons who 
dropped out of the school system prematurely. 42% of this age group have only finished 
lower secondary school, another fifth have completed polytechnic school. Around 80% of 
those aged between 16 and 20 indicated that they had no job. In this age group 14% of the 
clients are in inpatient treatment, with half of them currently undergoing substitution treat-
ment, a figure which has more than doubled since 2002. 59% are treated in a drug help ser-
vice for the first time. 
Beginning with the clients who turned to Austrian drug help services in 2006, the nationwide 
documentation system DOKLI62 was established to register these clients (see Chapter 4.2; 
GÖG/ÖBIG 2007a). In order to obtain statements on homeless persons without gainful em-
ployment younger than 20 years of age in the Austrian drug help system, additional analyses 
were made.  
Table 12.2: Selected sociodemographic parameters for members of the surveyed target groups, 
who are assisted in low threshold services* (n = 563) or longer-term outpatient services** 
(n = 4 200), by age and gender (%) 
Age and gender 
Younger than 20 20 years and older All age groups 
Selected sociodemographic  
parameters 
Men Women Men Women Men  Women 
Housing situation*: unstable (n = 417) 25 27 51 41 44 35 
Gainful employment*: no (n = 354) 77 85 80 88 79 87 
Obligation/referral**: yes (n = 3 856) 49 32 37 26 40 27 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006; representation by GÖG/ÖBIG 
Table 12.2 clearly shows that the incidence of unemployment and especially of an unstable 
housing situation rises with the age of clients, whereas obligatory treatment – in the context 
of criminal investigations – tends to be accounted for by younger rather than older persons 
and men rather than women.  
                                                
61 Basic documentation of clients of drug help services in Vienna established by the Vienna working group on documentation. 28 
centres with data sets of 3 2452 persons participated in the basic documentation for 2005. BADO data (client year 2006) are 
also included in the DOKLI data and are therefore contained in the DOKLI system as well as in DOKLI-specific evaluations. 
62 Data collected by the drug help services in Austria on a total of 4 200 persons who started undergoing longer-term outpatient 
treatment in 2006 are covered by DOKLI. 1 403 started longer-term inpatient treatment and 563 accepted low-threshold as-
sistance. 5 069 persons came to a drug help service for a short-term contact.  
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Table 12.3: Primary drugs of persons younger than 20 in unstable housing situation compared to 
primary drugs indicated by the same age group in a stable housing situation, among 
clients receiving low-threshold assistance, by gender (%; n = 120) 
Housing situation of  persons younger than 20, by gender 
Unstable Stable 
Primary drugs 
(multiple indications were possible) 
Men Women Men Women 
Opiates 58 33 7 26 
Cocaine group 0 17 2 0 
Stimulants 0 0 2 3 
Tranquilizers/hypnotics 37 25 2 0 
Hallucinogenic drugs 0 0 0 0 
Cannabis 21 25 75 74 
Solvents and inhalants 0 0 0 0 
Alcohol 11 17 20 24 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006; representation by GÖG/ÖBIG 
Regarding the primary drugs indicated in Table 12.3 (multiple answers were possible) there 
are substantial differences between persons in an unstable housing situation and those who 
live in a stable environment. In unstable housing situations, opiates and tranquilizers/hypno-
tics play a major role, whereas young people in stable housing situations prefer cannabis and 
alcohol, the women among them also opiates. 
Table 12.4: Predominant route of administration among 20 year-olds living in an unstable housing 
situation, compared to indications by the same age group in a stable housing situation, 
among clients receiving low-threshold assistance, by gender (%) 
Housing situation of those younger than 20, by gender 
Unstable Stable 
Predominant 
route of administration 
Men Women Men Women 
Heroin (n = 310)     
Injecting 56 20 21 27 
Smoking 0 20 9 5 
Snorting 44 60 69 66 
Substitution substances (n = 235)     
Injecting 38 38 37 38 
Eating and drinking (oral use) 63 38 53 44 
Snorting 0 25 9 15 
Cocaine (n = 325)     
Injecting 25 14 8 15 
Snorting 75 86 89 81 
Amphetamines (n = 283)     
Injecting 10 0 1 0 
Eating and drinking (oral use) 20 50 30 38 
Snorting 70 50 7 60 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006; representation by GÖG/ÖBIG 
Regarding the route of administration the group of men in unstable housing conditions indi-
cate that they preferably inject substances (see Table 12.4). The group of persons living in a 
stable environment mainly snort heroin and cocaine. In both groups, women rather inject or 
snort substitution substances while men prefer to use these substances orally (GÖG/ÖBIG 
2007a). 
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As to the frequency of drug use within the past 30 days, the group of persons living in unsta-
ble housing conditions shows markedly higher consumption frequencies with regard to most 
substances (GÖG/ÖBIG 2007a). 
Revealing insights into the lives of homeless drug users are provided by Margit Putre in her 
diploma thesis (2006)63. She demonstrates that most of the clients who sleep a lot develop 
drug dependence already at an early age (average age at problem use: 17 years) and have 
a long history of drug use. On average, the first contact to Ganslwirt is made seven years af-
ter the first phase of problem drug use. For the diploma thesis, four homeless drug users 
aged between 22 and 38 were interviewed, which means they are beyond the age span that 
is relevant for this chapter. Nevertheless, their reports are rendered here, as they used drugs 
already when they were young, and it is precisely the retrospective view on their lives up to 
the point of the interview that gives an impressive account of the examined group. 
One of the four respondents is a woman, which corresponds more or less to the average 
gender distribution of the persons documented in the drug help system (see Chapter 4.2). All 
four of them began using illicit drugs when they were between 16 and 18 years old, one per-
son indicated to have started drinking alcohol at age nine. They began to use drugs intrave-
nously at around 20. They used cannabis, alcohol and pharmaceuticals, heroin/morphine, 
ecstasy, LSD, speed and cocaine. They are all currently undergoing substitution treatment, 
with additional use of, e.g., alcohol and benzodiazepines, to varying degrees. The period of 
homelessness has lasted for between a few months and 17 years; in the latter case, the pe-
riod was interrupted by prison terms and hospital stays. The respondents reported their diffi-
cult family situation, being dominated by a violent father and neglected by a mother addicted 
to alcohol and pharmaceuticals, being referred to a home and restrained with tranquilisers 
because of hyperactivity from age ten on. The trigger for homelessness was that they broke 
up with their families of origin or with significant persons in their lives, which made them lose 
resources that had supported them. The male respondents had been addicted to drugs be-
fore becoming homeless, whereas in the case of the female respondent addiction followed 
after she lost her family and her home. The respondents suffer from hepatitis, cirrhosis of the 
liver and/or HIV, among other conditions (Putre 2006). 
Apart from people who use drugs as a coping strategy in the context of social problems, 
there is also a great number of users with dual diagnoses, i.e., addiction diseases with con-
comitant psychiatric disorders (depression, psychosis, borderline personality etc.), some of 
whom take drugs as a kind of self-medication in the sense of a consciously applied strategy 
of repression. In addition, there are still many young drug users who are infected with hepati-
tis C as a consequence of unsafe intravenous drug use. Other consequences are hardened 
veins, phlebitis and syringe abscesses (Drug Counselling Service Z6 and Mentlvilla, personal 
communications).  
                                                
63 In her diploma thesis Margit Putre, executive manager of the social medicine drug counselling service Ganslwirt conducted 
problem-centred interviews with four representative clients, selected among 41 persons who are the most frequent occupants 
of the emergency sleeping facility at Ganslwirt. 
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According to a study on self-reported delinquency of young people in Austria64, 27% of the 
respondents who report to have committed petty theft, indicate that they have experience of 
alcohol and drugs. In cases of aggravated theft, the corresponding share is 46%. 23% of the 
respondents who have observed increasing tendencies towards criminal behaviour among 
their friends also indicate experience of alcohol and drugs. In addition, young people report-
ing either offences or experience with drugs and alcohol also mention having had problems 
with their parents (Hager und Stummvoll 2006). 
12.2 Responses to drug problems among vulnerable 
groups 
Responses and measures taken in the context of drug problems among vulnerable groups 
aim to create an adequate political and legal framework on the one hand and to initiate activi-
ties in the field of prevention and treatment on the other. In this sense the Vienna Drug Policy 
Programme provides that members of society who have become marginalised be reinte-
grated into society and social vulnerability be prevented as far as possible (Bäcker und Mag-
nus 2006). In this respect integrative approaches with the aim to let the children and adoles-
cents stay in their families of origin wherever possible play a great role. Moreover the young 
person suffering from addiction should be offered a sufficient network of housing and care 
units where they can relax and get a hold on drug use (Mentlvilla, personal communication).  
At the level of jurisdiction, the structural improvement of Juvenile Courts pertaining to Prov-
ince Courts is planned. At the same time a location in Vienna’s third district shall serve as the 
location for re-establishing the Juvenile Court with an attached prison for juvenile delinquents 
(with approximately 350 places) and additional facilities.65 Established in 1929, the former 
Juvenile Court with public prosecutors and judges specially trained to take into account the 
specific conditions of adolescent criminal behaviour, was closed in 2003. 
Furthermore, under Section 13 of the Narcotic Substances Act (SMG) schools are obliged to 
offer targeted help to students who evidently abuse narcotic substances. In such a case the 
head of the school shall have the young person in question tested by the school physician 
and/or the school psychologist. Depending on the results of the examination, a health-related 
measure according to Section 11 (2) of the SMG may be necessary. If the student goes in for 
the tests as ordered, there is no obligation for the school to report them to the authorities. In 
this way the student concerned can stay on at their school and possible social marginalisa-
tion on account of drug use is prevented (GÖG/ÖBIG 2006). 
Also in the field of schools, the secondary prevention project Step by Step is aimed at the 
implementation of the above-mentioned Section 13 of the SMG. As a contribution to early de-
tection and crisis intervention it provides help for teachers in their contacts with students who 
show distress or use narcotic substances. Furthermore, networking with relevant actors, ser-
                                                
64 In this study carried out by the Institute for the Sociology of Law and Criminal Sociology in cooperation with the Austrian Insti-
tute for Youth Research 3 009 school students from Austrian major and small towns were interviewed on the issue of delin-
quency. 
65 www.jusline.at, press communication of 20 July 2007 
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vices and authorities is a possibility to form crisis intervention teams in schools; if they wish, 
these teams can receive coaching by experts from the Addiction Prevention Units free of 
charge.66 
At vocational schools, it is difficult to implement the existing action model as provided in Sec-
tion 13 of the SMG, due to the short period during which students stay at these schools 
which in rural areas are mostly organised as boarding schools with one period of instruction 
per semester. This causes problems as to the implementation of the early warning system 
and long-term assistance (Hutsteiner et al. 2005). 
Regarding newborn babies (in Vienna, between 50 and 60 a year) of drug-dependent moth-
ers, the decision on separating the children from their mothers or parents should not be con-
sidered as a general primary strategy. Rather, the possibilities of stabilising the individual life 
situation of the parents through appropriate, multi-disciplinary support should be considered 
and by helping the mothers or parents it should be avoided that the children have to live 
elsewhere. This is successful for about one third of the children concerned. Another third is 
taken to a home away from the mother immediately, and for the remaining third, a home is 
found within the first years of life (Berger und Elstner 2002; Bäcker und Magnus 2006).  
An integrative approach is also taken in practical youth welfare, with the drug competence 
centre MAG ELF as an interface between drug help services and youth welfare. The task of 
the centre is to protect children, on the basis of using the most moderate intervention. It is at-
tempted to find a solution which is as close as possible to the family in question. Only in 
emergency cases is the child taken away (Bäcker, personal communication). Also in Styria, 
there is a competence centre where persons working in the fields of drug help and youth wel-
fare regularly cooperate on the basis of a solution- and resource-oriented approach (Drogen-
beratung des Landes Steiermark 2007). The activities of ENCARE, in which regional net-
works focusing on children in drug-dependent families are established, should also be men-
tioned in this context (see Chapter 3.2).  
Experts assume that in addition to long periods of waiting for withdrawal and therapy places 
caused by ever more complicated bureaucracy, the lack of services supporting young people 
after a long-term therapy poses a great problem. Also, additional street social work projects 
should be supported, as in their outreach work and to some extent also follow-up counselling 
and repeated offers of contacts, street social workers may provide alternative values for drug 
users. What is also needed is services that give young people an adequate opportunity to 
develop a positive daily structure again, to complete school and professional training that 
were discontinued and to be integrated into the labour market (Mentlvilla, personal communi-
cation).  
There are a number of services offering emergency sleeping facilities, which are not specifi-
cally directed to addiction, but in which addiction to alcohol or drugs is no obstacle for admis-
sion. An example for this is the Vienna low-threshold service a_way, which provides emer-
gency beds for homeless adolescents aged between 14 and 18 (see  GÖG/ÖBIG 2006). 
                                                
66 www.Suchtvorbeugung.at (26. July 2007) 
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In 1997, VWS streetwork, on behalf of the Municipal Department for Public Health and Social 
Welfare of the City of Vienna (MA 15) drew up a strategy for planning social work in the field 
of male prostitution, which, however, has not yet been implemented. The target group is 
young men between 14 and 25 years of age, some of whom are already using hard drugs. In 
order to reach the goals of STD prevention, psychosocial support, prevention of destitution 
and poverty, as well as support during reintegration, a multifunctional contact point for male 
prostitutes including a telephone helpline is needed. The cooperation of various partners in 
the fields of health, medicine, legal and social matters is indispensable for taking further 
measures (VWS 2000).  
The project Way out, which had been started in 2002, was turned into a running project by 
means of an unlimited contract with cooperation partner NEUSTART, and provides regional, 
youth-directed services in Carinthia. Based on the principle of help instead of punishment, 
this secondary prevention project for adolescents and young adults between 14 and 21 years 
is an early intervention service for young  first-offence drug users. With a duration of ap-
proximately six months it provides targeted help interventions in the sense of health-related 
measures which can be carried out regionally in all areas of Carinthia if needed (Drobesch, 
personal communication; see also GÖG/ÖBIG 2006; EDDRA). 
Since June 2006 the addiction counselling unit B.I.T. in the Tyrol has also intensively dealt 
with the situation of children and young people in families with addiction problems. The work-
ing group established for this purpose consists of youth welfare officers, drug help services 
and Kontakt & Co, the Addiction Prevention Unit. The aim is to draw up a binding coopera-
tion guideline as a standard for everyday practical work (B.I.T., personal communication). 
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13 Drug-related Research 
The following selected issue chapter is an attempt to give an overview of national and re-
gional structures of drug- and addiction related research in Austria according to the guide-
lines of the EMCDDA67. The objective is to provide insights into political competencies, im-
plementation structures and financing systems of drug-related research funding, to provide 
an overview of the field of research in Austria by presenting five relevant research projects, 
and to sketch this area by listing the articles published by Austrian researchers in field-
specific (international) journals in 2006. Lastly, the national and regional structures for dis-
seminating the results of research are presented. 
13.1 Research structures 
Looking at the field of drug-related research in Austria one becomes aware of the great di-
versity and little planning in this field which is mainly characterised by the initiatives of indi-
vidual institutions and researchers. It is important to distinguish between research contracts 
and funded research. Research contracts are mainly awarded by the federal government 
(e.g., consumption surveys in  the general population and in schools; see Chapter 13.2) or 
the provincial governments (e.g., evaluation studies, demand surveys). For example, the 
Ministry of Health finances representative surveys and the Ludwig Boltzmann Institute of Ad-
diction Research. Research funding is applied for by research institutes and individual re-
searchers. The field of interaction between politics, practice and research has no established 
structures in Austria, but especially in the field of commissioned research, decisions are in-
fluenced by research results. There is no general research strategy or coordinating body for 
the field of drugs and addiction in Austria, either at national or at provincial level. 
In Austria there are two interdisciplinary research institutes specifically dedicated to the issue 
of addiction. The Ludwig Boltzmann Institute of Addiction Research68 (LBISucht) is based on 
a cooperation between the Anton Proksch Institute, which is the largest therapy centre as-
sisting persons addicted to alcohol and/or drugs in Austria, and the Ludwig Boltzmann Soci-
ety, an umbrella organisation with the aim of promoting scientific research in Austria. The LBI 
Sucht publishes the quarterly Wiener Zeitschrift für Suchtforschung. Research focuses on 
epidemiology, drug-specific problem areas (e.g., traffic safety), drug policy, social history, 
evaluation research, studies on addiction treatment and prevention as well as papers dealing 
with statistics and methodology. In recent years there were increased research activities 
within the framework of international studies in the field of evaluation of primary prevention. 
The Addiction Research Institute69 was established as a branch of the University of Innsbruck 
in 1990 and is based at the treatment centre for addiction patients Maria Ebene hospital in
                                                
67 The EMCDDA defines drug-related research as research into the use of drugs, addiction and its consequences as well as the 
responses to drug use and drug related problems. This definition covers basic and applied research. 
68  www.api.or.at/lbi  
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Chapter 13: Drug-related Research 
 83
Vorarlberg. The research undertaken at this Institute focuses on physical, psychological and 
social disorders and diseases in the context of alcohol, nicotine, illicit drugs and psychotropic 
substances. 
At university level drug-related research is mainly found in the medical field of hospitals. The 
Hospitals of Psychiatry of the Universities of Vienna and Innsbruck should be mentioned in 
this context as centres of continuous substitution-specific research (see Chapter 13.2). Sin-
gle projects in the field of basic research into social issues may be found at university de-
partments dedicated to social studies. Addiction- and drug-specific issues are also discussed 
in diploma theses and dissertations; social consequences are explored mostly at Social Work 
Colleges of Higher Education, whereas public health issues are mainly studied at Health 
Management Colleges of Higher Education. Individual drug help services, e.g., ChEck iT!, 
are also committed to questions that are relevant for research, and to a growing extent, pri-
vate institutes in the field of drug-related research accept contracts as well. Gesundheit 
Österreich GmbH / Austrian Health Institute (GÖG/ÖBIG) also carries out research in the 
context of drugs and addiction. Examples are the two studies on the requirements of preven-
tion regarding young people vulnerable to addiction and the prevalence estimates for prob-
lem drug use (see 2001b, ÖBIG 2002b, GÖG/ ÖBIG 2006). 
In Austria there is no specific institution competent for centralised allocation of means for 
drug- or addiction-relevant issues. Therefore drug-related research is included in the general 
structure of research promotion in Austria. In the field of basic research, competence mainly 
lies with the federal authorities. Because of the great number of funding institutions, no fund-
ing figures can be given either for research in general or for drug-specific research. 
At federal level, apart from research funding by the Federal Ministries there are major fund-
ing institutions that accept applications of drug-related research projects according to their 
focus. One example is the Austrian Research Promotion Agency (FFG)70, the central organi-
sation for the promotion of research and innovation in this country. It focuses on economi-
cally relevant and application-oriented research. The Austrian Science Fund (FWF)71 is Aus-
tria’s central institution for the promotion of basic research. It is committed to all academic 
fields in the same measure, and in its activities it closely adheres to the standards of the sci-
entific community. The Österreichische Nationalbank (OeNB), the central bank of the Repub-
lic of Austria, in 1966 founded the Jubilee Fund for the promotion of academic research and 
teaching. The means are awarded for scientific projects of high quality in the fields of eco-
nomic studies, medical science, social sciences and humanities.72 Especially in the field of 
health, the Healthy Austria Fund (GÖG/FGÖ) also finances application-oriented research 
projects and studies on the further development of health promotion and comprehensive pri-
mary prevention, as well as epidemiology, evaluation and quality assurance in these areas.73 
Other sponsors of addiction- and drug-related research can be found at the level of provinces 
and in the promotion programmes of the European Union (EU). The multiplicity of structural 
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levels involved (federal and provincial levels, EU level) and the great variety of research 
funding sources make it difficult to survey the sphere of research promotion in Austria. There 
are some Internet portals which may help to get an overview. In addition, each funding insti-
tution gives information on their own website. For example, the website of the City of Vi-
enna74 and the grants compass75 of the Federal Ministry of Transport, Innovation and Tech-
nology (BMVIT) provide a general navigation system for nationwide research promotion in 
Austria.  
13.2 Main recent studies and publications 
 
In Austria, a great variety of research approaches both at national and at provincial level can 
be registered in the field of drug-related research. In addition to evaluation studies, clinical 
comparisons (e.g., on substitution) and population surveys (e.g., addiction monitoring Vi-
enna, ESPAD, population survey Austria; see also Tables A1 and A2 in Annex A), qualitative 
research projects have been carried out as well (e.g., on the life situation of drug users). Be-
low five relevant studies are presented, all of which were conducted after 2000. In order to 
represent the broad range of drug-related research approaches, they have been selected 
according to the criteria of diversity in the field of research into drugs and addiction. 
The European study QUASI-Compulsory Treatment (QCT) of Drug Addicted Offenders 
was organised by the European Institute of Social Services (EISS); the Austrian contribution 
was coordinated by the Professor of Clinical Psychology of the University of Vienna. This 
study project was financed within the framework of the European Commission’s Fifth 
Framework Research Programme and had a running period of three years (10/2003 to 
9/2005)76. As the first systematic comparative evaluation, the QCT Europe study examined  
the efficacy and efficiency of existing QCT systems at national and European level in Austria, 
Germany, Italy, the Netherlands, Switzerland and the United Kingdom. QCT systems are de-
fined as applied therapeutic and psychosocial interventions following drug-related crimes 
(therapy obligations, therapy instead of punishment, compulsory therapy, drug therapy in 
prisons) with the aim of social integration of the drug-dependent offenders, the pronounce-
ment of legal probation and a longer-term perspective of a drug-free life.  
For the Austrian part of this longitudinal study a quasi-experimental design was chosen, 
which compared voluntary therapy clients to participants in a court measure, with the corre-
sponding control groups. In the interview period between July 2003 and January 2005 a 
qualitative and quantitative first interview after starting treatment (n = 150) and follow-up in-
terviews after six, twelve and 18 months (n = 67) were carried out, regardless of the course 
of treatment. The European Addiction Severity Index (EuropASI) and the questionnaire on 
perceived pressure were used as interview tools. During the first interview, the compulsory 
clients were compared to voluntary clients with regard to drug use, criminal behaviour, psy-
chological and medical problems as well as perceived pressure. The follow-up interview was 
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especially directed at the indicators of therapy completion and success of therapy in connec-
tion with drug use, criminal behaviour, physical and psychological health and social integra-
tion. The results do not indicate any difference in the total amount of perceived pressure. In 
both settings the clients perceive themselves to be under pressure, no difference was regis-
tered between experienced social pressure and pressure by the justice system. It follows that 
there is no negative influence of indirect pressure by court interventions on the discontinued 
therapy quota (Werdenich, personal communication, DrugNet Austria 10/2003).  
A. Stevens, D. Berto, U. Frick, V. Kerschl, T. McSweeney, S. Schaaf, M. Tartari, P. Turnbull, B. Trinkl, 
A. Uchtenhagen, G. Waidner, W. Werdenich (forthcoming). The victimisation of dependent drug users: Findings 
from a European Study. European Journal of Criminology, 4,4 (to be published in October 2007) 
A. Stevens, D. Berto, U. Frick, N. Hunt, V. Kerschl, T. McSweeney, K. Oeuvray, I. Puppo, A. Santa Maria, 
S. Schaaf, B. Trinkl, A. Uchtenhagen, W. Werdenich (2006). The relationship between legal status, perceived 
pressure and motivation in treatment for drug dependence: Results from a European study of quasi-compulsory 
treament. European Addiction Research, 12/2006, 197-209 
The cross section study Cocaine Use in Europe – A Multi-Centre Study investigating into 
cocaine use in three major groups of users was also financed by the European Commission. 
Besides Vienna nine other European cities (Hamburg, Stockholm, London, Barcelona, Zu-
rich, Dublin, Rome, Budapest) participated in the study77.  
The Austrian part of the study was coordinated by the University Hospital of Psychiatry of the 
Medical University of Vienna and supervised by Gabriele Fischer, the exact budget is un-
known. The objective was to examine the current situation of cocaine users, the assessment 
of the cocaine problem by experts and to obtain reliable findings on cocaine use. Data were 
collected by means of structured interviews with 211 cocaine users, who were divided into a 
treatment group (n = 70), a scene group (n = 71) and a party group (n = 70). In addition, so-
ciodemographic data such as age, level of education, employment status, monthly expenses 
for cocaine and crack and data on use patterns and physical and psychological health were 
collected. Toxicological tests of urine samples for cocaine were also analysed. The results 
showed that members of the scene group are oldest (around 29 years), have the highest un-
employment rate as well as the longest period and the highest frequency of use (22 days per 
month). In the treatment group, the lowest education level (number of school years) is found; 
what is striking, however, is that the members of this group show the greatest understanding 
of their drug use problem. The party group, on the contrary, highly underrates the dimensions 
of their drug use. The study confirms the European trend of a rise in cocaine use also for Vi-
enna. One of the greatest problems with regard to establishing adequate treatment struc-
tures for this group of drug users is that they are hard to contact. In addition, one of the most 
significant patterns of cocaine use is multiple substance use, an aspect which should be 
taken into account when developing treatment programmes (Fischer, personal communica-
tion). 
A. Bäwert, N. Primus, R. Jagsch, H. Eder, M. Zanki, K. Thau, G. Fischer (2006). Cocaine abuse in Vienna and 
European cities – a multi-center study. Wiener Klinische Wochenschrift., 118 (17-18)/2006, 521-530 
C. Haasen, M. Prinzleve, H. Zurhold, J. Rehm, F. Güttinger, G. Fischer, R. Jagsch, B. Olsson, M. Ekendahl, 
A. Vester, A. Camposeragna, A. M. Pezous, M. Gosop, V. Manning, G. Cox, N. Ryder, J. Gerevich, E. Bacskai, 
M. Casas, J. L. Matali, M. Krausz (2004). Cocaine Use in Europe – A Multi-Centre Study. European Addiction Re-
search, 10/2004, 139-146 
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At the University Hospital of Psychiatry, Division of Neurochemistry, of the Medical University 
Innsbruck a research project financed by the FWF on Nucleus Accumbens Acetylcholine 
and Substance Dependence is currently running (from March 2006 to March 2008) super-
vised by Gerald Zernig-Grubinger78. 
The aim of this project, which is based on animal laboratory tests, is to identify new pharma-
cotherapy and psychotherapy approaches to the treatment of substance dependence. 
Among the cerebral regions transmitting a fatal preference of the dependent person for the 
addictive substance, nucleus accumbens plays a key role. In the course of determining the 
neurotransmitter release in the centre of nucleus accumbens during the development of the 
reinforcement effect of remifentanil, a mu-opioid agonist, by means of in-vivo microdialysis 
and tandem mass spectrometric (LC/MS/MS-)analysis of dopamine, acetylcholine and re-
mifentanil it turned out that the development of the reinforcement effect is accompanied by 
an increase in acetylcholine release, whereas the release of dopamine, the expected prime 
neurotransmitter candidate for conditioning, remains unchanged. These results call for a far-
reaching modification of the theory of dopamine reward, at least regarding the initial stages 
of addiction. The present focus of experimenting is on neuronal cell responses triggered by 
the accumbal activation of the acetylcholine receptors and what forms of “addiction memory” 
can be influenced in this way. Within the framework of this research project, also the interna-
tional state of the art in clinical and pre-clinical addiction research is critically evaluated: an 
international team of 15 authors introduces especially those who are not familiar with the 
matter to the currently favoured models accounting for the increase of drug use in drug-
addicted persons and explains the clinical and pre-clinical basis of these models (Zernig-
Grubinger, personal communication).  
J. A. Crespo, K. Sturm, A. Saria, G. Zernig (2006). Activation of Muscarinic and Nicotinic Acetycholine Receptors 
in the Nucleus Accumbens Core Is Necessary for the Acquisition of Drug Reinforcement. The Journal of Neuro-
science, 26(22)/ 2006, 6004-6010 
G. Zernig, S. H. Ahmed, R. N. Cardinal, D. Morgan, E. Acquas, R. W. Foltin, P. Vezina, S. S. Negus, J. A.       
Crespo, P. Stöckl, P. Grubinger, E. Madlung, C Haring, M. Kurz, A. Saria (2007). Explaining the Escalation of 
Drug Use in Substance Dependence: Models and Appropriate Animal Laboratory Tests. Pharmacology, 80/ 2007, 
65-119 
In Vienna, the drug testing service ChEck iT! in 1998 and from 2001 to 2003 carried out a 
questionnaire survey on the Consumption Patterns of Recreational Drug Users which 
was financed from the regular budget of the service.79 
The aim of this survey was to identify and assess consumption trends among people attend-
ing large, commercial rave parties, beyond concentrating on ecstasy use patterns towards 
examining a broader range of substances and creating a more diverse research design. In 
the secondary analysis of the questionnaires collected at rave events (n = 827) on the one 
hand the development of prevalence for the individual substances was examined, and on the 
other, a cluster analysis of the phenomenon of leisure-time drug use is investigated more 
closely on the basis of indicated use frequency of individual substances over the past few 
days. The major part of the data were collected at events in the Vienna area, a smaller part 
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in Linz and Innsbruck. The result of the cluster analysis is that leisure-time users do not fit 
into one homogeneous group, but can be divided into four different groups of users. The first 
group (n = 225), non-users of illicit drugs, is composed of non-users, experimental users and 
ex-users of illegal substances. In the second group (n = 295), that of occasional users, be-
sides alcohol sometimes also cannabis and ecstasy, and in rarer cases speed, are con-
sumed. The third group (n = 196) comprises cannabis users who occasionally use other rec-
reational drugs. Compared to the second group, cannabis is used more regularly and there is 
increased use of speed, ecstasy and mushrooms. In the fourth group (n = 111), the high-risk 
group, all substances except alcohol and cannabis are used more frequently than in the 
other groups, and rave events are attended most often. For the (further) development of spe-
cific prevention measures it seems useful to analyse these four different groups of users in 
more detail. Especially the two groups (group 3 and 4) that show problem use patterns need 
specific assistance beyond on-the-spot services (Eggerth et al. 2005a).  
A. Eggerth, M. Keller-Ressel, S. Lachout, R. Schmid (2005b). Konsumtypen bei Freizeitdrogenkonsumenten in 
Österreich. Sucht: Zeitschrift für Wissenschaft und Praxis, 51/2005, 88-96 
The Institute for the Sociology of Law and Criminal Sociology in cooperation with LBISucht 
carried out the project Viennese Drug Policy of the last 30 Years Seen by its Addressees 
and Actors from March 2003 to December 2005, under the supervision of Irmgard Eisen-
bach-Stangl and Arno Pilgram80. The project was financed by the Vienna Social Fund (FSW), 
the exact costs are unknown. 
The project was aimed at presenting the development of the regional Vienna drug policy and 
planning between 1970 and 2002, in a phase when national drug strategies and plans were 
transferred to the European level. The perception of drug policy on the part of the drug users 
concerned and their relatives (addressees of drug policy) and on the part of those who im-
plement drug policy (actors), was included in the analysis. The first project phase (2003) fo-
cused on analysing documents and reconstructing drug policy in Vienna since 1970 from le-
gal texts, reports by authorities and drug help centres, statistics and studies. In the second 
phase (2004) guided interviews (n = 50 each) were held with policy actors in the field of 
health, justice and security at federal and municipal level, as well as with persons working in 
the prevention and treatment system of the police, courts and prisons on the one hand and 
with addressees of drug policy on the other. The text analysis of the interviews with the ac-
tors of drug policy focused on the definition of their own role, their view on drug users and 
their social environment. In the case of the addressees evaluation focused on the self-per-
ception of drug users as dependent on contacts with controlling authorities as well as on their 
view of drug policy measures and services in Vienna at different times and in comparison to 
other places. According to the results of the study, there have been five characteristic phases 
of drug policy in Vienna. During the first phase drug policy took place exclusively at national 
level in the form of punishing measures. In the second phase drug-related treatment meas-
ures were tentatively added to the police measures. This was the starting point for involve-
ment at regional level. During the third phase, treatment options became the main approach 
towards solving drug problems, and at the same time regional drug strategies were consoli-
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dated. As a result, in the fourth phase Drug Coordinators were established and became 
competent for all drug-related measures with the exceptions of punishment and the newly 
developing addiction prevention. The fifth phase is characterised by the integration of re-
gional drug policy into regional social policy81. The results of this research project were not 
published in scientific journals. 
One relevant focus of research in Austria is surveys or comparative studies on various sub-
stitution substances. These studies are carried out above all by the University Hospital of 
Psychiatry at the Medical University of Vienna and at the Clinical Department of General 
Psychiatry of the Medical University of Innsbruck and are published internationally (see list of 
publications on the following page). 
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Selected field-specific articles published in 2006 and 2007 in international journals following exter-
nal reviews 
P. Baumann, C. Hiemke, S. Ulrich, G. Eckermann, H. L. Kuss, G. Laux, B. Muller-Oerlingenhausen, M. L. Rao, P. Riede-
rer, G. Zernig (2006). Therapeutic Drug Monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-
TDM group. Revue Médicale Suisse, May 24; 2 (67), 1413-8, 1429-2, 1424-6 
A. Bäwert, N. Primus, R. Jagsch, H. Eder, M. Zanki, K. Thau, G. Fischer (2006). Cocaine abuse in Vienna and European 
cities – a multi-center study. Wiener Klinische Wochenschrift, 118 (17-18)/2006, 521-530 
M. Busch (2006). Der epidemiologische Schlüsselindikator „Drogenbezogene Todesfälle und Mortalität von Drogenkon-
sumentinnen und Drogenkonsumenten“ in der Europäischen Union und in Norwegen. Suchttherapie, 7/2006, 154-161 
J. A. Crespo, K. Sturm, A. Saria, G. Zernig (2006). Activation of Muscarinic and Nicotinic Acetycholine Receptors in the 
Nucleus Accumbens Core is Necessary for the Acquisition of Drug Reinforcement. The Journal of Neuroscience, 26(22)/ 
2006, 6004-6010 
M. Ertl, S. Giacomuzzi, Y. Riemer, A. Vigl, G. Kemmler, H. Hinterhuber, M. Kurz (2006). Abstinenzzuversicht und 
Beikonsumverhalten substituierter Drogenabhängiger in Abhängigkeit vom Beschäftigungsstatus. Neuropsychiatrie, 
4/ 2006, 265-272    
G. Fischer (2007). Influence of Peak and Trough Levels of Opioid Maintenance Therapy on Driving Aptitude. European 
Addiction Research, 13/ 2007, 127-135 
G. Fischer, B. Kayer (2006). Substanzabhängigkeit vom Morphintyp – State of the Art: Erhaltungstherapie mit syntheti-
schen Opioiden. Psychiatrie und Psychotherapie, 2/2 2006, 39-54 
G. Fischer, R. Ortner, K. Rohrmeister, R. Jagsch, A. Baewert, M. Langer, H. Aschauer (2006). Methadone versus 
buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction, 101(2)/2006, 275-281 
S. Giacomuzzi, M. Pavlic, K. Libiseller, Y. Riemer (2007). Intramuskulärer Beikonsum von retardiertem Morphin bei 
ambulanter Opiatsubstitution mit Buprenorphin. Suchttherapie, 8/2007, 41-42 
S. Giacomuzzi, M. Ertl, M. Pavlic, K. Libiseller, Y. Riemer, G. Kemmler, H. Rössler, P. Grubwieser, W. Rabl, H. 
Hinterhuber (2006). Maintenance Treatment of Opioid Dependence and Patterns of Non-prescribed Drug Use: Results 
of a 4-Year Trial. Letters in Drug Design & Discovery, 3 (10)/2006, 731-740  
S. Giacomuzzi, G. Kemmler, M. Ertl, Y. Riemer (2006). Opioid Addicts at Admission versus Slow-Release Oral Mor-
phine, Methadone and Sublingual Buprenorphine Maintenance Treatment Programme Participants. Substance Use & 
Misuse, 41(2)/2006, 223-244 
B. Haas, F. Popp (2006). Why Do People Injure Themselves? Psychopathology, 39/2006, 10-18 
R. Haller, H. Hinterhuber, K. Mann (2006). Maintenance pharmacotherapies for opioid dependence: Recommendations. 
Neuropsychiatrie, 20/ 2006, 140-150 
W. Jessner, M. Strasser, I. Graziadei, F. Berr, W. Vogel (2006). Sustained remission of chronic hepatitis C after acute 
hepatitis B superinfection. Scandinavian Journal of Infectious Diseases, 38 (9)/2006, 818-821 
N. D. Kapusta, K. Ramskogler, I. Hertlinger, R. Schmid, A. Dvorak, H. Walter, O. M. Lesch (2006). Epidemiology of 
substance use in a representative sample of 18-year-old males. Alcohol Alcohol, 41(29/2006, 188-192 
L. Kraus, A. Uhl (2006). Substanzkonsum und Sterblichkeit: Das Dilemma der Kausalität. Suchttherapie, 4/2006, 
162-172 
L. Kraus, A. Uhl (2006). Wie nahe kommt die Forschungsrealität dem Wunsch, kausale Beziehungen zwischen Sub-
stanzkonsum und Tod herzustellen? Suchttherapie, 4/2006, 141-142 
E. Madlung, D. Dunkel, C. Haring (2006). Substitutionsmittel und Beikonsum bei Opiatabhängigen. Suchttherapie, 
7/2006, 18-23 
E. Madlung, C. Haring, J. A. Crespo, A. Saria, P. Grubinger, G. Zernig (2006). Methadone doses upon multiple readmis-
sions to inpatient detoxification: Clinical evidence for very moderate opioid tolerance. Pharmacology, 78(1)/2006, 38-43 
G. Rumpold, M. Klingseis, K. Dornauer, M. Kopp, S. Doering, S. Hofer, B. Mumelter, G. Schussler (2006). Psychotropic 
substance abuse among adolescents: a structural equation model on risk and protective factors. Substance Use and 
Misuse, 41 (8)/2006, 1155-1169 
A. Stevens, D. Berto, U. Frick, N. Hunt, V. Kerschl, T. McSweeney, K. Oeuvray, I. Puppo, A. Santa Maria, S. Schaaf, 
B. Trinkl, A. Uchtenhagen, W. Werdenich (2006). The Relationship between Legal Status, Percieved Pressure and Moti-
vation in Treatment for Drug Dependence: Results from a European Study of Quasi-Compulsory Treatment. European 
Addiction Research, 12 (4)/2006, 197-209 
A. Uhl (2006). Darstellung und kritische Analyse von Kostenrechnungen im Bereich des Substanzmissbrauchs. 
Sucht: Zeitschrift für Wissenschaft und Praxis, 52 (2)/2006, 121-132 
C. G. Widschwendter, G. Zernig, A. Hofer (2007). Quetiapine cross reactivity with urine methadone immunoassays. 
The American Journal of Psychiatry, 164 (1)/2007, 172 
B. Winklbaur, N. Ebner, G. Sachs, K. Thau, G. Fischer (2006). Substance abuse in patients with schizophrenia. 
Dialogues in Clinical Neuroscience, 8 (1)/2006, 37-43 
G. Zernig, S. H. Ahmed, R. N. Cardinal, D. Morgan, E. Acquas, R. W. Foltin, P. Vezina, S. S. Negus, J. A. Crespo, 
P. Stöckl, P. Grubinger, E. Madlung, C. Haring, M. Kurz, A. Saria (2007). Explaining the Escalation of Drug Use in 
Substance Dependence: Models and Appropriate Animal Laboratory Tests. Pharmacology, 80/2007, 65-119 
Chapter 13: Drug-related Research 
 90
Publications of 2006 by Austrian researchers in international journals are included in the list 
of publications (see previous page). This collection is based on extensive research on the 
Internet via the web pages of the Austrian Library Network (OBVSG), the National Library of 
Medicine (NLM) and the German Medpilot meta database. Furthermore, issues of drug-
specific journals as well as the achievement reports of individual University Hospitals in Aus-
tria and of the drug-specific research institutes were viewed. The Newsletter DrugNet Austria 
published by the REITOX Focal Point Austria (GÖG/ÖBIG) was also consulted for reference. 
The list of publications exclusively contains publications in journals with peer review. 
13.3 Collection and dissemination of research results 
Gesundheit Österreich GmbH and the Austrian Health Institute (GÖG/ÖBIG) in its function as 
REITOX Focal Point of the EMCDDA has regular contacts with relevant research institutions 
and experts. The Newsletter DrugNet Austria, an electronic quarterly out sent to 600 per-
sons, offers an added possibility to present studies and research result in short. The national 
report on the drug situation in Austria also sums up recent studies, research projects and re-
sults on the various addiction-related topics every year.  
Wiener Zeitschrift für Suchtforschung is Austria’s only scientifically recognised specific publi-
cation focusing on addiction and drugs. It has been published since 1977 as a quarterly by 
the Anton Proksch Institute in cooperation with the Ludwig Boltzmann Institute of Addiction 
Research (LBISucht). This journal contains information on the interdisciplinary research into 
the use of and dependence on psychotropic substances as well as into addiction treatment in 
theory and practice. Thematically open issues alternate with focal issues on subjects such as 
methadone or alcohol in the workplace. There is an external review procedure for articles to 
be published, and an abstract in English.  
Articles on addiction and drugs are also published in journals from the fields of clinical medi-
cine or social sciences, which are listed below: 
Wiener Zeitschrift für Suchtforschung – www.api.or.at/wzfs/   
Editors  API and LBISucht 
Contents: interdisciplinary research into the use of and dependence on psychotropic substances; addic-
tion treatment in theory and practice; thematically open issues alternate with focal issues (e.g., 
on methadone or alcohol in the workplace) 
Discipline:  multi-disciplinary 
Language:  German with English abstract 
Issues/year 4 
Peer review yes 
Neuropsychiatrie: Psychiatrie, Psychotherapie und Public Mental Health  
www.dustri.de/zd/ne/44welcome.htm  
Editors  Hartmann Hinterhuber and Ullrich Meise, both Innsbruck 
Contents: Overviews, original papers, case histories, news from the field of science, questions from prac-
tice, letters to the editors, readers’ questions from practice and answers, political and ethical is-
sues of the profession, information on representatives of the profession, conference announce-
ments, book reviews etc. in all fields of neurology and psychiatry 
Discipline:  neurology, psychiatry 
Language:  German with English abstract 
Issues/year 4 
Peer review  yes 
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Wiener klinische Wochenschrift – The Middle European Journal of Medicine  
http://springerlink.metapress.com/content/112448/  
Editors  Members of the Medical University Vienna and the Society of Physicians in Vienna 
with collaboration of the members of the Medical Universities in Graz and Innsbruck 
Contents:  scientific journal of medicine covering the entire range of clinical medicine as well as issues 
concerning medicine and society, such as medical ethics, social medicine, history of medicine. 
Editorials and leading articles on topical issues, overviews, case reports and a broad range of 
special themes. Focus on Middle Europe 
Discipline:  clinical medicine 
Language:  German, English 
Issues/year 1 volume containing 24 issues 
Peer review yes 
Wiener Medizinische Wochenschrift – www.springerlink.com/content/112449/  
Editors: Institutes and hospitals of the Medical Universities Vienna, Graz and Innsbruck and the 
Scientific Society of Physicians in Styria 
Contents:  scientific journal of medicine with contributions from all over Europe. The articles cover 
  a broad, Europe-wide range of clinical and pre-clinical medicine 
Discipline:  clinical medicine 
Language:  German, English 
Issues/year 1 volume containing 24 issues 
Peer review yes 
Österreichische Zeitschrift für Soziologie – www.soz.univie.ac.at/oezs/  
Editors:   Austrian Sociological Society (ÖGS) 
Contents:  articles, information on completed research projects, reports of events, short description of  
  sociology institutes, book reviews, discussion of sociological issues. Thematically open issues  
  alternate with focal issues 
Discipline:  sociology, social studies 
Language:  German with English abstract 
Issues/year 4 
Peer review yes 
Kontraste – www.gespol.jku.at/e1275/index_ger.html  
Editors:   Social Sciences Association and  
Institute of Social and Societal Policy – University of Linz 
Contents:  reports on social policy: poverty and labour market policy, 
health policy problems and social insurance, women’s issues and human rights topics 
Discipline:  social studies 
Language:  German with English abstract 
Issues/year 10 
Peer review no 
Furthermore, Austrian studies and new research results are also published in books (see for 
example Beubler, Haltmayer, Springer 2007; Eisenbach-Stangl, Lentner, Mader 2005), and 
most research institutes also publish their scientific papers on their own websites (see the 
websites mentioned in this chapter). At national level, rather than one nationwide addiction 
research conference with regular meetings, there is a variety of expert meetings and confer-
ences on specific issues with a regional or international approach (e.g., ReDUse – New As-
pects and Developments in Recreational Drug Use82 in October 2007 in Vienna; and a con-
ference on addiction, co-morbidity and treatment – new ways of treatment for addiction pa-
tients83 in January 2008 in Vienna). 
                                                
82 www.checkyourdrugs.at/data/_static/reduse/  
83 www.api.or.at/pdfs/vorankuendigung_2008.pdf  
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Personal communications, alphabetical order 
 
Name and page Organisation or function 
Anderwald, Christine (p. 46) Caritas Marienambulanz outpatient department, Graz 
B.I.T. (p. 81) Drug and addiction counselling unit, Tyrol 
Bäcker, Wolfgang (p. 80) MAG ELF – Department 6 – Social Education Services 
– Drug Counselling and Treatment Services, Vienna 
Bauer, Dr. Bernhard (p. 46) Head of department, Caritas Marienambulanz outpa-
tient department, Graz 
Drobesch, Dr. Barbara (p. 81) Director of the province unit for addiction prevention, 
Carinthia 
Drug Counselling Service Z6 (p. 78) The Drug Counselling Service of the youth centre Z6 
provides counselling and assistance for adolescents 
and adults vulnerable or addicted to drugs and to rela-
tives of those concerned, Innsbruck 
Duspara, Vinko (p. 46) Lukasfeld therapy department, Maria Ebene 
foundation, Vorarlberg 
Ederer, DSA Klaus Peter (p. 18, 39, 51) Addiction coordinator, Styria 
Fischer, Dr. Gabriele (p. 46, 85) University professor, Clinical Department of General 
Psychiatry, drug outpatient department at the General 
Hospital Vienna 
Giacomuzzi, DDr. Salvatore M. (p. 52) Outpatient department of dependence diseases/drug 
outpatient department of the Psychiatric University 
Hospital of Innsbruck 
Haller, Dr. Beatrix (p. 18) Federal Ministry for Education, the Arts and Culture 
Haller, Dr. Reinhard (p. 63) University professor, Addiction Research Institute of the 
Medical University of Innsbruck 
Haltmayer, Dr. Hans (p. 46, 52, 63) Vienna Social Projects Association (VWS) 
Hörhan, Dr. Ursula (p. 34) Addiction coordinator, Lower Austria 
Kahl, Walter (p. 72) Federal Ministry of Justice, V/1 
Kern, Harald (p. 54) Addiction coordinator, Tyrol  
Mader, Christian (p. 72) Federal Ministry of the Interior, Bundeskriminalamt 
(Federal Criminal Agency), drug offences unit 
Mayrhofer, Dr. Herbert (p. 40) Medical director of H.I.O.B. counselling centre, 
Vorarlberg 
Mellish, Petra (p. 18, 19, 20) Addiction Prevention, Coordination and Counselling 
Unit, Lower Austria 
Mentlvilla (p. 32, 74, 78, 79, 80) Emergency sleeping facility of Caritas Innsbruck 
Neubacher, Thomas (p. 32) Addiction coordinator, Vorarlberg 
Prehslauer, Dr. Brigitte (p. 7, 9, 31, 33, 34, 
54) 
Drug coordinator, Carinthia 
Schwarzenbrunner, Thomas (p. 52, 53) Addiction and drug coordinator, Lower Austria 
Stolz-Gombocz, Dr. Ingrid (p. 46) Assistant medical director, Anton Proksch Institute, 
long-term therapy of drug addicts with 
personality disorders, Mödling, Lower Austria 
Werdenich, Dr. Wolfgang (p. 85) Federal Ministry of Justice, prison Favoriten, Vienna 
Zernig-Grubinger, Dr. Gerald (p. 86) University professor, Clinical department of psychiatry/ 
experimental psychiatry, Medical University of Innsbruck
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DATABASES 
 
EDDRA = Exchange on Drug Demand Reduction Action 
Internet database of the EMCDDA: http://eddra.emcdda.eu.int/eddra  
Austrian projects in the EDDRA database (as of August 2007): 
Abrakadabra – (Re-)socialisation of drug addicts by integration in the labour market 
(Caritas der Diözese Innsbruck, Tyrol) 
Addiction information in schools supported by experts 
(kontakt+co - Suchtpräventionsstelle, Tyrol) 
Addiction prevention in early childhood: An advanced training course for kindergarten 
teachers 
(VIVID - Fachstelle für Suchtprävention, Styria) 
Addiction prevention within the apprenticeship of the Austrian Federal Railways 
(Institut für Suchtprävention, Vienna) 
Addiction prevention within the Styrian Soccer Association 
(VIVID – Fachstelle für Suchtprävention, Styria) 
Addiction programme: Promote health, prevent addiction 
(Bundesministerium für Unterricht und kulturelle Angelegenheiten, Vienna) 
Ambulance for addiction diseases at the University Hospital of Innsbruck, Department for 
Psychiatry 
(Universitätsklinik für Psychiatrie - Innsbruck, Tyrol) 
Become Independent: education programme for prevention in schools  
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
Campaign „Empower our Children“ 
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
Caritas Marienambulanz. Drug related street work, an outreach service in the field of 
medical care and treatment. 
(Caritas der Diözese Graz Seckau, Styria) 
CONTACT: Liaison service for hospitals 
(Fonds Soziales, Vienna) 
DAPHNE project: Addiciton as chance of survival? For women with experience of violence. 
(Verein Dialog und Verein Wiener Sozialprojekte, Vienna) 
DP drugaddicts@work. Equal ESF community initiative programme for reintegrating people 
with problematic drug use into the labour market. 
(Fonds Soziales, Vienna) 
Drug-free areas in Innsbruck prison 
(Justizanstalt Innsbruck, Tyrol)  
Drug free zone Hirtenberg prison 
(Justizanstalt Hirtenberg, Lower Austria) 
Drug Out: Innsbruck prison’s therapy unit 
(Justizanstalt Innsbruck, Tyrol) 
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Early detection and intervention with regard to problematic drug use and addiction 
(kontakt+co – Suchtpräventionsstelle, Tyrol) 
Employment Programme WALD (Forest) 
(H.I.O.B. - Anlauf- und Beratungsstelle für Drogenabhängige, Vorarlberg) 
Erlenhof: An inpatient treatment centre for addicts 
(Pro mente Upper Austria) 
European networking in addiction prevention 
(Institut Suchtprävention, Upper Austria) 
Fantasy instead of Ecstasy: Addiction prevention through peer group education in 
a vocational high school in Neumarkt in Salzburg 
(AKZENTE Salzburg - Suchtprävention, Salzburg) 
Generation E: Workshop for creative parents work 
(Institut für Suchtprävention, Fonds Soziales, Vienna) 
Grüner Kreis: A treatment facility for adolescents 
(Verein Grüner Kreis, Lower Austria) 
“Guat beinand’!”: Addiction prevention in communities and city districts 
(Akzente Salzburg – Suchtprävention, Salzburg) 
Health Promotion and Addiction Prevention in the Workplace  
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
High enough? – Practical kit for addiction prevention in the field of youth work 
(VIVID Fachstelle für Suchtprävention, Styria) 
H.I.O.B.: Help, information, orientation and counselling for drug addicts  
(H.I.O.B. - Anlauf- und Beratungsstelle für Drogenabhängige, Vorarlberg) 
In motion: A multiplier project for addiction prevention at schools  
(Institut Suchtprävention - eine Einrichtung von pro mente, Upper Austria) 
Job assistance - subproject of the Vienna Job Exchange in the context of the Equal devel-
opment partnership 
(Wiener Berufsbörse, Vienna) 
Living together in the 2. district. Program for the prevention of addiction in schools, 
children and youth work in urban areas. 
(Institut für Suchtprävention, Vienna) 
Local Capital for Social Purposes (a pilot action of the DG V of the EU) Programme: 
“Socially Innovativ 2000” (EU regional management Eastern Styria) 
(Volkshilfe Steiermark, VIVID Fachstelle für Suchtprävention, Regionalbüro Oststeiermark, 
Styria) 
Log In: Measures for the integration and health promotion of former drug users 
(Anton Proksch Institute, Lower Austria) 
Long-term therapy, Anton Proksch-Institute, Mödling  
(Anton Proksch Institute, Lower Austria) 
Long-term therapy facility CARINA 
(Stiftung Maria Ebene, Vorarlberg) 
Long-term treatment of drug dependence Senobio, Schnifis, Vorarlberg 
(Senobio, Vorarlberg)  
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Low threshold service Ganslwirt 
(Verein Wiener Sozialprojekte, Vienna) 
Lukasfeld: A short term therapy for young illegal drug addicts 
(Stiftung Maria Ebene hospital, Vorarlberg) 
Making kids strong through Sports 
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
MDA basecamp – mobile drug work in recreational settings 
(Jugendzentrum Z6, Tyrol) 
Medico-psycho-social Sanatorium „Schweizer Haus Hadersdorf“ 
(Evangelisches Haus Hadersdorf - WOBES, Vienna) 
Needles or Pins: Vienna: A European Project to develop innovative projects for the social 
and labour integration of people with drug related problems. 
(Beratungsstelle DIALOG, Vienna) 
Needles or Pins: A European Project to develop innovative projects for the social and 
professional rehabilitation of people with drug problems. Sub-project of Vorarlberg 
(Die Fähre, Vorarlberg) 
Needles or Pins: Occupational reintegration of (former) drug addicts. 
(Beratungsstelle DIALOG, Vienna) 
Pib – prevention in companies 
(kontakt+co - Suchtpräventionsstelle, Tyrol) 
Pilot projekt: Addiction prevention in Trofaiach 
(b.a.s. (betrifft alkohol und sucht) – steirischer Verein für Suchtkrankenhilfe, Styria) 
Probation assistance for prisoners at Vienna Favoriten prison provided by 
voluntary staff 
(Verein für Bewährungshilfe und soziale Arbeit – Bewährungshilfe, Vienna) 
SAS: Pupils searching for alternative solutions. A pupil multiplier project of primary addiction 
prevention based on the concept of peer group education. 
(VIVID - Fachstelle für Suchtprävention, Styria) 
Scientific project: ChEckiT! 
(Verein Wiener Sozialprojekte, Vienna) 
Social medicine counselling centre Ganslwirt 
(Verein Wiener Sozialprojekte, Vienna) 
Socio economical company: Fix und Fertig (“All ready”) 
(Verein Wiener Sozialprojekte, Vienna) 
Stationenmodell: Primary addiction prevention in schools 
(Fachstelle für Suchtvorbeugung, Koordination und Beratung, Lower Austria) 
Step by Step: A programme for early detection and crisis intervention at schools 
(VIVID – Fachstelle für Suchtprävention, Styria) 
Streetwork mobile youth work: “Rumtrieb” Wiener Neustadt 
(Verein für Jugend und Kultur Wr. Neustadt, Lower Austria) 
Substitution treatment in the Outpatient Clinic for Addictions in Innsbruck 
(Outpatient Clinic for Addictions Innsbruck, Tyrol) 
Supervised housing 
(Verein Wiener Sozialprojekte, Vienna) 
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Supromobil: Secondary prevention of the Foundation Maria Ebene 
(Stiftung Maria Ebene, Vorarlberg) 
The Umbrella Network Programme: Analysis of border issues with regard to HIV, AIDS 
and STD problems and the development of cooperative border crossing preventative 
measures. 
(Institut für Sozialdienste, Vorarlberg) 
Therapy for parents and children at Grüner Kreis 
(Verein Grüner Kreis, Lower Austria) 
Toy-free Kindergarten: Addiction prevention by promoting life skills  
(ISP - Informationsstelle für Suchtprävention, Vienna) 
Travelling exhibition with the aim of addiction prevention: “Have you got the hang of 
everything?“ 
(Fachstelle für Suchtprävention, Lower Austria) 
Treatment and care of addicted offenders in Vienna Favoriten prison 
(Justizanstalt Wien-Favoriten, Vienna) 
URBAN: Vienna Gürtel Plus. Secondary prevention for young people in urban areas  
(Drogenberatungsstelle Change, Vienna) 
Vienna Job Exchange 
(Wiener Berufsbörse, Vienna) 
Viennese pilot project “Pregnancy and Addiction”: Aftercare of the children. 
Comprehensive care project for substance abusing mothers and their children 
(Neuropsychiatrische Abteilung für Kinder und Jugendliche am KH Rosenhügel, Vienna) 
Viennese pilot project “Pregnancy and Addiction”: Comprehensive care for substance 
dependent mothers and their children 
(AKH, Vienna) 
Viktoria’s birthday: Primary addiction prevention for primary school pupils. 
(Fachstelle für Suchtprävention, Lower Austria) 
Way Out: Early intervention for young drug-using first offenders.  
(Kooperation der Landesstelle Suchtprävention und Neustart, Carinthia) 
Youth and addiction counselling centre “Auftrieb” 
(Verein für Jugend und Kultur Wr. Neustadt, Lower Austria)  
Youth counselling centre „Waggon” 
(TENDER – Verein für Jugendarbeit, Lower Austria) 
Youth without borders?! Mladi brez meja?! – Addiction prevention in the district of 
Radkersburg 
(blue|monday gesundheitsmanagement, Styria) 
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WebSites  
Please find below websites of relevant institutions and associations in the field of drugs and 
addiction in Austria.  
For a comprehensive list of European and international websites on drugs and addiction 
please consult http://www.oebig.at under Activities/ Prevention/ Illegal drugs/ Links 
Provincial Drug or Addiction Coordinators: 
Addiction Coordinators for the Province of Burgenland 
http://www.burgenland.at 
Drug Coordinators for the Province of Carinthia 
www.gesundheit-kaernten.at 
Addiction Coordinators of the Province of Lower Austria 
http://www.noel.gv.at/service/gs/gs4/noesuchtkoordination.htm 
Drug and Addiction Coordinators of the Province of Upper Austria 
http://www.land-oberoesterreich.gv.at/cps/rde/xchg/SID-3DCFCFC3-
8C8F5206/ooe/hs.xsl/554_DEU_HTML.htm  
Drug Coordinators of the Province of Salzburg 
http://www.salzburg.gv.at/themen/gs/soziales/leistungen_und_angebote/abhaengigkeit/a
bhaengigkeit_drogenkoordination.htm   
Addiction Coordinators of the Province of Styria 
http://www.drogenberatung-stmk.at/ 
Addiction Coordinators of the Province of the Tyrol 
http://www.jugendweb.at/drogen/drogen_ein_det.asp?ID=19  
Addiction Coordinators of the Province of Vorarlberg 
http://www.vorarlberg.at/vorarlberg/gesellschaft_soziales/gesellschaft/suchtkoordination/
start.htm  
Addiction and Drug Coordinators Vienna (SDW), 
http://www.drogenhilfe.at 
Provincial Addiction Prevention Units: 
Burgenland: Fachstelle für Suchtprävention Burgenland 
http://www.psd-bgld.at  
Carinthia: Landesstelle für Suchtprävention Kärnten 
http://www.gesundheit-kaernten.at/gesundheitsserverhtml/page.asp?MEN_ID=77  
Lower Austria: Fachstelle für Suchtvorbeugung, Koordination und Beratung, NÖ 
http://www.suchtvorbeugung.at 
Upper Austria: Institut Suchtprävention, OÖ 
http://www.praevention.at  
Salzburg: AKZENTE Suchtprävention – Fachstelle für Suchtvorbeugung Salzburg 
http://www.akzente.net/Suchtpraevention.7.0.html  
Styria: VIVID – Fachstelle für Suchtprävention, Steiermark 
http://www.vivid.at/http://www.vivid.at  
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Tyrol: Kontakt&co – Suchtprävention. Jugendrotkreuz, Tirol 
http://www.kontaktco.at 
Vorarlberg: SUPRO – Werkstatt für Suchtprophylaxe, Vorarlberg 
http://www.supro.at 
Federal Ministries: 
Federal Ministry for Health, Family and Youth 
http://www.bmgfj.gv.at  
Federal Ministry of the Interior 
http://www.bmi.gv.at   
Federal Ministry of Justice 
http://www.bmj.gv.at 
Federal Ministry for Education, the Arts and Culture 
http://www.bmukk.gv.at  
Federal Ministry of Science and Research 
http://www.bmwf.gv.at  
Federal Ministry for Social Security and Consumer Protection 
http://www.bmsk.gv.at 
Federal Ministry for Transport, Innovation and Technology 
http://www.bmvit.gv.at  
Monitoring and research: 
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) 
http://www.emcdda.europa.eu 
Institut für Suchtforschung der Universität Innsbruck mit Sitz am Krankenhaus Maria Ebene 
(Addiction Research Institute of the University of Innsbruck, based at the hospital Maria 
Ebene) 
http://www.suchtforschung.at 
Ludwig Boltzmann Institute of Addiction Research at Anton Proksch Institute 
http://www.api.or.at/lbi/index.htm 
ÖBIG – Österreichischer Suchthilfekompass (Austrian Addiction Help Compass) 
http://suchthilfekompass.oebig.at  
ÖBIG – Einheitliches Dokumentationssystem der Klienten und Klientinnen der Drogenhilfe  
(Uniform documentation and reporting system of clients of Austrian drug help centres) 
http://tdi.oebig.at  
Other websites: 
AIDS assistance 
http://www.aidshilfen.at 
Allgemeines Krankenhaus in Wien (General Hospital Vienna) 
http://www.meduniwien.ac.at 
ARGE Suchtvorbeugung (Working Group for Addiction Prevention) 
http://www.suchtvorbeugung.net 
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Anton Proksch Institute 
http://www.api.or.at  
b.a.s. – Styrian society for addiction issues 
http://www.bas.at 
Blue Monday Gesundheitsmanagement (health management) 
http://www.bluemonday.at 
Bundesarbeitsgemeinschaft Streetwork – Mobile Jugendarbeit Österreich (federal associa-
tion of mobile youth street work in Austria) 
http://www.bast.at 
Carina – Therapiestation (treatment centre) 
http://www.mariaebene.at/carina/  
Caritas Innsbruck 
http://www.caritas-innsbruck.at  
Caritas Graz – Kontaktladen (contact point) 
http://caritas-graz.at  
ChEck iT! – Vienna Social Projects Association (VWS) 
http://checkyourdrugs.com 
CONTACT – hospital connection service 
http://www.drogenhilfe.at/rathilfe/skh/r-s-contact.htm 
dialog – counselling and care centre 
http://www.dialog-on.at  
Do it yourself – low-threshold centre for drug users 
http://www.doit.at  
Drogenberatung des Landes Steiermark (Drug Counselling Centre of the Province of Styria) 
http://www.drogenberatung-stmk.at 
ENCARE Austria 
http://www.encare.at  
Ex und Hopp – drug counselling 
http://www.exundhopp.at 
Fachzeitschrift für Online-Beratung und computervermittelte Kommunikation (Magazine for 
online counselling and computer-aided communication) 
http://www.e-beratungsjournal.net 
Fonds Gesundes Österreich 
http://www.fgoe.org/startseite 
Ganslwirt – Verein Wiener Sozialprojekte (low-threshold centre; Vienna Social Projects As-
sociation) 
http://www.vws.or.at/ganslwirt  
Grüner Kreis – Society for the rehabilitation and integration of addicted persons 
http://www.gruenerkreis.at 
Haus am Seespitz (short-term therapy centre for drug patients) 
http://sogis.i-med.ac.at/ich-brauche-hilfe/einrichtungsdaten.cfm?eid=47 
H.I.O.B. – (drug counselling centre) 
http://www.caritas-vorarlberg.at 
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Jugendstreetwork Graz (youth street work) 
http://caritas-
graz.at/home.php?cakt=einr&id=2&einrakt=&narchiv=&armonat=&arjahr=&suche=&einri
d=&ibhid=&mitid 
Klinische Abteilung für Allgemeine Psychiatrie; Universitätsklinik für Psychiatrie in Wien  
(Clinical department of general psychiatry, Vienna University Hospital of Psychiatry) 
http://www.medizin-medien.info/dynasite.cfm?dssid=4263 
Komfüdro – communication centre for drug users 
http://www.caritas-innsbruck.at/einrichtungen.cfm?mode=showseite1&e_id=15 
Krankenhaus Rosenhügel (hospital) 
http://www.wienkav.at/kav/nkr/ 
Verein LOG IN Association 
http://www.login-info.at  
Lukasfeld – (therapy centre) 
http://www.mariaebene.at  
Marienambulanz (outpatient centre) 
http://www.caritas-graz.at/home.php?cakt=einr&id=68 
MDA basecamp –  (mobile drug prevention in the Tyrol) 
http://www.mdabasecamp.com  
MDA basecamp – (online counselling) 
http://www.onlinedrogenberatung.at 
Needles or Pins – dialog 
http://www.dialog-on.at/article_69.html 
Neustart – Bewährungshilfe, Konfliktregelung, Soziale Arbeit (probation assistance, conflict 
management, social work) 
 http://www.neustart.at/ 
Otto-Wagner-Spital – drug institute 
http://www.wienkav.at/kav/ows/medstellen_anzeigen.asp?suchstring=912 
Österreichische Caritaszentrale – (Caritas social integration enterprise) 
http://www.esf.at/projekte/arbeitslose/projekte_ida.html 
Österreichischer Verein für Drogenfachleute (Austrian Association of Experts in the Field of 
Drugs) 
http://www.oevdf.at  
Österreichisches Netzwerk Gesundheitsfördernde Schulen (Austrian Network of Health-
Promoting Schools) 
http://www.schule.at/gesundheit  
Plattform Drogentherapien – information on opiate addiction 
http://www.drogensubstitution.at  
pro mente Oberösterreich (psychosocial care association) 
http://www.promenteooe.at 
Schulpsychologie Bildungsberatung (school psychology, education counselling) 
http://www.schulpsychologie.at 
Schultüte (FSW/ISP Vienna; school project)  
http://schultuete.at  
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Schweizer Haus Hadersdorf (counselling and treatment centre) 
http://www.shh.at  
Stadt Wien - City of Vienna 
http://www.magwien.gv.at 
Stiftung Maria Ebene (foundation, hospital) 
http://www.mariaebene.at  
Streetwork Graz (street social work) 
http://caritas-
graz.at/home.php?cakt=einr&id=11&einrakt=&narchiv=&armonat=&arjahr=&suche=&einr
id=&ibhid=&mitid= 
Substanz – Verein für suchtbegleitende Hilfe (association for accepting drug assistance) 
http://www.substanz.at 
Supromobil (secondary prevention) 
http://www.supromobil.at 
Therapiestation Erlenhof (treatment centre) 
http://www.therapiestation-erlenhof.at  
Tiroler JugendWeb – Drogen, Sucht, Hilfe (Tyrolean youth network for drug assistance) 
http://www.jugendweb.at/drogen/ 
Verein für eine Legalisierung von Cannabis (legalise cannabis association) 
http://www.legalisieren.at  
VIVA (drug counselling centre) 
http://www.gesundheit-
kaernten.at/gesundheitsserverhtml/page.asp?MEN_ID=109&SEI_ID=99&LST_ID=48 
Vorarlberger Drogenhilfe (drug help services) 
www.suchthaufen.at  
VWS (Vienna Social Projects Association) 
http://www.vws.or.at  
Verein Jugend & Kultur Wiener Neustadt (youth and culture association) 
http://www.jugendundkultur.at  
Wiener BerufsBörse (Vienna Job Exchange)  
http://www.berufsboerse.at  
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Table A1: Overview of selected general population surveys on drug experience among the Austrian 
population from 2000 to 2007  
Study 
(author(s), year of 
publication) 
Area covered 
Year of data 
collection 
(period covered) 
Target group 
(sample) 
Drug types surveyed Percentage of 
respondents with 
drug experience 
Age group            % 
Bevölkerungsbefragung OÖ /  
drug survey, Upper Austria 
(market 2000) 
Upper Austria 
2000 
(lifetime) 
General  
population 
aged 15 and older 
(n = 1 011) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Morphine  
LSD 
Smart drugs 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
21 
4 
1 
4 
1 
3 
1 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(FSW and IFES 2002) 
Vienna 
2001 
(lifetime) 
General  
population 
aged 15 and older 
(n = 650) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opiates 
15 + 
15 + 
15 + 
15 + 
15 + 
14 
1 
1 
1  
1 
Suchtmittelstudie Steiermark / 
drug survey, Styria 
(IFES 2002) 
Styria 
2002 
(lifetime) 
General 
population  
aged 14 to 60  
(n = 1 000) 
Illicit drugs (total) 
Cannabis  
Other illicit drugs 
14–60 
14–60 
14–60 
14 
13 
2 
Bevölkerungsbefragung OÖ /  
general population survey, Up-
per Austria 
(Seyer 2005) 
Upper Austria 
2003 
(lifetime) 
General 
population 
aged 15 and older 
(n = 1 018) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Heroin 
Morphine 
LSD 
Solvents and inhalants 
Biogenic drugs 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
23.7 
3.9 
3.6 
3.7 
2.0 
2.1 
3.3 
5.8 
3.9 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(IFES 2004a) 
Vienna 
2003 
(lifetime) 
General 
population 
aged 15 and older 
(n = 750) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opiates 
Biogenic drugs 
Other illicit drugs (e. g., LSD) 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
16 
2 
2 
3  
1 
3 
2 
Bevölkerungsbefragung 
Österreich /  
general population survey, 
Austria 
(Uhl et al. 2005a) 
Austria 
2004 
(lifetime) 
General 
population 
aged 14 and older 
 (n = 4 547) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opiates 
Biogenic drugs 
LSD 
Solvents and inhalants 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
20.1 
3.0 
2.4 
2.3  
0.7 
2.7 
1.7 
2.4 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(IFES 2005a) 
Vienna 
2005 
(lifetime) 
General 
population 
aged 15 and older 
(n = 600) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opiates 
Biogenic drugs 
Other illicit drugs (e. g., LSD) 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
17 
2 
2 
2  
2 
3 
2 
Bevölkerungsbefragung OÖ /  
general population survey, Up-
per Austria 
(Seyer et al. 2007) 
Upper Austria 
2006 
(lifetime) 
General 
population 
aged 15 to 59  
(n = 1 125) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Heroin 
Morphine  
LSD 
Solvents and inhalants 
Biogenic drugs 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
27.6 
7.3 
7.6 
5.8 
4.2 
4.4 
4.6 
8.0 
7.4 
Gesundheitsbefragung 
Österreich (ATHIS) / 
Austrian Health Interview Sur-
vey (ATHIS) 
(Klimont et al. 2007) 
Austria 
2006/7 
(lifetime) 
General 
population 
aged 15 to 64 
(n = 11 822) 
Cannabis  
Cannabis 
Cannabis  
Cannabis  
Cannabis 
Cannabis 
15 + 
15–24 
25–34 
35–44 
45–54 
55–64 
9.7 
13.0 
15.0 
10.1  
6.7 
2.8 
Summarised by GÖG/ÖBIG 
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Table A2: Overview of selected youth surveys on drug experience among young people in Austria 
from 1999 to 2006  
Study 
(author(s), 
year of publication 
Area covered 
Year of data 
collection 
(period covered) 
Target group 
(sample) 
Drug types surveyed Percentage of 
respondents with 
drug experience 
Age group           % 
Jugendstudie Tirol / 
youth survey, Tyrol 
(Schüßler et al. 2000) 
Innsbruck 
1999 
(lifetime) 
Young people from 
14  to 19 
(n = 493) 
Hashish 
Other illicit drugs 
14–19 
14–19 
22 
3 
Schulstudie Burgenland / 
school survey, Burgenland 
(Schönfeldinger 2002) 
Burgenland 
2001 
(lifetime) 
Students in their 
7th to 13th school 
years 
(n = 1 899) 
Cannabis 
Ecstasy 
Cocaine 
Heroin 
Speed 
Hallucinogens 
Solvents and inhalants 
Biogenic drugs 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
20 
  4 
  2 
   1 
  3 
  3  
20 
  8  
HBSC-Studie / 
HBSC study 
(Dür and Mravlag 2002) 
Austria 
2001 
(lifetime) 
Students aged 15  
(n = 1 292) 
Cannabis 15 14 
Berufsschulstudie Salzburg / 
vocational school survey, 
Salzburg 
(Klopf and Weinlich 2004) 
Salzburg 
2003 
(lifetime) 
Trainees at vocational 
school from 15 to 25  
(n = 609) 
Cannabis 
Ecstasy 
Cocaine 
LSD  
Hallucinogenic mushrooms 
Solvents and inhalants 
15–25 
15–25 
15–25 
15–25 
15–25 
15–25 
 31 
  7 
  5 
  5 
  9 
15 
Bevölkerungsbefragung OÖ / 
general population survey, 
Upper Austria  
(Seyer 2005) 
Upper Austria 
2003 
(lifetime) 
Adolescents and young 
adults from 15 to 24  
(n = 567) 
Cannabis 
Ecstasy 
Heroin 
Amphetamines 
Cocaine 
LSD 
Solvents and inhalants 
Biogenic drugs 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
34.3 
8.3 
4.7 
8.9 
6.2 
5.7 
12.5 
10.0 
ESPAD Österreich / 
ESPAD Austria 
(Uhl et al. 2005b) 
 
Austria 
2003 
(lifetime) 
Students from 14 to 17  
(n = 5 281) 
Cannabis 
Ecstasy  
Cocaine 
Crack 
Heroin 
Amphetamines 
GHB 
LSD 
Solvents and inhalants 
Magic mushrooms 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
22 
3 
2 
2 
1 
5 
1 
2 
15 
4  
Berufsschulstudie Steiermark / 
vocational school survey, Styria 
(Hutsteiner, Seebauer, 
Auferbauer 2005) 
Styria 
2005 
(lifetime) 
Trainees at vocational 
school from 15 to 19  
(n = 3 919) 
Cannabis 
Party drugs 
Cocaine 
Crack 
Opiates 
Amphetamines 
Hallucinogens 
Solvents and inhalants 
Magic mushrooms 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
27.1 
4.8 
2.0 
1.1 
1.4 
3.1 
1.8 
11.4 
8.9 
HBSC-Studie / 
HBSC study 
(Dür and Griebler 2007) 
Austria 
2005/6 
(lifetime) 
Students aged 15 
(n = 1 239) 
Cannabis 15 14 
Bevölkerungsbefragung OÖ / 
general population survey, 
Upper Austria 
(Seyer et al. 2007) 
Upper Austria 
2006 
(lifetime) 
Adolescents and young 
adults from 15  to 24 
(n = 669) 
Cannabis 
Ecstasy 
Heroin 
Morphine 
Amphetamines 
Cocaine 
LSD 
Solvents and inhalants 
Biogenic drugs 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
36.9 
12.3 
7,7 
8.5 
12.3 
10.0 
9.0 
16.5 
130 
Summarised by GÖG/ÖBIG 
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Table A3: Number of directly drug-related deaths in Austria by cause of death from 1997 to 2006  
Cause of death 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Intoxication by opiate(s)  39 27 25 18 17 17 40 38 31 27 
Poly-drug intoxication with opiate(s) 92 81 101 147 119 119 115 133 134 137 
Poly-drug intoxication by narcotic drug(s) without 
opiates 
5 1 2 2 3 3 8 4 4 5 
Psychoactive medicines 5 8 8 * * * * * * * 
Intoxication of unknown type 0 0 0 0 0 0 0 10 22 28 
Directly drug-related deaths/total 141 117 136 167 139 139 163 185 191 197 
* = as of 2000 no longer taken into account 
Source: BMGFJ, calculations by GÖG/ÖBIG 
Table A4: Number of directly drug-related deaths in Austria by province from 1997 to 2006 
Province 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 1997–2006 
Burgenland 2 2 0 0 0 0 2 5 3 3 17 
Carinthia 3 3 7 2 5 7 6 4 6 7 50 
Lower Austria 12 9 8 11 14 12 13 31 29 38 177 
Upper Austria 6 6 2 11 8 6 13 15 13 14 94 
Salzburg 11 11 7 6 7 7 5 7 8 6 75 
Styria 13 5 6 11 9 13 14 12 17 12 112 
Tyrol 8 12 14 11 16 13 13 15 17 16 135 
Vorarlberg 5 6 5 5 11 6 5 8 6 6 63 
Vienna 81 63 87 110 69 75 92 88 92 95 852 
Total 141 117 136 167 139 139 163 185 191 197 1 575 
Source: BMGFJ, calculations by GÖG/ÖBIG 
Table A5: Number of directly drug-related deaths in Austria by age group and total by gender from 
1997 to 2006  
Age 
group 
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
 abs. % abs. % abs. abs. abs. % abs. % abs. % abs. % abs. % abs. % abs. % 
19 or younger 18 12.8 7 6.0 16 16 19 11.4 20 15.1 18 12.9 20 12.3 40 21.6 28 14.7 40 20.3 
20–24 32 22.7 35 29.9 23 23 33 19.8 21 14.4 20 14.4 37 22.7 40 21.6 48 25.1 51 25.9 
25–29 25 17.7 20 17.1 23 23 31 18.6 19 13.7 24 17.3 28 17.2 30 16.2 36 18.8 34 17.3 
30–34 30 21.3 20 17.1 27 27 27 16.2 27 19.4 23 16.5 24 14.7 19 10.2 25 13.1 19 9.7 
35–39 23 16.3 16 13.7 28 28 27 16.8 25 18.0 24 17.3 29 17.8 23 12.4 19 9.9 15 7.6 
40 or older 13 9.2 19 16.2 19 19 30 17.4 27 19.4 30 21.6 25 15.3 33 17.8 35 18.3 38 19.3 
Total 141 100 117 100 136 136 167 100 139 100 139 100 163 100 185 100 191 100 197 100 
Women 23 16.3 16 13.7 38 38 35 21.0 22 15.8 25 18.0 30 18.4 38 20.5 43 22.5 42 21.3 
Men 118 83.7 101 86.3 98 98 132 79.0 117 84.2 114 82.0 133 81.6 147 79.5 148 77.4 155 78.7 
abs. = absolute figures 
Source: BMGFJ, calculations by GÖG/ÖBIG 
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Table A6: Distribution of directly drug-related deaths in Austria by cause of death and age in 2006  
Age group 
Cause of death 
< 15 15–19 20–24 25–29 30–34 35–39 40–44 45–49 > 49 Total 
One opiate 0 11 5 4 0 2 1 1 2 26 
Several opiates 0 0 0 0 0 0 0 1 0 1 
+ alcohol 0 1 1 6 3 1 3 1 0 16 
+ psychoactive medicines 0 18 17 16 3 2 2 3 1 62 
Opiates 
 + Alcohol + psychoactive  
medicines 0 1 5 2 3 3 3 3 0 20 
Narcotic drug(s) only 0 2 5 0 1 1 0 1 1 11 
ND + alcohol 0 0 2 0 0 1 1 1 0 5 
ND + psychoactive medicines 0 2 5 2 2 1 1 2 0 15 
Opiates 
and other 
narcotic 
drugs 
ND + alcohol + psychoactive 
medicines 0 1 2 0 2 1 1 1 0 8 
Narcotic drug(s) only 0 0 0 0 0 0 0 1 0 1 
ND + alcohol 0 0 0 1 0 1 0 0 0 2 
ND + psychoactive medicines 0 0 1 0 0 0 0 0 1 2 
Narcotic 
drugs 
without 
opiates 
ND + alcohol + psychoactive 
medicines 0 0 0 0 0 0 0 0 0 0 
Intoxication of unknown type 0 4 8 3 5 2 4 2 0 28 
In
to
xi
ca
tio
ns
 
Directly drug-related deaths/total 0 40 51 34 19 15 16 17 5 197  
   of these: men 0 31 36 28 15 13 15 14 4 155 
ND = narcotic drug(s) 
Source: BMGFJ, calculations by GÖG/ÖBIG 
 
 
 
 
119
Table A7: Distribution of directly drug-related deaths in Austria by cause of death and province in 2006  
Province 
Cause of death 
B C LA UA S ST T VB V A 
One opiate 1 0 7 2 1 0 0 0 15 26 
Several opiates 0 0 0 0 0 0 0 0 1 1 
+ alcohol 1 0 4 0 0 0 7 1 3 16 
+ psychoactive medicines 1 4 12 6 1 9 5 1 23 62 
Opiates 
+ alcohol +  psychoactive 
medicines 0 3 3 3 0 2 2 2 5 20 
Narcotic drug(s) only 0 0 1 0 1 0 0 1 8 11 
ND + alcohol 0 0 1 1 0 0 0 0 3 5 
ND + psychoactive 
medicines 0 0 5 0 2 0 1 0 7 15 
Opiates and 
other narcotic 
drugs 
ND + alcohol  + 
psychoactive medicines  0 0 4 1 1 0 1 1 0 8 
Narcotic drug(s) only 0 0 0 0 0 0 0 0 1 1 
ND + alcohol 0 0 0 0 0 0 0 0 2 2 
ND + psychoactive 
medicines 0 0 0 0 0 0 0 0 2 2 
Narcotic drugs 
without 
opiates 
ND + alcohol + 
psychoactive medicines 0 0 0 0 0 0 0 0 0 0 
Intoxication of unknown type 0 0 1 1 0 1 0 0 25 28 
In
to
xi
ca
tio
ns
 
Directly drug-related deaths/total 3 7 38 14 6 12 16 6 95 197 
 Direct drug-related deaths per 100 000 
inhabitants aged 15 to 64 years 1.6 1.9 3.6 1.5 1.7 1.5 3.4 2.4 8.4 3.5 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, ST = Styria, T = Tyrol, VB = Vorarlberg,       
V = Vienna, A = Austria 
Source: BMGFJ, calculations by GÖG/ÖBIG 
Table A8: Development of AIDS cases in Austria by risk situation from 1997 to 2006 
Risk situation 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Homo-/bisexual contact 26 28 27 12 21 19 7 14 13 16 
Intravenous drug use 23 25 28 22 26 20 12 13 13 4 
Heterosexual contact 18 25 31 28 33 39 21 28 17 25 
Other cause/unknown 35 21 15 23 11 15 10 12 12 9 
Total 102 99 101 85 91 93 50 67 55 54 
Source: BMGFJ, calculations by GÖG/ÖBIG 
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Table A9: Distribution of reports to the police for violation of the Narcotic Drugs Act/Narcotic 
Substances Act in Austria by first offenders and repeat offenders, development 
from 1997 to 2006 
Reports 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Total number of reports 17 868 17 141 17 597 18 125 21 862 22 422 22 245 25 215 25 892 24 008 
First offenders 9 278 8 672 9 868 9 343 11 033 11 269 12 117 14 346 15 569 15 808 
Repeat offenders 8 325 8 228 7 463 8 296 10 052 10 380 9 288 9 990 9 520 7 636 
Difference between sum of individual figures and total figure = unknown offenders 
Since 1998: all reports, not only narcotic drugs but also psychotropic substances 
Note: on 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. 
Source: BMI/Bundeskriminalamt (Federal Criminal Agency) 
Table A10: Distribution of reports to the police for violation of the Narcotic Drugs Act/ 
Narcotic Substances Act (narcotic substances only) in Austria from 1997 to 2006 
Province 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Burgenland 759 707 603 843 712 805 984 967 923 1 033 
Carinthia 961 1 076 1 208 1 088 1 758 1 676 1 659 1 464 1 529 1 190 
Lower Austria 2 686 2 519 2 389 2 624 2 975 3 319 3 017 3 531 3 632 3 050 
Upper Austria 2 256 2 334 1 946 1 887 2 677 3 054 2 782 3 521 3 769 3 209 
Salzburg 855 1 053 840 718 1 471 1 384 868 1 077 1 092 1 001 
Styria 1 125 973 1 367 1 305 1 601 1 910 1 570 1 705 1 516 1 435 
Tyrol 2 204 2 212 2 152 2 687 2 449 2 229 2 102 2 695 2 775 2 607 
Vorarlberg 933 1 144 1 848 1 183 1 447 1 265 1 146 1 044 1 008 1 240 
Vienna 6 089 4 606 4 858 5 233 6 212 6 210 7 652 8 524 8 797 7 925 
Total 17 868 16 624 17 211 17 568 21 302 21 852 21 780 24 528 25 041 22 690 
Difference between sum of individual province figures and total figure = reports not attributable to province 
Note: on 1 January 1998 the Narcotic Drug Act was replaced by the Narcotic Substances Act, which also includes psychotropic 
substances. For the purpose of comparison, only reports related to narcotic drugs have been considered for the period af-
ter 1998. 
Source: BMI/Bundeskriminalamt (Federal Criminal Agency) 
Table A11: Distribution of reports to the police for violation of the Narcotic Drugs Act/ 
Narcotic Substances Act in Austria by drug type from 1997 to 2006 
Drug type 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Cannabis 16 124 16 376 17 236 17 001 19 760 19 939 17 706 20 252 20 900 19 021 
Heroin and opiates 3 434 2 850 2 524 2 413 3 802 3 954 4 717 4 770 4 720 3 516 
Cocaine + crack 2 764 2 103 2 608 2 494 3 416 3 762 4 785 5 365 5 491 4 252 
LSD 893 736 532 477 506 327 214 196 160 164 
Ecstasy 1 942 1 411 1 517 2 337 2 940 2 998 2 473 2 362 2 106 1 763 
Amphetamines 1 068 – – 1 041 1 215 1 357 1 619 1 741 1 664 1 503 
Psychotropic substances – 802 750 780 822 736 603 903 1 085 1 701 
Other drugs 850 – –- – 1 288 1 524 1 311 1 826 2 471 3 299 
– = not evaluated separately or not specified 
Note: on 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. Because of data broken down by 
type of drug, one report to the police may have been listed under several headings, therefore the added figures may differ 
from the  total number of reports. 
Source: BMI/Bundeskriminalamt (Federal Criminal Agency) 
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Table A12: Distribution of reports to the police for violation of the Narcotic Substances Act in Austria  
by drug type and province in 2006 
Drug type B C LA UA S ST T VB V Total 
Cannabis 1 078 1 408 2 465 3 244 1 114 1 573 2 805 1 367 3 967 19 021 
Heroin and opiates 87 23 535 492 63 163 168 160 1 825 3 516 
Cocaine + crack 140 135 519 367 145 188 434 280 2 044 4 252 
LSD 21 3 24 16 4 14 39 29 14 164 
Ecstasy 148 59 459 227 87 165 238 140 240 1 763 
Amphetamines 111 28 445 379 54 131 78 89 188 1 503 
Psychotropic substances 6 14 83 30 3 27 61 12 1 465 1 701 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, ST = Styria, T = Tyrol, VB = Vorarlberg,       
V = Vienna 
Note: because of data broken down by type of drug, one report to the police may have been listed under several headings, 
therefore the added figures may differ from the total number of reports.  
Source: BMI/Bundeskriminalamt (Federal Criminal Agency) 
Table A13: Convictions under the Narcotic Drugs Act/Narcotic Substances Act and total number of 
convictions in Austria from 1997 to 2006 
Year Total number of Convictions under  Convictions under  Convictions in Austria 
 convictions 
under the NDA/NSA 
Section 12 NDA/ 
Section 28 NSA 
Section 16 NDA/ 
Section 27 NSA 
Total number Under the NDA/NSA 
(percentages) 
1997 3 797 1 036 2 717 65 040   5.8 
1998 3 327 1 041 2 207 63 864   5.2 
1999 3 359 1 022 2 230 61 954   5.4 
2000 3 240 933 2 245 41 624   7.8 
2001 3 862 1 141 2 671 38 763 10.0 
2002 4 394 1 108 3 243 41 078 10.7 
2003 4 532 1 161 3 318 41 749 10.9 
2004 5 706 1 441 4 229 45 185 12.6 
2005 6 128 1 357 4 702 45 691 13.4 
2006 5 795 1 464 4 246 43 414 13.3 
NDA = Narcotic Drugs Act 
NSA = Narcotic Substances Act 
On 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act 
Section 12 NDA / Section 28 NSA = trafficking, possession etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 16 NDA / Section 27 NSA = trafficking, possession etc. of small quantities of narcotic drugs 
Note: these figures only refer to the leading offence, i.e., the offence with the highest range of punishment, so not all convictions 
under the NDA, or the NSA, respectively, are covered. 
Source: Statistics Austria (Criminal Court Statistics) 
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Table A14: Final convictions under the Narcotic Substances Act in Austria by age, gender and basis of 
conviction in 2006  
Basis of conviction  14–19 years 20–24 years 25–29 years 30–34 years > 34 years Total 
NSA total Men 1 046 1 883 905 527 814 5 175 
 Women 145 194 97 61 123 620 
Section 28 NSA Men 211 422 235 154 277 1 299 
 Women 32 52 26 19 36 165 
Section 27 NSA Men 833 1 459 660 360 495 3 807 
 Women 113 141 68 39 78 439 
NSA = Narcotic Substances Act 
Section 28 NSA = trafficking, possession etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 27 NSA = trafficking, possession etc. of small quantities of narcotic drugs 
Note: these figures only refer to the leading offence i.e., the offence with the highest range of punishment, so not all convictions 
under the NSA are covered.  
Source: Statistics Austria (Criminal Court Statistics) 
Table A15: Final convictions under the Narcotic Substances Act, young people and adults, basis of 
conviction and type of punishment in 2006 
Prison sentence Basis of conviction  Fine 
Probation No probation Partial probation 
Other 
Punishment1 
Total 
NSA total Young people 161 155 58 39 45 458 
 Adults 1 599 1 530 1 441 603 164 5 337 
Section 28 NSA (felonies) Young people 10 26 15 17 4 72 
 Adults 54 275 667 343 53 1 392 
Section 27 NSA (misdemeanours) Young people 151 129 43 22 41 386 
 Adults 1 522 1 220 752 258 108 3 860 
Young people = person younger than 19 at the time of the offence 
NSA = Narcotic Substances Act 
Section 28 NSA = trafficking, possession etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 27 NSA = trafficking, possession etc. of small quantities of narcotic drugs 
1 Other punishment: partial probation (Section 43 A (2) StGB), referrals to institutions (Section 21(1), 21 (2), 22 and 23 StGB), 
no additional punishment (Section 40 StGB) and, only in the case of young people, conviction with punish-
ment reserved (Section 13 JGG) and conviction without punishment (Section 12 JGG). 
Note: these figures only refer to the leading offence i.e., the offence with the highest range of punishment, so not all convictions 
under the NSA are covered. 
Source: Statistics Austria (Criminal Court Statistics) 
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Table A16: Development of alternatives to punishment applied in Austria from 1997 to 2006  
Waiving of reports/  
suspension of proceedings 
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Total 5 817 7 468 6 989 8 049 8 145 8 974 9 023 9 666 11 660 10 379 
Section 35 NSA (waiving of report) – 6 557 5 979 6 924 7 346 7 817 7 902 8 599 10 668 9 173 
Of these: Section  35 (4) NSA 
(cannabis) 
– 1 380 1 330 1 410 1 570 1 876 1 499 2 016 2 697 1 895 
Section  37 NSA (suspension of 
proceedings) 
– 911 1 010 1 125 799 1 157 1 121 1 067 992 1 206 
NSA = Narcotic Substances Act 
Section 35 NSA = provisional waiving of reports to the police by the public prosecutor 
Section 35 (4) NSA = waiving of reports to the police in the case of small quantities of cannabis for personal use 
Section 37 NSA = provisional suspension of proceedings by the court 
Note: on 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act. A specification of the kind of  al-
ternative to punishment can be given only for the period since 1998. Data on Section 39 of the NSA (stay of execution – 
therapy instead of punishment) are not available at present. 
Source: BMGFJ, calculations by GÖG/ÖBIG 
Table A17: Number of seizures of narcotic drugs/substances in Austria from 1997 to 2006 
Narcotic drug/substance 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Cannabis 4 957 4 683 5 079 4 833 5 249 5 294 5 422 6 202 6 012 5 770 
Heroin 861 654 452 478 895 836 1 263 1 383 1 371 883 
Cocaine 651 531 519 554 768 863 1 271 1 475 1 507 1 044 
Amphetamines 221 – – 141 161 202 294 324 312 299 
LSD 113 61 56 42 32 20 33 29 20 20 
Ecstasy 253 135 215 330 352 308 276 286 295 248 
Psychotropic substances – 14 74 65 1 0 6 5 2 2 
Psychotropic medicines – 521 517 501 566 515 432 678 823 1 300 
– = not evaluated separately or not specified 
Note: on 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act, which also includes psychotropic 
substances. 
Source: BMI/Bundeskriminalamt (Federal Criminal Agency) 
Table A18: Seizures of narcotic drugs/substances in Austria by quantity from 1997 to 2006 
Narcotic drug/substance 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Cannabis (kg) 912 1 336 451 1 806 456 743.1 925.9 1 680.9 819.9 1 880.4 
Heroin (kg) 102 118 78 230 288 59,5 42.8 235.0 282.2 34.33 
Cocaine (kg) 87 99 63 20 108 36.9 58.3 75.5 244.9 61.76 
Amphetamines (kg) 7.9 – – 1 3 9.4 54.2 25.7 8.9 38.17 
LSD (trips) 5 243 2 494 2 811 865 572 851 298 2 227.5 2 108.5 10 831.5 
Ecstasy (number of pills) 23 522 114 677 31 129 162 093 256 299 383 451 422 103 122 663 114 103.5 30 854.5 
Psychotropic substances (kg) – 0.128 4.004 1.294 0.002 0 0.2 0.1 0.002 0.032 
Psychotropic medicines (units) – 82 018 36 437 38 507 31 377 20 081 15 649 21 119 27 104 44 416 
– = not evaluated separately or not specified  
Note: on 1 January 1998 the Narcotic Drugs Act was replaced by the Narcotic Substances Act, which also includes psychotropic 
substances 
Source: BMI/Bundeskriminalamt (Federal Criminal Agency) 
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Table A19: Ingredients of samples bought as ecstasy and analysed by the ChEck iT! Project at parties 
and clubbings from 1999 to 2006 
Samples bought as ecstasy 
(percentages) Ingredients 
1999 
(n = 155) 
2000 
(n = 326) 
2001 
(n = 271) 
2002 
(n = 269) 
2003 
(n = 95) 
2004 
(n = 95) 
2005 
(n = 57) 
2006 
(n = 134) 
MDMA 85.81 81.90 77.12 68.03 83.45 71.58 70.2  74.6 
MDMA + MDE 0.00 3.07 2.21 14.13 7.59 9.47 0.0 1.5 
MDMA + MDA 0.00 0.92 1.48 6.69 0.00 0.00 0.0 0.7 
MDE and/or MDA 0.65 1.23 7.01 0.37 0.00 7.37 0.0 0.0 
MDMA + caffeine 1.29 1.53 0.00 0.74 0.69 1.05 5.3 5.2 
MDMA + amphetamines 0.65 0.61 0.37 0.00 0.69 0.00 1.8 1.5 
MDMA + various combinations* 3.87 2.15 0.37 0.00 3.45 1.05 12.3 0.0 
PMA/PMMA 0.00 1.23 0.37 0.00 0.69 0.00 0.0 0.0 
Amphetamines 3.87 1.53 0.00 1.86 1.38 0.00 1.8 4.5 
Methamphetamine 0.00 0.61 2.58 1.49 0.00 0.00 0.0 0.7 
Caffeine 0.00 0.92 0.00 1.49 0.00 1.05 0.0 0.7 
Chinine/quinidine 0.00 0.61 1.11 0.00 0.00 0.00 0.0 0.0 
Various combinations* 3.87 3.68 7.38 5.20 2.07 8.42 8.8 10.4 
* Various combinations: combinations of more than two amphetamine derivates and/or other substances and/or unknown sub-
stances 
Source: Vienna Social Projects Association (VWS) 
Table A20: Ingredients of samples bought as speed and analysed by the ChEck iT! Project at parties 
and clubbings from 1999 to 2006 
Samples bought as speed 
(percentages) 
Ingredients 
1999 
(n = 67) 
2000 
(n = 93) 
2001 
(n = 51) 
2002 
(n = 87) 
2003 
(n = 57) 
2004 
(n = 41) 
2005 
(n = 33) 
2006 
(n = 75) 
Amphetamines 53.73 56.99 60.78 45.98 35.09 21.95 33.3 24.0 
Amphetamines + caffeine 4.48 9.68 9.80 8.05 15.79 19.51 6.1 29.3 
Amphetamines + methamphetamine 1.49 0.00 0.00 0.00 0.00 0.00 0.0 0.0 
Amphetamines + various combinations* 20.90 7.53 3.92 17.24 29.82 39.02 24.2 24.0 
Methamphetamine 7.46 3.23 1.96 3.45 1.75 2.44 3.0 0.0 
Caffeine 1.49 3.23 11.76 8.05 0.00 4.88 9.1 1.3 
MDMA 2.99 3.23 0.00 1.15 0.00 0.00 6.1 4.0 
Ephedrine total 0.00 0.00 0.00 0.00 0.00 0.00 0.0 0.0 
Various combinations* 7.46 16.13 11.76 16.09 17.54 12.20 18.2 17.3 
* Various combinations: combinations of more than two amphetamine derivates and/or other substances and/or unknown sub-
stances 
Source: Vienna Social Projects Association (VWS) 
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Table A21: Number of persons currently registered for substitution treatment in Austria in the BMGFJ 
monitoring system by treatment/continued treatment and province in 2006 
Treatment B C LA UA S ST T VB V 
Continued treatment 71 221 834 511 380 778 273 408 3 576 
First treatment 23 68 201 74 27 157 25 70 410 
Total* 94 289 1 035 585 407 935 298 478 3 986 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, ST = Styria, T = Tyrol, VB = Vorarlberg,       
V = Vienna 
Note: continued treatment means treatment started before the respective year, or repeated treatment of persons who have 
undergone substitution treatment in the past. First treatment means treatment of persons who have never undergone 
substitution treatment before. The figures relate to treatments reported to the BMGFJ, which partly differ considerable 
from the figures collected at provincial level. 
* The total number of substitution treatments in Austria is higher than the sum of substitution treatments by province since re-
cords of the provinces are incomplete in some cases. 
Source: BMGFJ, calculations by GÖG/ÖBIG 
Table A22: Current health problems by age group and gender (percentages), clients of the year 2005 
(n = 2 244)  
   Age group 
Total Men Women 16–20  21–25  26–30  31–35  36–40  > 40 Current health problems 
65 64 68 48 57 69 71 75 80 
Chronic hepatitis C 35 35 34 14 27 39 44 48 47 
Dental problems 23 23 22 12 22 29 26 27 25 
Gastrointestinal problems 16 14 20 15 14 16 15 17 19 
Psychiatric diseases 10 10 11 10 8 11 10 12 12 
Dermatological and venous problems 10 9    12 6 7 10 11 13 16 
Aids, HIV infection 4 4 5 1 3 5 6 5 7 
Spasms, epileptic seizures 6 5 7 5 6 8 5 6 4 
Chronic hepatitis B 4 4 4 1 3 2 7 6 8 
Chronic ill health 1 2 1 – 2 1 1 3 3 
Gynaecological problems 4 * 13 6 5 2 2 3 3 
STD (sexually transmitted diseases) 1 * 1 * * 1 1 * – 
Other health problems 8 9 7 8 6 7 8 8 16 
No current health problems 35 36 32 52 43 31 29 25 20 
* = share of less than 1% 
– = share of 0% 
Source: IFES 2006 
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Table A23: Persons starting drug-specific treatment or assistance in 2006, by age and gender; 
percentages 
Short-term 
contacts 
Low threshold 
assistance 
Long-term out-
patient treatment 
Long-term in-
patient treatment 
Gender Gender Gender Gender 
Age 
M F Total M F Total M F Total M F Total 
0 to 4 0 0 0 0 0 0 0 0 0 0 0 0 
5 to 9 0 0 0 0 0 0 0 0 0 0 0 0 
10 to 14 0 1 0 2 5 3 0 1 1 0 0 0 
15 to 19 22 18 21 19 30 23 19 27 21 9 20 12 
20 to 24 32 25 30 30 25 29 32 34 32 35 34 35 
25 to 29 19 18 18 19 15 17 20 16 19 26 24 26 
30 to 34 10 13 11 10 13 11 12 9 11 12 12 12 
35 to 39 8 10 8 8 7 8 7 6 7 10 5 9 
40 to 44 6 9 7 7 4 6 6 4 5 5 2 4 
45 to 49  3 4 3 4 1 3 3 2 3 2 2 2 
50 to 54 1 1 1 1 1 1 1 1 1 0 0 0 
55 to 59 0 1 0 0 0 0 0 0 0 0 0 0 
60 to 64 0 0 0 0 0 0 0 0 0 0 0 0 
65 to 69 0 0 0 0 0 0 0 0 0 0 0 0 
70 to 74 0 0 0 0 0 0 0 0 0 0 0 0 
75 to 79 0 0 0 0 0 0 0 0 0 0 0 0 
80 or older 0 0 0 0 0 0 0 0 0 0 0 0 
Valid indications 3 503 1 586 5 089 398 165 563 3 106 1 094 4 200 1 039 364 1 403 
Unknown 0 0 0 0 0 0 0 0 0 0 0 0 
Missing - - - - - - - - - - - - 
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field “unknown” was indicated and missing means that no indication was made. 
Sampled population: all clients 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006 
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Table A24: Persons starting drug-specific treatment or assistance in 2006, by gender and livelihood; 
percentages 
Short-term 
contacts 
Low threshold 
assistance 
Long-term out- 
patient treatment 
Long-term in- 
patient treatment 
Gender Gender Gender Gender 
Livelihood/employment 
M F Total M F Total M F Total M F Total 
Gainful employment – – – 18 12 16 30 26 29 14 11 13 
Registered as unemployed – – – 35 29 33 40 28 37 49 32 45 
Welfare assistance – – – 10 18 12 8 12 9 9 17 11 
Child, school student, university student – – – 9 17 11 5 11 6 4 7 5 
Military service, alternative military service, 
parenthood leave, retired 
– – – 5 4 5 6 8 6 6 8 7 
Housework, (re)training, other – – – 3 3 3 3 7 4 2 2 2 
No gainful employment, no other form of live-
lihood 
– – – 5 3 5 4 3 4 3 3 3 
No gainful employment,  other form of liveli-
hood unknown 
– – – 15 14 15 6 4 5 14 19 15 
Valid indications – – – 278 120 398 2 542 916 3 458 1 010 345 1 355 
Unknown – – – 57 16 73 105 48 153 20 17 37 
Missing – – – 63 29 92 459 130 589 9 2 11 
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field “unknown” was indicated and missing means that no indication was made. 
Sampled population: all clients. The corresponding data are not collected for short-term contacts. 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006 
Table A25: Persons starting drug-specific treatment or assistance in 2006, by place of residence and 
gender; percentages 
Short-term 
contacts 
Low threshold 
assistance 
Long-term out- 
patient treatment 
Long-term in- 
patient treatment 
Gender Gender Gender Gender 
Place of residence 
M F Total M F Total M F Total M F Total 
Burgenland – – – – – – 3 3 3 3 2 3 
Carinthia – – – – – – 7 6 6 2 3 2 
Lower Austria – – – – – – 10 11 10 12 15 12 
Upper Austria – – – – – – 24 20 23 9 6 8 
Salzburg – – – – – – 2 2 2 2 3 2 
Styria – – – – – – 7 8 7 12 17 13 
Tyrol – – – – – – 10 8 9 9 12 10 
Vorarlberg – – – – – – 3 1 2 8 9 8 
Vienna – – – – – – 35 41 36 43 34 40 
Foreign country – – – – – – 0 0 0 1 1 1 
Valid indications – – – – – – 3 026 1 061 4 087 1 000 355 1 355 
Unknown – – – – – – 54 22 76 37 7 44 
Missing – – – – – – 26 11 37 2 2 4 
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field “unknown” was indicated and missing means that no indication was made. 
Sampled population: all clients; from Vorarlberg only data of inpatient centres are available. 
The corresponding data are not collected for short-term contacts and low-threshold assistance. 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006 
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Table A26: Persons starting drug-specific treatment or assistance in 2006, by present housing 
situation and gender; percentages 
Short-term 
contacts 
Low threshold 
assistance 
Long-term care 
outpatient 
Long-term care 
inpatient 
Gender Gender Gender Gender 
Present housing situation 
M F Total M F Total M F Total M F Total 
Stable (e.g., flat of one’s own) – – – 52 57 53 88 88 88 83 88 84 
Unstable (e.g., homeless) – – – 43 35 41 7 8 7 9 5 8 
In institution, plus stable housing situation – – – 4 7 5 4 3 4 7 5 6 
In institution, plus unstable housing situation – – – 1 0 1 1 1 1 2 2 2 
Valid indications – – – 295 122 417 3 009 1 044 4 053 1 000 339 1 339 
Unknown – – – 46 16 62 78 38 116 36 22 58 
Missing – – – 57 27 84 19 12 31 3 3 6 
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field “unknown” was indicated and missing means that no indication was made. 
Sampled population: all clients. 
The corresponding data are not collected for short-term contacts. 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006 
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Table A27: Persons starting drug-specific treatment or assistance in 2006, by primary drug and 
gender; percentages 
Short-term 
contacts 
Low threshold 
assistance 
Long-term out 
patient treatment 
Long-term in- 
patient treatment 
Gender Gender Gender Gender 
Primary drug  
(multiple indications admissible) 
M F Total M F Total M F Total M F Total 
Opiates 31 44 36 38 32 36 53 66 57 73 81 75 
Heroin 26 40 32 25 22 24 38 47 40 51 55 52 
Methadone 2 3 2 4 2 3 5 6 5 15 13 14 
Other substitution substances 11 11 11 17 14 16 22 30 24 35 40 36 
Other opiates, or opiates not specified 1 1 1 4 2 3 4 4 4 3 2 2 
Cocaine group 7 11 9 11 10 10 11 11 11 19 22 20 
Cocaine 7 11 9 11 10 10 11 10 11 19 22 20 
Crack 0 0 0 0 0 0 0 1 0 1 1 1 
Cocaine not specified 0 0 0 0 0 0 0 0 0 0 0 0 
Stimulants 4 3 3 3 1 3 6 6 6 6 5 6 
Amphetamines (e.g., speed) 2 2 2 2 1 2 4 4 4 5 4 5 
MDMA (ecstasy), other derivatives 2 2 2 2 0 1 4 4 4 4 4 4 
Stimulants not specified 0 0 0 0 0 0 0 0 0 0 0 0 
Tranquilisers/hypnotics 9 22 15 15 17 16 9 14 10 18 19 18 
Benzodiazepines 9 22 14 15 17 16 9 13 10 17 18 17 
Barbiturates 0 0 0 0 0 0 0 1 0 1 0 0 
Other hypnotics/tranquilisers 1 2 2 0 1 0 0 0 0 2 2 2 
Hallucinogenic drugs 0 0 0 0 0 0 1 1 1 2 1 2 
LSD 0 0 0 0 0 0 1 1 1 2 1 2 
Hallucinogenic drugs not specified  0 0 0 0 0 0 0 0 0 0 0 0 
Cannabis 42 25 35 30 23 28 38 23 34 21 15 20 
Solvents and inhalants 0 0 0 0 0 0 0 0 0 0 1 1 
Alcohol 9 13 11 7 12 8 7 4 7 7 6 6 
Biogenic drugs 0 0 0 0 0 0 0 0 0 0 0 0 
Other drugs 0 0 0 0 1 0 0 0 0 0 1 0 
Only use not relevant for treatment 21 22 21 13 17 15 4 5 4 1 1 1 
Additional drug only 3 2 2 14 17 15 5 4 5 5 3 4 
Valid indications 1 587 1 245 2 832 442 178 620 3 858 1 401 5 259 1 768 601 2 369 
Number of persons with valid indications 1 143 805 1 948 304 130 434 2 514 885 3 399 937 315 1 252 
Unknown 2 280 751 3 031 28 11 39 297 125 422 73 35 108 
Missing 80 30 110 66 24 90 295 84 379 29 14 43 
Note: all lines except Valid indications, Number of persons with valid indications, Unknown and Missing give percentages that 
relate to the number of persons making valid indications. Unknown means that the field “unknown” was indicated and 
missing means that no indication was made. 
Bold type indicates main categories. 
Sampled population: all clients. 
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006 
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Table A28: Persons starting drug-specific treatment or assistance in 2006, by intravenous drug use 
and age; percentages 
Short-term 
contacts 
Low threshold 
assistance 
Long-term out- 
patient treatment 
Long-term in- 
patient treatment 
Age Age Age Age 
Intravenous drug use 
< 20 20–29 > 29 < 20 20–29 > 29 < 20 20–29 > 29 < 20 20–29 > 29 
No 83 53 30 67 23 14 73 53 39 18 20 14 
Yes 17 47 70 33 77 86 27 47 61 82 80 86 
Valid indications 521 814 481 100 149 81 805 1 864 955 149 736 337 
Unknown 39 215 284 32 66 54 76 258 178 17 85 31 
Missing 509 1 418 808 11 44 26 12 31 21 3 26 19 
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field “unknown” was indicated and missing means that no indication was made. 
Sampled population: all clients.  
Source: GÖG/ÖBIG, DOKLI analysis of client year 2006 
Table A29: Austrian population statistics by age group and gender in 2005 
Age group Men Women Total 
  0 to under 5 years 204 801 193 708 398 509 
  5 to under 10 years 221 520 211 142 432 662 
10 to under 15 years 249 592 236 944 486 536 
15 to under 20 years 250 435 238 149 488 584 
20 to under 25 years 266 092 260 410 526 502 
25 to under 30 years 258 364 253 459 511 823 
30 to under 35 years 290 984 293 524 584 508 
35 to under 40 years 351 911 343 612 695 523 
40 to under 45 years 357 225 347 245 704 470 
45 to under 50 years 305 728 303 804 609 532 
50 to under 55 years 251 134 256 487 507 621 
55 to under 60 years 235 800 243 896 479 696 
60 to under 65 years 225 017 243 936 468 953 
65 to under 70 years 185 770 209 578 395 348 
70 to under 75 years 136 170 172 695 308 865 
75 to under 80 years 110 578 169 345 279 923 
80 to under 85 years 66 749 153 259 220 008 
85 and older 33 991 100 252 134 243 
Total 4 001 861 4 231 445 8 233 306 
  0 to under 15 years 675 913 641 794 1 317 707 
15 to under 30 years 774 891 752 018 1 526 909 
30 to under 45 years 1 000 120 984 381 1 984 501 
45 to under 60 years 792 662 804 187 1 596 849 
60 to under 75 years 546 957 626 209 1 173 166 
75 and older 211 318 422 856 634 174 
Total 4 001 861 4 231 445 8 233 306 
 
Source: Statistics Austria, calculations by GÖG/ÖBIG 
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AC Addiction Coordinator 
ADHS attention deficit hyperactive disorder  
AIDS acquired immune deficiency syndrome 
API Anton Proksch Institute 
AR Addiction Representative 
BADO (Vienna) Basic Documentation 
BAST Federal Streetwork Association 
BGBl Federal Collection of Statutes 
BMeiA Federal Ministry for European and International Affairs  
BMUKK Federal Ministry for Education, the Arts and Culture 
BMF Federal Ministry of Finance 
BMGFJ Federal Ministry for Health, Family and Youth 
BMI Federal Ministry of the Interior 
BMJ Federal Ministry of Justice 
BMLFUW Federal Ministry of Agriculture, Forestry Environment and Water Management 
BMLV Federal Ministry of Defence 
BMSG Federal Ministry for Social Security and Consumer Protection  
BMVIT Federal Ministry for Transport, Innovation and Technology 
BZP Benzylpiperazines 
DC Drug Coordinator 
DOKLI nation-wide treatment documentation system of clients of drug help centres in 
Austria 
DR Drug Representative 
DSM IV Diagnostic and Statistical Manual of Mental Disorders 
DTA drug treatment contact point 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EDDRA Exchange on Drug Demand Reduction Action 
EEG electroencephalogram 
EKG electrocardiogram 
ENCARE European Network for Children Affected by Risky Environments within the Fam-
ily 
ESPAD European School Survey Project on Alcohol and other Drugs 
EU European Union 
FFG Austrian Research Promotion Agency 
FGÖ Healthy Austria Fund 
FSW Vienna Social Fund 
FWF Austrian Science Fund 
GBL gamma butyrolacetone 
GHB gamma hydroxybutyric acid 
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GÖG Gesundheit Österreich GmbH 
GÖG/ÖBIG Gesundheit Österreich GmbH / Austrian Health Institute 
GÖG/FGÖ Gesundheit Österreich GmbH / Healthy Austria Fund 
GPS General Population Survey 
HAV hepatitis A virus 
HBV hepatitis B virus 
HBVcAb hepatitis B core antibody 
HBVsAb hepatitis B surface antibody 
HBVsAg hepatitis B surface antigen 
HCV hepatitis C virus 
HCV-Ab HCV antibody 
HCV-RNA RNA (ribonucleic acid) of the hepatitis C virus 
HIV human immunodeficiency virus 
ICD-10 International Classification of Diseases and Related Health Problems 
IFES Institute for Empirical Research 
i.v. intravenous 
JGG  Juvenile Court Act 
LBISucht Ludwig Boltzmann Institute of Addiction Research 
LSD d-lysergic acid diethylamide 
MA Municipal Department 
mCPP meta-chlorophenyl piperazine 
MDA 3,4-methylenedioxyamphetamine 
MDE 3,4-methylenedioxy-N-ethylamphetamine 
MDMA 3,4-methylenedioxy-methylamphetamine 
MUSTAP Multi-session Standardised Printed Programmes 
NLM National Library of Medicine 
ÖBIG Austrian Health Institute 
OeNB central bank of the Republic of Austria 
ÖGABS Austrian Society of Pharmacologically Assisted Treatment of Addiction 
ÖGPP Austrian Association for Psychiatry and Psychotherapy 
PCR polymerase chain reaction 
QCT quasi-compulsory treatment 
REITOX European Information Network on Drugs and Drug Addiction 
(Réseau Européen d’Information sur les Drogues et les Toxicomanies) 
RNA ribonucleic acid 
SGG Narcotic Drugs Act 
SMG Narcotic Substances Act 
SÖB socioeconomic enterprises 
STD sexually transmitted diseases 
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StGB  Criminal Code 
TB tuberculosis 
VWS Vienna Social Projects Association 
WHO World Health Organisation 
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List of Austrian Standard Tables and Structured Questionnaires of 2007  
The following list gives an overview of all Standard Tables and Structured Questionnaires drawn up 
for Austria in 2007 and submitted to the EMCDDA. Here, all Structured Questionnaires referred to in 
the text are mentioned, also those that were updated in previous years. If you are interested in obtain-
ing any table or questionnaire please contact Ms Monika Löbau: loebau@oebig.at . 
STANDARD TABLES 01: BASIC RESULTS AND METHODOLOGY OF POPULATION SURVEYS ON DRUG 
USE (Upper Austria) 
STANDARD TABLES 01: BASIC RESULTS AND METHODOLOGY OF POPULATION SURVEYS ON DRUG 
USE (Health Survey Austria) 
STANDARD TABLE 02: METHODOLOGY AND RESULTS OF SCHOOL SURVEYS ON DRUG USE 
(HBSC)  
STANDARD TABLES 03: CHARACTERISTICS OF PERSONS STARTING TREATMENT FOR DRUGS (DOKLI) 
STANDARD TABLES 03: CHARACTERISTICS OF PERSONS STARTING TREATMENT FOR DRUGS 
(Substitution treatments) 
STANDARD TABLE 05: ACUTE/DIRECT DRUG-RELATED DEATHS 
STANDARD TABLE 06: EVOLUTION OF ACUTE/DIRECT DRUG-RELATED DEATHS  
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Anton Proksch Institute: HBV, HCV, HIV) 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Lukasfeld short-term therapy department: HBV, HCV, HIV) 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Marienambulanz outpatient department, Graz: HBV, HCV, HIV) 
STANDARD TABLES 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Vienna Social Projects Association (VWS) – Ganslwirt: HBV, HCV, 
HIV) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (drug outpatient department of General Hospital Vienna: HCV, HIV) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (drug-related deaths: HCV, HIV) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (DOKLI: HBV, HCV, HIV)  
STANDARD TABLE 11: ARRESTS/REPORTS FOR DRUG LAW OFFENCES 
STANDARD TABLE 13: NUMBER AND QUANTITY OF SEIZURES OF ILLICIT DRUGS 
STANDARD TABLE 14: PURITY AT STREET LEVEL OF ILLICIT DRUGS 
STANDARD TABLE 15: COMPOSITION OF ILLICIT DRUG TABLETS 
STANDARD TABLE 16: PRICE AT STREET LEVEL OF ILLICIT DRUGS 
STANDARD TABLE 34: TREATMENT DEMAND INDICATOR (TDI) DATA   
STRUCTURED QUESTIONNAIRE 22/25: UNIVERSAL PREVENTION (last update: 2007) 
STRUCTURED QUESTIONNAIRE 23: HARM REDUCTION MEASURES TO PREVENT INFECTIOUS 
DISEASES IN INJECTING DRUG USERS (last update: 2006) 
STRUCTURED QUESTIONNAIRE 26: SELECTIVE PREVENTION (last update: 2007) 
STRUCTURED QUESTIONNAIRE 28: SOCIAL REINTEGRATION (last update: 2006) 
STRUCTURED QUESTIONNAIRE 31: TREATMENT AS AN ALTERNATIVE TO IMPRISONMENT APPLICABLE 
FOR DRUG USING OFFENDERS IN THE EUROPEAN UNION (last up-
date: 2006)  
STRUCTURED QUESTIONNAIRE 32: POLICY AND INSTITUTIONAL FRAMEWORK (last update: 2006) 
MUSTAP PROGRAMMES QUESTIONNAIRES: EIGENSTÄNDIG WERDEN (Becoming Independent; Lower 
Austria, Tyrol) 
MUSTAP PROGRAMMES QUESTIONNAIRE: EXPERTENGESTÜTZTE SCHULISCHE SUCHTINFORMATION 
(expert-aided information on addiction in schools; Tyrol)  
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